(A joint stock limited liability company incorporated in the People's Republi

2024
ANNUAL REPORT

Con en s

	P
CORPORATE INFORMATION	2
FINANCIAL HIGHLIGHTS	4
CHAIRMAN'S STATEMENT	5
MANAGEMENT DISCUSSION AND ANALYSIS	7
REPORT OF THE BOARD	47
REPORT OF THE SUPERVISORY COMMITTEE	64
CORPORATE GOVERNANCE REPORT	65
DIRECTORS, SUPERVISORS AND SENIOR MANAGEMENT	83
AUDITOR'S REPORT	97
CONSOLIDATED BALANCE SHEETS	103
PARENT COMPANY BALANCE SHEETS	106
CONSOLIDATED INCOME STATEMENT	109
PARENT COMPANY INCOME STATEMENT	112
CONSOLIDATED CASH FLOW STATEMENT	114
PARENT COMPANY CASH FLOW STATEMENT	117
CONSOLIDATED STATEMENT OF CHANGES IN OWNERS' EQUITY	119
STATEMENT OF CHANGES IN PARENT COMPANY OWNERS' EQUITY	123
NOTES TO THE FINANCIAL STATEMENTS	125
DEFINITIONS	287

Corporate Information

Board of Directors

Executive Directors

Mr. GUAN Wei (Chairman)
Ms. WANG Li
Mr. WANG Jun

Non-executive Directors

Mr. QIN Hao
Mr. LI Cheng

Independent Non-executive Directors

Ms. HONG Wei
Ms. JIN Lei
Mr. CHAN Siu Kee Hugh

Audit Committee

Ms. HONG Wei (Chairman)
Mr. LI Cheng
Ms. JIN Lei

Nomination Committee

Mr. CHAN Siu Kee Hugh (Chairman)
Mr. GUAN Wei
Ms. JIN Lei

Remuneration Committee

Ms. JIN Lei (Chairman)
Ms. HONG Wei
Mr. CHAN Siu Kee Hugh

Strategy and Risk Management Committee

Mr. GUAN Wei (Chairman)
Ms. HONG Wei
Mr. QIN Hao

Supervisory Committee

Mr. XU Nan (Chairman)
Mr. XU Yong
Ms. HANG Yan
Mr. XIE Tao
Mr. QIAN Cheng

Joint Company Secretaries

Mr. WANG Jun
Mr. WONG Wai Chung

Authorised Representatives

Mr. GUAN Wei
Mr. WONG Wai Chung

Auditor

BDO China Shu Lun Pan Certified Public Accountants LLP

Legal Advisers as to Hong Kong Law

Clifford Chance

Registered Office and Headquarters in the PRC

Shuangrui Road
Huangdu Street
Wenzhou
PRC

Corporate Information

Principal Place of Business in Hong Kong

40/F, Dah Sing Financial Centre
248 Queen's Road East
Wanchai
Hong Kong

Hong Kong Share Registrar

Computershare Hong Kong Investor Services Limited
Shops 1712-1716,
17th Floor, Hopewell Centre
183 Queen's Road East
Wanchai
Hong Kong

Stock Code

2120

Company's Website

[redacted]

Investor Relations

Telephone: (86) 577 8877 1689
Fax: (86) 577 8878 9117
Email: [redacted]@[redacted]

Financial Highligh s

P F D I

	For he ear ended December 31,				
	2024	2023	2022	2021	2020
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
				(R)	(R)
R	1,654,289	1,596,266	1,484,903	1,297,430	989,012
P	68,099	99,182	15,605	95,691	83,509
I	17,702	12,250	26,574	54,831	30,662
N	50,398	86,932	-10,969	40,860	52,847
N C	65,610	85,948	-24,221	44,036	64,961
P	-15,212	984	13,252	-3,176	-12,114

	As of December 31,				
	2024	2023	2022	2021	2020
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
				(R)	(R)
T	3,004,953	3,047,687	2,637,787	2,377,955	2,161,262
T	1,661,651	1,639,481	1,311,885	1,097,676	946,349
T	1,343,302	1,408,206	1,325,903	1,280,279	1,214,913
E C	1,223,013	1,265,065	1,201,585	1,208,264	1,122,248
N	120,289	143,141	124,318	72,015	92,665

Chairman's S a emen

D. S ,

F , B D W K H C ., L ., I G D 31, 2024.

I 2024, C ' . A G . G R L S H , , , , , , .

W . I O G . O D R P G 25 RMB1.056 M , . D R P G RMB462 L , K ' G ' . F , , , , , ,

Chairman's S a emen

A , I I , I
. W . T
. W , ,
, ,
, .

GUAN W. ,
C ,

, , PRC
A , 22, 2025

Management Discussion and Analysis

B R O

Psychiatric Specialized Medical Service Industry and Geriatric Healthcare Industry in China

P S M S I

M H C . A , C . A , C . P . M , C

F

O O 25, 2016, C C C C P S C H C 2030 P O , . I . B 2030,

O D 18, 2019, 12 N H C P D H C A C A M H A P (2019-2022), . I , H C .

O S 9, 2021, S C N H R A P (2021-2025), H C 100 ,

Management Discussion and Analysis

On July 10, 2022, 21 [illegible] National Development and Reform Commission (NDRC) [illegible] the Healthy China Action Promotion Committee [illegible] 14 Five-Year Plan, [illegible] Implementation [illegible]

On August 27, 2022, the General Office of the State Council issued the 14 Five-Year Plan for National Health [illegible]

On December 14, 2022, the Central Committee of the Communist Party of China and the State Council issued the Outline of Healthy China Action (2022-2035), [illegible] Central [illegible]

On February 22, 2023, the Department of Medical Administration of the National Health Commission of the People's Republic of China issued the 2023, [illegible] Medical [illegible]

On February 23, 2023, the General Office of the National Development and Reform Commission and the General Office of the National Health Commission issued the Notice on Further Improving the Pricing Policy for Medical Service Projects, which [illegible] Medical [illegible]

On July 18, 2024, the Central Committee of the Communist Party of China and the State Council issued the Decision on Further Deepening Reform and Promoting Chinese-style Modernization, which [illegible] Implementation [illegible] Building [illegible]

Managemen Disc ssion and Anal sis

G H I

A C A N B S
2024, C 60 310 22% . B
C

W I
C

Management Discussion and Analysis

On May 17, 2016, the General Office of the Communist Party of China Committee and the General Office of the State Council issued the Opinions on Implementing the Healthy China 2030 Plan, which proposed to ...

On October 25, 2016, the Communist Party of China Central Committee and the State Council issued the Healthy China 2030 Plan Outline, which proposed to ... The ...

On January 25, 2017, the National Development and Reform Commission and the National Health and Family Planning Commission issued the Development Plan for Medical Institutions (2016-2030), which ...

On January 9, 2017, the National Development and Reform Commission and the 13th Five-Year Plan for Development and Reform in the Health Sector, which ...

On March 6, 2017, the State Council issued the 13th Five-Year Plan for National Economic and Social Development, which ...

On March 23, 2017, the State Council issued the Opinions on Promoting the Development of Medical Insurance and Commercial Health Insurance and Related Matters, which ...

On January 16, 2017, the General Office of the State Council issued the Opinions on Promoting the Development of Elderly Care Services, which ...

Management Discussion and Analysis

On July 21, 2017, the National Development and Reform Commission issued the Guidelines for the Development of Service Industries (2017-2025), which clearly proposed to actively develop...

On August 21, 2017, the Ministry of Finance, the Ministry of Civil Affairs, the Ministry of Human Resources and Social Security, the National Health and Family Planning Commission and the China Securities Regulatory Commission jointly issued the Implementation Opinions on Encouraging Social Capital to Invest in the Medical and Health Field...

On July 21, 2018, the National Health Commission and the National Development and Reform Commission issued the Basic Standards for Hospital Construction, which specified the basic standards for the construction of hospitals at different levels...

On July 15, 2019, the State Council Office issued the Healthy China Action (2019-2030), which proposed to...

On November 18, 2021, the State Council Office issued the Several Opinions on Further Encouraging and Standardizing the Development of Private Hospitals...

Managemen Disc ssion and Anal sis

O M 13, 2021, F S T N P ' C O F F -Y P N E S D L -R O T Y 2035, I

O D 30, 2021, S C 14 F -Y P N E C S D E C S S

O F 7, 2022, 15 N H C , M E , M S T 14 F -Y P H A I ,

O M 21, 2023, G O C C C C P G O S C O B C B E C S S . A I

O J 15, 2024, G O S C O D S E E W- E 26 4 . T . T

O D 12, 2024, N H C M C A , N H S A N A T C M , N D C B A G O B H -Q D I M E C S (《關於促進醫養結合服務高質量發展的指導意見》). T

Managemen Disc ssion and Anal sis

B siness Re ie

I 2024, C ’ . I , N H S A , . I . D R P , (提質增效、穩中求進) , G ,

Managemen Disc ssion and Anal sis

D R P W K H, Q K H Y K H . T C K P H H K H , G ' R . O T H . I , S Y H C Y H , . H , B . Y H J S H , . T G .

E H B

E

U C ' , , (老齡健康) , C ' (銀發經濟) . T G , - . T .

A D 31, 2024, G 2,580 RMB461.9 2024, 30.4% G ' . D R P , G H W C H . Y Y H C K H . H , P C Y H W O Y G H .

Management Discussion and Analysis

Business Highlights

In 2024, G... I... G... 25... 164 (85 SCI...), 6... (5...), ... I..., G... S... S... C... C... I... T... P... P... (浙江省小而強臨床培育創新團隊項目) (...). M..., G... P..., I... S... T... C... B... D... P... A..., D... D... T... P..., ... I... W... M... U..., G... + ... G..., ... I... G... I... A... D... S... S... - S... A... B... G..., ...

Business Outlook

T... G..., ...:

( ) ... F... 2022、2024, ... 69.3%, 68.7% 71.7% ... I... G..., ... G..., ...;

( ) ... U... PRC, ... W... G..., ...;

( ) ... H... I... G..., ...

Managemen Disc ssion and Anal sis

P

I 2025, C

O , C

O

T G ,

I

G

I

M , G

G

G

G

AI ,

L G

T G

I

R L S H

Management Discussion and Analysis

Financial Review

T G RMB1,654.3 R P 3.6%
2023. A RMB1,517.8 ,
2.2% 2023. D R P ,
25.9% (2023: 25.4%). T G RMB438.4 ,
6.6% 2023. D R P ,
C R P RMB65.6 , 23.7%
2023. E RMB16.5 ,
C R P RMB78.0 , 9.3%
2023. D R P , G RMB99.6
(2023: RMB265.0), RMB165.4 2023,
RMB134.9 D 31, 2024
D 31, 2023. A L P D , G RMB234.9
D 31, 2024.

R C R

T G : ( ) ; ( )
; ( ) .

T :

	For he ear ended December 31,	
	2024 (RMB'000)	2023 (RMB'000)
Re en e from opera ing o ned hospi als	1,517,773	1,485,161
I : R	1,055,907	1,058,069
R	461,866	427,092
Re en e from o her heal hcare rela ed b siness	135,921	105,756
O her re en e no rela ed o heal hcare b siness	595	5,349
To al re en e	1,654,289	1,596,266

Management Discussion and Analysis

R

R (Billing Revenue)
G ’ G G
’ T
B R G

T B R G ’ :

	For the year ended December 31,	
	2024	2023
	(RMB’000)	(RMB’000)
Billing Revenue from owned hospitals	1,582,054	1,537,406
Including: R	1,107,269	1,095,073
R	474,785	442,333
Less: Variable considerations	64,281	52,245
Revenue from operating owned hospitals, net	1,517,773	1,485,161

F R P G ’ B R RMB1,582.1 ,
2.9% 2023,
. D R P ,
RMB64.3 , RMB12.0 2023,
B R 4.1% (2023: 3.4%).

Management Discussion and Analysis

The following table sets forth the Billing Revenue, Billing Revenue from Psychiatric Healthcare Business and Billing Revenue from Elderly Healthcare Business of the Group for the years indicated:

	For the year ended December 31,	
	2024	2023
	(RMB'000)	(RMB'000)
Billing Revenue from psychiatric healthcare business	**1,107,269**	1,095,073
Core	**745,959**	736,163
Ancillary	**361,310**	358,910
Billing Revenue from elderly healthcare business	**474,785**	442,333
Core	**379,458**	371,757
Ancillary	**95,327**	70,576

During the Reporting Period, the Group recorded revenue of RMB1,582.1 million, representing an increase of RMB44.6 million or 2.9% from 2023, primarily attributable to the contribution from Wenzhou Kangning Hospital, Wenzhou Oubei Yuguang Hospital, Yueqing Kangning Hospital, Yueqing Yuguang Hospital, Cangnan Yuguang Hospital, Linhai Kangning Hospital, Dongtou Kangning Hospital, Cangnan Kangning Hospital and Dongtou Rehabilitation Hospital, which commenced operations in 2023. The Group's gross profit margin remained relatively stable at 6.3% in 2024 and 2023, respectively.

The following table sets forth the Billing Revenue and Billing Revenue from Psychiatric Healthcare Business of the Group for the years indicated, by geographical region:

Management Discussion and Analysis

Psychiatric healthcare business

	For the year ended December 31,	
	2024	2023
Inpatients		
Inpatient beds	8,928	8,728
Effective inpatient beds	3,267,648	3,185,720
Utilization rate (%)	88.4	85.9
Number of inpatient admissions	2,889,163	2,736,235
Total inpatient revenue from psychiatric healthcare services (RMB'000)	844,076	841,617
Average inpatient revenue per admission (RMB)	292	308
Psychiatric healthcare inpatient revenue from medical insurance schemes (RMB'000)	89,656	87,951
Average psychiatric healthcare inpatient revenue per admission from medical insurance schemes (RMB)	31	32
Total inpatient revenue (RMB'000)	933,732	929,568
Total average inpatient spending per bed-day (RMB)	323	340
Outpatients		
Number of outpatient visits	474,581	395,277
Total outpatient revenue from psychiatric healthcare services (RMB'000)	45,078	45,025
Average outpatient revenue per visit (RMB)	95	114
Psychiatric healthcare outpatient revenue from medical insurance schemes (RMB'000)	128,459	120,480
Average psychiatric healthcare outpatient revenue per visit from medical insurance schemes (RMB)	271	305
Total outpatient revenue (RMB'000)	173,537	165,505
Total average outpatient spending per visit (RMB)	366	419
Total treatment and general healthcare services revenue (RMB'000)	889,154	886,642
Total pharmaceutical sales revenue (RMB'000)	218,115	208,431

Management Discussion and Analysis

During the Reporting Period, the Group recorded revenue of approximately RMB933.7 million, representing a decrease of approximately 0.4% from 2023. Specifically, revenue from Yunnan Kangning Hospital, Qingdao Kangning Hospital and Jinshan Hospital increased by approximately 5.6% from the corresponding period in 2023. Luoyang Kangning Hospital, Dalian Lushun Hospital and Changsha Yuhua Hospital recorded a decrease in revenue of approximately 5.0% from 2023. Wuhan Kangning Hospital, Chengdu Kangning Hospital and Shenyang Kangning Hospital recorded revenue contributions of approximately 84.3% (2023: 84.9%) of the Group's revenue.

During the Reporting Period, the Group recorded gross profit of approximately RMB173.5 million, representing a decrease of approximately 4.9% from 2023. Gross profit margin increased by approximately 12.6% from 2023 to approximately 20.1%. Operating profit margin increased by approximately 15.7% (2023: 15.1%) from the corresponding period in 2023.

During the Reporting Period, the Group recorded profit attributable to owners of the Company of approximately 0.3% from 2023. Gross profit margin increased by approximately 80.3% (2023: 81.0%), operating profit margin increased by approximately 4.6% from 2023, net profit margin increased by approximately 19.7% (2023: 19.0%) from the corresponding period in 2023. In addition, the Group recorded an increase in net profit margin attributable to owners of the Company of approximately 9.6% (2023: 9.5%), and an increase in net profit margin attributable to owners of the Company after deducting non-recurring profit or loss of approximately 74.0% (2023: 72.8%).

Management Discussion and Analysis

Elderly healthcare business

	For the year ended December 31,	
	2024	2023
Inpatients		
I[illegible]	2,580	2,540
E[illegible]	944,280	927,100
U[illegible] *(%)*	96.1	79.3
N[illegible]	907,255	735,131
T[illegible] *(RMB'000)*	346,074	304,856
A[illegible] *(RMB)*	382	415
P[illegible] *(RMB'000)*	93,599	84,639
A[illegible] *(RMB)*	103	115
Total inpatient revenue *(RMB'000)*	439,673	389,495
Total average inpatient spending per bed-day *(RMB)*	485	530
Outpatients		
N[illegible]	83,661	105,293
T[illegible] *(RMB'000)*	15,632	23,174
A[illegible] *(RMB)*	187	220
P[illegible] *(RMB'000)*	19,480	29,664
A[illegible] *(RMB)*	233	282
Total outpatient revenue *(RMB'000)*	35,112	52,838
Total average outpatient spending per visit *(RMB)*	420	502
Total treatment and general healthcare services revenue *(RMB'000)*	361,706	328,030
Total pharmaceutical sales revenue *(RMB'000)*	113,079	114,303

Management Discussion and Analysis

D R P B R RMB439.7
12.9% 2023, 23.4%
W O Y G H , C Y H Y Y H . I
B R 92.6% (2023: 88.1%) B R

D R P B R RMB35.1
33.5% 2023, 20.5%
16.3%
P C Y H . O B R
7.4% (2023: 11.9%) B R

D R P B R
10.3% 2023,
B R 76.2% (2023:
74.2%), B R 1.1%
2023, 23.8% (2023: 25.8%) B R . I
B R B R
21.3% (2023: 21.7%), B R
B R 55.5% (2023:
56.1%).

C G ’
T G ’ :

	For he ear ended December 31, 2024 (RMB’000)	2023 (RMB’000)
P	340,120	365,896
E	464,874	435,287
D	127,032	121,071
C	68,571	65,183
T	16,112	21,092
O	108,708	99,391
Cos of re en e of o ned hospi als	**1,125,417**	1,107,920

Management Discussion and Analysis

During the Reporting Period, the Group recorded revenue of approximately RMB1,125.4 million, representing a year-on-year increase of 1.6% from 2023. In particular: (i) revenue from our self-operated hospitals increased by 7.0% from 2023; (ii) revenue from our managed hospitals increased by 6.8% from 2023; and (iii) revenue from our outpatient clinics decreased by 4.9% from 2023.

For the Reporting Period, the Group's gross profit margin was 30.2% (2023: 33.0%). The Group's net profit margin was 41.3% (2023: 39.3%). The Group's adjusted net profit margin was 11.3% (2023: 10.9%).

Revenue

The Group's revenue is derived from the provision of medical services at our hospitals and outpatient clinics, which is recognized when the relevant medical services are rendered to patients. During the Reporting Period, the Group recorded revenue from our self-operated hospitals of approximately RMB135.9 million, representing a year-on-year increase of RMB90.1 million (2023: RMB64.4 million).

Other Income

The Group's other income mainly consisted of government grants. During the Reporting Period, the Group recorded other income of approximately RMB0.6 million (2023: RMB5.3 million).

Cost of Revenue and Cost of Materials

During the Reporting Period, the Group's cost of revenue was approximately RMB438.4 million, representing a year-on-year increase of 6.6% from 2023. The Group's cost of materials was approximately RMB392.4 million, representing a year-on-year increase of 4.0% from 2023. The Group's cost of revenue and cost of materials are set out below:

	For the year ended December 31,	
	2024	2023

Management Discussion and Analysis

D... R... P... ... G... ... 26.5% (2023: 25.8%), ... 0.5... 2023.

T... S...

D... R... P... ... G... ... RMB12.3 ... (2023: RMB6.5 ...), ... RMB4.9 ... 2023.

S... E...

D... R... P... ... G... ... RMB10.0 ... (2023: RMB17.1 ...). T... ... G... ... 0.7% (2023: 1.2%).

A... E...

D... R... P... ... G... ... T... ... G...:

	For the year ended December 31,	
	2024 (RMB'000)	2023 (RMB'000)
E...	133,002	117,426
D...	30,792	29,101
C...	9,037	19,853
T...	4,978	4,725
O...	49,537	41,921
To al adminis ra i e e penses	227,346	213,026

D... R... P... ... G... ... RMB227.3 ... , ... 6.7% ... 2023, ... 13.3% ... 2023. T... ... G... 15.0% (2023: 14.3%).

Management Discussion and Analysis

Revenue Decrease Explanation

During the Reporting Period, the Group's revenue increased by approximately RMB4.1 million, or 12.5%, from approximately RMB32.5 million in 2023 to approximately RMB36.5 million in 2024, primarily due to the increase in the number of patient visits and the increase in the average revenue per patient visit. The following table sets forth the breakdown of revenue by service lines for the periods indicated:

	For the year ended December 31,	
	2024	2023
	(RMB'000)	(RMB'000)
Consultation	25,088	20,552
Diagnosis	9,827	8,436
Comprehensive Inspection	1,604	3,427
Others		51
Total	36,519	32,466

During the Reporting Period, the Group's revenue increased by approximately RMB4.1 million, or 12.5%, from approximately RMB32.5 million in 2023 to approximately RMB36.5 million in 2024, primarily due to the increase in the number of patient visits and the increase in the average revenue per patient visit. The Group's gross profit increased by approximately 2.4% (2023: 2.2%), primarily due to the increase in the number of patient visits and the increase in the average revenue per patient visit.

Management Discussion and Analysis

F E N

O T :

	For the year ended December 31,	
	2024 (RMB'000)	2023 (RMB'000)
I	-3,123	-5,266
F	157	-4
B	33,143	30,180
I	8,458	9,755
I	7,900	5,694
O	1,058	1,093
Finance expenses, net	47,593	41,452

D R P G RMB47.6 , RMB6.1 2023, RMB5.2 2023.

Management Discussion and Analysis

Income Tax Expense

Our income tax expense for the years ended December 31, 2024 and 2023 was as follows:

	For the year ended December 31,	
	2024	2023
	(RMB'000)	(RMB'000)
Subsidiaries subject to EIT	-1,089	-6,465
Deferred tax	1,844	698
Income tax refund		-300
	755	-6,067

During the Reporting Period, we paid dividends of RMB0.8 million.

Gearing Ratio

During the Reporting Period, we had net cash of RMB26.5 million (2023: RMB9.4 million).

Asset Pledge

During the Reporting Period, we had pledged deposits of RMB16.5 million (2023:), which were pledged to China Construction Bank (Asia) Corporation Limited. RMB10.8 million of the pledged deposits will be released upon the repayment of RMB5.7 million.

Management Discussion and Analysis

Non-operating Income and Expenses

For the year ended December 31, 2024 and 2023, the Group recorded non-operating income of RMB1.5 million and RMB9.5 million, respectively, and non-operating expenses of RMB8.8 million and RMB11.8 million, respectively. The table below sets forth the breakdown of non-operating income and expenses for the periods indicated:

	For the year ended December 31,	
	2024 (RMB'000)	2023 (RMB'000)
Government grants	86	566
Donations	47	5,975
Others	1,396	3,004
Non-operating income	**1,529**	**9,545**
Loss on disposal of property, plant and equipment	1,117	291
Donations	2,698	4,494
Expenses for social welfare activities	2,669	3,830
Others	2,299	3,201
Non-operating expenses	**8,783**	**11,816**

Donations recorded by Renhe Pharmacy, a subsidiary of the Group, decreased by RMB1.5 million, or 35.7%, from RMB4.2 million in 2023 to RMB2.7 million in 2024, primarily due to a decrease in donations to Guangdong Provincial Charity Federation from RMB5.9 million in 2023 to RMB4.2 million in 2024. Donations recorded by Renhe Pharmacy decreased by RMB3.0 million, or 71.4%, from RMB4.2 million in 2023 to RMB1.2 million in 2024, primarily due to a decrease in donations to Guangdong Provincial Charity Federation from RMB1.8 million in 2023 to nil in 2024.

Income Tax Expenses

Renhe Pharmacy recorded income tax expenses of RMB17.7 million in 2024 (2023: RMB12.3 million), representing an effective tax rate of 44.5% in 2024 and 2023. In 2024 and 2023, the effective tax rate was higher than the statutory tax rate of 25% primarily because Renhe Pharmacy recorded losses in 2024 and 2023, for which no deferred tax assets were recognized, and 26.0% and 12.4%, respectively, of the losses were attributable to non-controlling interests.

Managemen Disc ssion and Anal sis

Financial Posi ion

I .

A D. 31, 2024, RMB50.6 (D. 31, 2023: RMB60.6),

A. R.

A D. 31, 2024, RMB571.8 (D. 31, 2023: RMB420.4), 36.0% D. 31, 2023,

D. R. P., G.' 54 (2023: 46).

O. R. B.

A D. 31, 2024, RMB96.1 (D. 31, 2023: RMB79.5).

L. E. I.

A D. 31, 2024, RMB99.4 (D. 31, 2023: RMB139.1), H. H. M. C., L. RMB21.6 G. R. P. C. H. K. H. C., L. RMB10.8 .

O. N. F. A.

A D. 31, 2024, RMB36.8 (D. 31, 2023: RMB65.1), G.' C. J. M. & H. S. I. E. I. F. P. (L. L. P.)(重慶金浦醫療健康服務產業股權投資基金合夥企業(有限合夥)).

F. A.

A D. 31, 2024, RMB889.5 (D. 31, 2023: RMB794.9), RMB115.9 L. C. H. R. P. .

Management Discussion and Analysis

Cash and Bank Balances

As at December 31, 2024, the Group's cash and bank balances amounted to RMB185.2 million (as at December 31, 2023: the Group's cash and bank balances amounted to RMB187.0 million). The cash and bank balances of the Group were mainly denominated in RMB, HKD and USD.

Restricted Cash Assets

As at December 31, 2024, the Group's restricted cash assets amounted to RMB161.8 million (as at December 31, 2023: RMB189.1 million), mainly including the Group's restricted cash assets amounted to RMB36.1 million.

Investment Assets

As at December 31, 2024, the Group's investment assets amounted to RMB291.5 million (as at December 31, 2023: RMB320.3 million), mainly including the Group's investment assets amounted to RMB24.9 million as at December 31, 2024.

Goodwill

As at December 31, 2024, the Group's goodwill amounted to RMB114.2 million (as at December 31, 2023: RMB119.9 million), mainly including the goodwill amounted to RMB5.7 million arising from the acquisition of Jiangsu Hengyi Hospital.

Long-term Receivables and Equity Investments

As at December 31, 2024, the Group's long-term receivables and equity investments amounted to RMB150.4 million (as at December 31, 2023: RMB175.9 million), mainly including the Group's long-term receivables amounted to RMB11.6 million as at December 31, 2024 and the Group's equity investments amounted to RMB36.9 million as at December 31, 2024.

Deferred Tax Assets

As at December 31, 2024, the Group's deferred tax assets amounted to RMB56.2 million (as at December 31, 2023: RMB45.1 million), mainly including the deferred tax assets amounted to RMB6.5 million arising from the Group's tax losses.

Accounts Payable

As at December 31, 2024, the Group's accounts payable amounted to RMB131.9 million (as at December 31, 2023: RMB110.1 million).

Receipts in Advance and Contract Liabilities

As at December 31, 2024, the Group's receipts in advance and contract liabilities amounted to RMB21.3 million (as at December 31, 2023: RMB26.6 million).

Management Discussion and Analysis

Overview

As at December 31, 2024, the Group had cash and cash equivalents of RMB81.3 million (as at December 31, 2023: RMB150.3 million), mainly deposited in Qingyang Hengli, Linkou Kanghe Hospital and Changhua Kanghe Hospital.

Liquidity and Capital Resources

The following table sets forth a summary of the Group's cash flows:

	For the year ended December 31,	
	2024 (RMB'000)	2023 (RMB'000)
Net cash generated from operating activities	99,639	265,033
Net cash used in investing activities	-172,055	-215,017
Net cash (used in)/generated from financing activities	-76,917	96,107
Net (decrease)/increase in cash and cash equivalents	-149,491	146,127

Net Cash Generated from Operating Activities

During the Reporting Period, the net cash generated from operating activities was RMB99.6 million, which was primarily attributable to (i) profit before income tax of RMB50.4 million, (ii) depreciation and amortization of RMB43.0 million, and (iii) changes in working capital of RMB154.8 million. Net cash generated from operating activities increased by 62.4% from 2023, which was primarily attributable to the increase in trade payables from RMB134.9 million as at December 31, 2024 to RMB177.6 million as at December 31, 2023.

Net Cash Used in Investing Activities

During the Reporting Period, the net cash used in investing activities was RMB172.1 million, which was primarily attributable to the payment for the acquisition of property, plant and equipment of RMB192.2 million for the construction of Liuying Hengli, Qingyang Hengli, Linkou Kanghe Hospital, Jinshan Hengli and Linkou Kanghe Hospital.

Net Cash Generated from Financing Activities

During the Reporting Period, the net cash used in financing activities was RMB-76.9 million.

Management Discussion and Analysis

S I A D

T G R P .

A L P D G B

Indebtedness

B . B

A D 31, 2024, G RMB946.2 (D 31, 2023: RMB864.7), RMB367.0 RMB448.5 R P .

C L

A D 31, 2024, G G .

A P

D R P , G ' W K H W Q L D N . 826751, W Q L D N . 826750, (2016) W R E R N . 0010144, (2016) W R E R N . 0010142, (2021) W R E R N . 0081628, W G Y (2015) N . 1-11836, W G Y (2015) N . 1-11833 M B . W L S , (2017) C C R E R N . 0018361 ICBC B . O S . A D 31, 2024, RMB430.7 . L Y H (2020) W R E R N . 0068897 BOCOM W C C S . A D 31, 2024, RMB115.6 . J S H (2022) J R E R N . 0002503 J N . 331122202000043 J R C B . W S . A D 31, 2024, RMB25.0 . Q Y H (2022) Q R E R N . 0045588 C CITIC B . W R R S . A D 31, 2024, RMB58.3 .

Management Discussion and Analysis

Liquidity

The Group generally finances its operations with internally generated cash flows. As at December 31, 2024, the Group had cash and cash equivalents of RMB26.7 million, and net current assets of RMB151.3 million.

Financial Resources

For the purpose of financing the Group's operations, expansion and investments, the Group may from time to time obtain bank borrowings, lease liabilities, and other borrowings. The Company's

The Group's cash and cash equivalents are mainly denominated in HKD and RMB. The Group's

As at December 31, 2024, the Group's

Gearing Ratio

As at December 31, 2024, the Group's gearing ratio (calculated as total liabilities divided by total assets) was 55.3% (December 31, 2023: 53.8%).

Employees, Remuneration and Training

As at December 31, 2024, the Group had 4,869 employees (December 31, 2023: 4,765 employees). During the Reporting Period, the total remuneration (including Directors' remuneration) was RMB644.1 million (2023: RMB607.4 million). The

RMB132.3 million (

Group). The

Managemen Disc ssion and Anal sis

E I S

I G C E I S Y 2018 W K H C ., L . (**Eq i Incen i e Scheme**), C 2017 J 13, 2018. I C ' A , B C , E I S C ' E I S , B J 24, 2021. U C M 29, 2018, M 30, 2018, M 14, 2021, J 18, 2021 J 25, 2021.

U E I S , 165 , 1,818,529 . P 23 , 180,516 . P ( ) 13 , 540,229 . A 8 , 79,274 . A E I S 193 , 2,460,000 . T 3.39% C 48 RMB10.47 .

A 2,460,000 E I S J 18, 2021, R P E I S . T , E I S .

Managemen Disc ssion and Anal sis

T E I S :

(1) P

T E I S C , C ' G , S ' C ' C ' C ' T E I S S ' PRC C L A A .

(2) S P

( ) S P

A P G G E I S .

P D , S , G ( ), ( ), , B , B P 36 E I S .

( ) L P E I S

T P B .

Management Discussion and Analysis

(3) Development Strategy and Business Plan

(1) Future Development Strategy

To continue to implement the hospital's development strategy, and to

Managemen Disc ssion and Anal sis

(4) V E I S

( ) V E I S

T E I S 10 2017 (. A 26, 2018), E I S . A E I S 3 .

( ) L E I S

T I S P 48 P I S .

( ) U E I S

I S 48 (J 28, 2022) (J 29, 2018); I S E I S .

(5) G E I S

( ) T P P P .

( ) T C D N P .

( ) T P D N C .

( ) W C , P I S ( ) C C .

( ) T C E I S P P S P .

Management Discussion and Analysis

(6) Grant of Restricted Shares under the 2024 Restricted Share Incentive Scheme

(a) The Grant of Restricted Shares under the 2024 Restricted Share Incentive Scheme: The Grant Price of Restricted Shares under the 2024 Restricted Share Incentive Scheme is RMB10.47 per Share; the Grant Price of Restricted Shares under the 2024 Restricted Share Incentive Scheme is RMB10.47 per Share.

(b) Basis for Determining the Grant Price of Restricted Shares under the 2024 Restricted Share Incentive Scheme

Based on the principle of combining incentives with constraints, the Grant Price of Restricted Shares under the 2024 Restricted Share Incentive Scheme is RMB10.47 per Share, which is not less than the higher of (Focused Incentive, Effective Incentive):

(a) 50% of the average trading price of the Company's H Shares on the Hong Kong Stock Exchange for the 60 trading days prior to the date of the Announcement (i.e. May 29, 2018), i.e. HK$40.00 per Share (converted into RMB32.50 per Share);

(b) 50% of the average trading price of the Company's H Shares on the Hong Kong Stock Exchange for the 120 trading days prior to the date of the Announcement.

(c) Grant Price of Restricted Shares under the 2024 Restricted Share Incentive Scheme

The Grant Price of Restricted Shares under the 2024 Restricted Share Incentive Scheme is 32.22% of the average trading price of the Company's H Shares on the Hong Kong Stock Exchange for the 120 trading days prior to the date of the Announcement, i.e. RMB10.47 per Share.

Management Discussion and Analysis

D[illegible] D[illegible] 31, 2024, [illegible] I[illegible] S[illegible] E[illegible] I[illegible] S[illegible] [illegible]:

Name/Category of Grantee	Date of Grant	Vesting Date (Unlocking Date)	Grant Price (RMB/Share)	Balance of Incentive Shares Granted but not Vested as at January 1, 2024	Balance of Incentive Shares Granted and Vested as at January 1, 2024	Granted during the Reporting Period	Vested (Unlocked) during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Balance of Incentive Shares Granted but not Vested as at December 31, 2024
D[illegible]										
Ms. WANG L[illegible]	J[illegible] 18, 2021	J[illegible] 28, 2022	10.47		248,328					
S[illegible]										
Ms. XIE T[illegible]	J[illegible] 18, 2021	J[illegible] 28, 2022	10.47		4,776					
O[illegible]										
Ms. XU Y (S[illegible] Ms. WANG H[illegible])	J[illegible] 18, 2021	J[illegible] 28, 2022	10.47		28,653					
Ms. WANG H[illegible] (Y[illegible] S[illegible] Ms. WANG L[illegible])	J[illegible] 18, 2021	J[illegible] 28, 2022	10.47		95,511					
Ms. WANG B[illegible] (R[illegible]) (N[illegible] Ms. WANG L[illegible] Ms. WANG H[illegible])	J[illegible] 18, 2021	J[illegible] 28, 2022	10.47		4,776					
Ms. XU Q[illegible] (R[illegible]) (Y[illegible] S[illegible] Ms. XU Y)	J[illegible] 18, 2021	J[illegible] 28, 2022	10.47		4,776					
Ms. GUAN W[illegible] (Y[illegible] B[illegible] Ms. GUAN W[illegible])	J[illegible] 18, 2021	J[illegible] 28, 2022	10.47		19,102					
Ms. SUN F[illegible] (R[illegible])	J[illegible] 18, 2021	J[illegible] 28, 2022	10.47		14,327					
Ms. SUN H[illegible] (N[illegible] Ms. WANG L[illegible] Ms. WANG H[illegible])	J[illegible] 18, 2021	J[illegible] 28, 2022	10.47		30,563					

Management Discussion and Analysis

Name/Category of Grantee	Date of Grant	Vesting Date (Unlocking Date)	Grant Price (RMB/Share)	Balance of Incentive Shares Granted but not Vested as at January 1, 2024	Balance of Incentive Shares Granted and Vested as at January 1, 2024	Granted during the Reporting Period	Vested (Unlocked) during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Balance of Incentive Shares Granted but not Vested as at December 31, 2024
Mr. HANG Li (Research Fellow) (Spouse of Mr. GUAN Wei)	June 18, 2021	June 28, 2022	10.47		4,776					
Senior Management (Total)	April 20, 2018	June 28, 2022	10.47		133,715					
	April 16, 2021	June 28, 2022	10.47		47,755					
Core Technology Personnel and Other Employees	April 20, 2018	June 28, 2022	10.47		1,605,540					
	April 26, 2019	June 28, 2022	10.47		180,516					
	April 16, 2021	June 28, 2022	10.47		36,886					
Total					2,460,000					

As at the End of the Reporting Period, the Directors, Supervisors and Senior Management of the Company [illegible]

Managemen Disc ssion and Anal sis

H S A Te. S

T C C L P' R C A C H S A Te. S 2023 C S 27, 2023. U C S 8, 2023 C S 27, 2023, A 12, 2024, A 23, 2024 J 18, 2024.

P H S A Te. S C T H S A Te. S H S A Te. S C H S - S C C ' . S H S H S A Te. S 5% (3,730,015) C H S A Te. S . T B / H S A Te. S

U H S A Te. S ( ) 36 364,100 . T ( ) 36 616,000 . T ( ) 52 335,000 . A 7 75,000 . A H S A Te. S 101 1,240,100 . T 1.71% C ( ) . F C S 8, 2023 C S 27, 2023, A 12, 2024, A 23, 2024 J 18, 2024.

A R P , 3,730,015 H S A Te. S R P , 2,039,000 H S A Te. S .

Managemen Disc ssion and Anal sis

A HS A T S :

P

) T C ;

) T C S ;

) T C D ;
C
C ;
C
S C .

P

Managemen Disc ssion and Anal sis

S

T HS A To. S 3,730,015 HS 5%
( ) C L P D.

M P

T A S HS A To. S
C (A S HS A To.
S , A S) 1% C
.

V

T HS HS A To. S
A L P B / D .

P

T A S HS A To. S B
/ A (A L). T
HS , HS A To. S
. S , A HS A To.
S .

R S

T HS A To. S A D (. S 27, 2023)
. A L P D , HS A To.
S 8 7 .

Management Discussion and Analysis

D... D... 31, 2024, ... H S ... A ... T... S... :

Name/Category of Grantee	Date of Grant	Grant Price (RMB/Share)	Number of Shares Granted but not Vested as at January 1, 2024	Number of Shares Granted during the Reporting Period	Closing Price of Relevant Shares Immediately before the Date of Grant of Awards during the Reporting Period (HK$/Share)	Fair Value of Relevant Shares on the Date of Grant during the Reporting Period (Note 1) (HK$/Share)	Number of Shares Vested during the Reporting Period	Weighted Average Closing Price of Relevant Shares Immediately before the Date of Vesting of Awards during the Reporting Period (HK$/Share)	Number of Shares Lapsed during the Reporting Period	Number of Shares Cancelled during the Reporting Period	Number of Shares Granted but not Vested as at December 31, 2024
D...											
WANG L...	A... 23, 2024	0		99,300	11.08	10.8		13.25			99,300
	A... 23, 2024	7		50,000	11.08	10.8		13.25			50,000
WANG J	A... 23, 2024	0		59,100	11.08	10.8		13.25			59,100
	A... 23, 2024	7		50,000	11.08	10.8		13.25			50,000
Five Individuals with Highest Emoluments (Excluding Directors)											
XU X...	A... 23, 2024	7		30,000	11.08	10.8		13.25			30,000
XU Y	A... 12, 2024	0		57,500	11.42	11.2		13.25			57,500
	A... 23, 2024	7		30,000	11.08	10.8		13.25			30,000
YE M...	A... 12, 2024	0		21,000	11.42	11.2		13.25			21,000
Other Employees (Excluding Directors and Five Individuals with Highest Emoluments)											
E...	A... 12, 2024	0		126,200	11.42	11.2		13.25			126,200
	A... 23, 2024	7		395,000	11.08	10.8		13.25			395,000
	J... 18, 2024	7		322,000	11.90	11.94		13.33			322,000
T...				1,240,100							1,240,100

Managemen Disc ssion and Anal sis

N 1: F R
P N 12 S

N 2: T H S A T S :

Ves ing Period	Ves ing Time	Ves ing Percen age
F	F 12	25%
S	F 12 24	25%
T	F 24 36	25%
F	F 36 48	25%

E T P

T C . T C
( )

Repor of he Board

T B G D 31, 2024.

P A

T G C . D C N F S E E S G

D G M D A E R P R B M . C S

B R

T G M D A T G G M D A B O

F H R

T G D 31, 2024 F H . T G ' D 31, 2024

I R

P C G R C S I R

E P

T G . W G T G . D C E , S G R C HKEX H K S . E

Repor of he Board

C R L R

T C PRC C L, H K L R, SFO, H K C O, C . T C S , B D .

L G M H L PRC (《中華人民共和國精神衛生法》), L P ' R C P B M H C (《中華人民共和國基本醫療衛生與健康促進法》), M R M I (《醫療機構管理條例》) R I M R M I (《醫療機構管理條例實施細則》).

T G . I

T C . T D G 2024 L P D .

P I P

F D 31, 2024, G .

U P I P O

T H S M B H K S E N 20, 2015. T C , HK$693.2 (RMB580.7) . O M 30, 2017 M 23, 2018, B . T C P N 10, 2015 B .

Repor of he Board

P F D

T B P F D . B 2024 (L P D C 72,670,000), RMB3 (-), 10 . T RMB21,801,000 (-), 33.2% (2024 P F D RMB32,701,000, 49.8%). T P F D RMB. T D S RMB, H S H K . T P F D H K H K RMB P ' B C P F D (C). T 2024 C .

S P F D P F D J 28, 2025. T C , , H P F D .

A D 31, 2024, S .

T R E

I E I T L P ' R C (《中華人民共和國企業所得税法》) J 1, 2008, C 10% S H S . A H S S , HKSCC N L , , , S S . T , , S . I H S S . T C S H S .

Repor of he Board

I HS H K M
10% PRC C
S 10%. S
HS 10% PRC.
C S
10%. I HS
10% C
S C H K
I S L . T C
S HS 10%
20% PRC C
I HS
20% PRC.
PRC, C
20%.

S C

D C R P N 5
F S (36)

R C , A 26, 2024
C CSRC A 26, 2024 2,500,000
D S HS .

T CSRC S C
J 28, 2024
. S C L C H K S E
2,500,000 H S (Con er ed H Shares). O J 19, 2024, H
K S E S . T C HS
HS A 23, 2024, C HS H K S E
9:00 . A 26, 2024.

P C , A 26, 2024, J 3, 2024, J 19, 2024 A 23, 2024
HS .

R

D G R P C S
C O ' E N 5 F S (37), (39) (40)

D R

A D 31, 2024, G RMB344.3 .

P , P E

D G R P N
V F S (12)

Repor of he Board

M. C S

F D 31, 2024, G ' 2.0% 3.9%, G '. F D 31, 2024, G ' 30% G '. T G . D , C .

F D 31, 2024, G ' 7.9% 31.1%, G '

N D , S (H K L R), S , D , 5% C ' ( ) G ' D 31, 2024.

S I

D R P , G .

D I

F D 31, 2024, G .

E A

F D 31, 2024, G , .

D

F D 31, 2024, G RMB2.7 .

S

D C ' D 31, 2024 N F S E E S G .

Repor of he Board

D

T D R P :

E ec i e Direc ors

M . GUAN W (C)
M . WANG L
M . WANG J

Non-e ec i e Direc ors

M . QIN H
M . LI C

Independen Non-e ec i e Direc ors

M . HONG W
M . JIN L
M . CHAN S K H

S

T S R P :

M . XU N (C)
M . XU Y
M . XIE T
M . QIAN C
M . HANG Y

Repor of he Board

B R A K I F P

F G D 31, 2024, F H M D A

D ' S ' I T , A C S

S R B C T N F S R C D S , D S , D 31, 2024 R P .

C S ' I C S

S R B C T N F S R C S G C R P .

M C

D R P , C C .

Repor of he Board

N - A

P N - A , C S / ( ) ( ) (G) , G ' (G) G . D N - A D 31, 2024, C O N (R C S B) C S .

T C C S N - A D 31, 2024 . T - D C S ' N - A D 31, 2024.

D ' C E ' E F I H E

P D ' D 31, 2024 N F S R . T C C G R .

N D R P .

D ' I C B

D R P , D (H K L R) G .

Repor of he Board

D', S' C E' I S

A D 31, 2024, D, S C S, S C (P XV SFO) C H K S. E D 7 8 P XV SFO (/ SFO), C 352 SFO, C H K S. E M C :

Name	Class of Shares	Na re of In eres	N mber of Shares	To al N mber of Shares	Appro ima e Percen age in Shares of he Same Class[1]	Appro ima e Percen age of he Compan 's To al Iss ed Share Capi al[1]
M. GUAN W [2]	D S	B	18,350,250(L)	21,744,750(L)	41.21%	29.92%
		I	3,394,500(L)			
	H S	I	149,300(L)	149,300(L)	0.75%	0.21%
M. WANG L [2]	D S	B	3,394,500(L)	21,744,750(L)	41.21%	29.92%
		I	18,350,250(L)			
	H S	B	149,300(L)	149,300(L)	0.75%	0.21%
M. WANG J	H S	B	159,100(L)	159,100(L)	0.80%	0.22%
	D S	B	100,000(L)	100,000(L)	0.19%	0.14%
M. XU Y [3]	D S	I	4,540,000(L)	4,540,000(L)	8.61%	6.25%

N :

(L): L

(1) T 52,760,000 D S 19,910,000 H S (72,670,000 S) C D 31, 2024.

(2) M. GUAN W M. WANG L , M. GUAN W S M. WANG L , M. WANG L S M. GUAN W P XV SFO.

(3) M. XU Y 50% S J E M C (L P) (上海金浙企業管理中心(有限合夥)) S J E M C (L P) (上海金浙企業管理中心(有限合夥)) W J E I P (L P). T , P XV SFO, M. XU Y D S C .

Repor of he Board

S D 31, 2024, . B D S C S S C (P XV SFO) : ( ) C H K S. E D 7 8 P XV SFO (D S C SFO); ( ) C S 352 SFO; ( ) C H K S. E M C.

I S S

A D 31, 2024, C S 336 SFO D (D S C) C H K S. E D 2 3 P XV SFO, 5% C :

Name	Class of Shares	Na re of In eres	N mber of Shares	Appro ima e Percen age in Shares of he Same Class[1]	Appro ima e Percen age of he Compan 's To al Iss ed Share Capi al[1]
C E R I I F C., L. (中央企業鄉村產業投資基金股份有限公司)	D S	B	7,466,666(L)	14.15%	10.27%
S J E M C. (L P) (上海金淅企業管理中心(有限合夥))[2]	D S	I	4,540,000(L)	8.61%	6.25%
FAN Y [2]	D S	I	4,540,000(L)	8.61%	6.25%
SUN J [2]	D S	I	4,540,000(L)	8.61%	6.25%
S J J E. I M C., L. (上海金浦健服股權投資管理有限公司)[2]	D S	I	4,540,000(L)	8.61%	6.25%
W J E. I P (L P) (溫州金寧股權投資合夥企業(有限合夥))	D S	B	4,540,000(L)	8.61%	6.25%
XU Y [6]	D S	I	5,785,350(L)	10.97%	7.96%
S T I L.P. (上海檀英投資合夥企業(有限合夥))	D S	B	4,519,003(L)	8.57%	6.22%

Repor of he Board

Name	Class of Shares	Na re of In eres	Nmber of Shares	Appro ima e Percen age in Shares of he Same Class[1]	Appro ima e Percen age of he Compan 's To al Iss ed Share Capi al[1]
S L. I L.P. (上海樂進投資合夥企業(有限合夥))[3]	D S	I	4,519,003(L)	8.57%	6.22%
LIN L..	D S	I	6,506,309(L)	12.33%	8.95%
S L V I M C., L (上海正心谷投資管理有限公司) (S S I M C., L)[4]	D S	I	6,506,309(L)	12.33%	8.95%
W I C., L. (萬得信息技術股份有限公司)	D S	I	3,333,000(L)	6.32%	4.59%
S H. E M C. (L P) (上海荷花緣企業管理中心(有限合夥))	D S	I	3,333,000(L)	6.32%	4.59%
W I E. I (J) P (L P) (萬得影響力股權投資(嘉興) 合夥企業(有限合夥)) (Wind In es men)	D S	B	3,333,000(L)	6.32%	4.59%
CITIC S. I C., L. (中信証券投資有限公司)	D S	B	2,780,000(L)	5.27%	3.83%
CITIC S. C L (中信証券股份有限公司)[5]	D S	I	2,780,000(L)	5.27%	3.83%
O. M A LLC	H S	I	1,454,000(L)	7.30%	2.00%
O. M C LLC	H S	I	2,150,900(L)	10.80%	2.96%
O. M P M F L	H S	B	1,279,900(L)	6.43%	1.76%
O. M P II, L.P.	H S	B	1,052,000(L)	5.28%	1.45%
UBS G AG	H S	I	1,029,400(L)	5.17%	1.42%
OU H (鄒海麗)	H S	B	1,680,000(L)	8.44%	2.31%
WANG H [6]	D S	B	3,984,350(L)	10.97%	7.96%
		I	1,801,000(L)		
	H S	B	309,000(L)	1.55%	0.43%
K S H L	H S	B	2,986,300(L)	15.00%	4.11%
T T C (HK) L	H S	T	2,986,300(L)	15.00%	4.11%

Repor of he Board

N :

(L): L

(1) T 52,760,000 D S 19,910,000 H S (72,670,000 S) C D 31, 2024.

(2) FAN Y 50% S J E M C (L P) (上海金淅企業管理中心(有限合夥)) S J E M C (L P) (上海金淅企業管理中心(有限合夥)) W J E I P (L P) (溫州金寧股權投資合夥企業(有限合夥)). SUN J 33.94% W J E I P (L P) (溫州金寧股權投資合夥企業(有限合夥)). S J J E I M C ., L . (上海金浦健服股權投資管理有限公司) W J E I P (L P). T P XV SFO, FAN Y , S J E M C (L P) (上海金淅企業管理中心(有限合夥)), SUN J S J J E I M C ., L . (上海金浦健服股權投資管理有限公司) D S W J E I P (L P) (溫州金寧股權投資合夥企業(有限合夥)) C .

(3) S L. I L.P. (上海樂進投資合夥企業(有限合夥)) 99.99% S T I L.P. (上海檀英投資合夥企業(有限合夥)). T P XV SFO, S L. I L.P. (上海樂進投資合夥企業(有限合夥)) D S S T I L.P. (上海檀英投資合夥企業(有限合夥)) C .

(4) S L V I M C ., L (上海正心谷投資管理有限公司) (S S I M C ., L (上海盛歌投資管理有限公司)) S Q I M P (L.P.) (上海乾剛投資管理合夥企業(有限合夥)) S T I L.P. (上海檀英投資合夥企業(有限合夥)). T P XV SFO, S L V I M C ., L D S S Q I M P (L.P.) (上海乾剛投資管理合夥企業(有限合夥)) (1,987,356 D S C) S T I L.P. (上海檀英投資合夥企業(有限合夥)) C .

(5) CITIC S. I C ., L .. (中信証券投資有限公司) CITIC S. C L (中信証券股份有限公司). T , CITIC S. C L (中信証券股份有限公司) D S CITIC S. I C ., L . (中信証券投資有限公司) C P XV SFO.

(6) M . WANG H N R. K I M L.P. (寧波仁愛康寧投資管理合夥企業(有限合夥)) N E K I M P (L P) (寧波恩慈康寧投資管理合夥企業(有限合夥)) 56.75% 37.10%, T P XV SFO, M . WANG H D S C . M . XU Y M . WANG H M . XU Y D S M . WANG H P XV SFO.

S D 31, 2024, D , (D , S C) , S S C D 2 3 P XV SFO, C S 336 SFO.

Repor of he Board

D ' S ' R A S D S

S E I S , R P C D , S , C (18) S , C .

C T

O A 12, 2024, R C B H S A T S , B (D) 99,300 57,500 A S M . WANG L , D C , M . XU Y , C , 156,800 H S , RMB0 S . T . HK$11.42, H S H K S . E A 11, 2024, 99,300 A S HK$1,134,006, 57,500 A S HK$656,650, HK$1,790,656. T A S M . WANG L M . XU Y C , C , C . T B A S M . WANG L M . XU Y H S A T S . F H S A T S , H S A T S . A

Repor of he Board

R C ' A 12, 2024
A S H S A T S (**Anno ncemen**). A
A A, A 12, 2024, B 59,100 H S M. WANG J ,
D C , RMB0 S (**Pre io s Gran**). O A 23, 2024,
H S A T S, B 50,000 A S M.
WANG J , D C , RMB7 S, 50,000 H S ,
RMB350,000 (**Gran**). T HK$11.08 H S
H K S E A 22, 2024, 50,000 A
S HK$554,000. T A S M. WANG J
C ,
C ,
C . T B
A S M. WANG J H S A T S .
F H S A T S H S A T S
. A M. WANG J D C , P G
G C C 14A H K L R .
P H K L R , P G
0.1%, P G
' C 14A H K L R . T
G 0.1%, P G G
12 . A
P G G 0.1% 5%,
G ( )
S ' C 14A H K L
R . F C ' A 23, 2024.

S B N F
S R
C 14A H K L R . A
C C 14A H K L R
C 14A H K L R .

Repor of he Board

P , , S R L S

D R P , / , , C , C 1,930,300 ,

Repor of he Board

C G

Repor of he Board

A

T BDO C S L P C P A LLP (BDO).

R C ' J 30, 2022 D 16, 2022, N 18, 2022.

D C S R C , B C LLP (S G P) (P C) . S P C 2021 , P C C ' J 30, 2022.

U A C , BDO C S L P C P A LLP C ' J 30, 2022, P C' ' C ' 2021 A G M S .

I C L P ' R C , H K L R A A C B D C ' 2021 A G M S D 16, 2022, BDO C S L P C P A LLP C ' H- 2022 C ' 2022. I C ' - 2022, C C ' 2022 C A S B E C ' 2022, C ' C ' C H K L R . T 2021 A G M S C ' 2022 A G M S .

E C .

F B
GUAN W
C

PRC
A 22, 2025

Repor of he S per isor Commi ee

T S :

I 2024, C L P , R C , A S C , S C D R P , S C , I .

D R P , S C , .

T S C : D , . T . T , . N .

I 2025, S C : F ; S ; T . T .

F S C
XU N
C

PRC
A 22, 2025

Corporate Governance Report

Corporate Culture

The Group's corporate culture is rooted in its core values, vision, and mission, which collectively guide its operations and strategic direction. These principles emphasize integrity, innovation, and a commitment to delivering high-quality healthcare services. The Group fosters a culture that values teamwork, continuous improvement, and patient-centered care, ensuring that all employees align with its long-term goals and contribute to its sustainable growth.

Values

Respect, Love, Sincerity, Harmony

We believe that respecting patients, colleagues, and partners is the foundation of trust. We provide care with love and compassion, treating every individual as we would our own family. We act with sincerity, ensuring transparency and honesty in all our interactions. Through harmony, we build a supportive and collaborative environment that enhances both patient outcomes and employee well-being.

Vision

A Benchmark Group in Medical Industry

We aspire to be a leading healthcare group that sets the standard for excellence in medical services. We are committed to continuous improvement, innovation, and delivering high-quality care that exceeds expectations. We strive to be a trusted partner for patients, communities, and healthcare professionals alike.

Mission

Build Diversified Medical Complex Platform, Medical Demand Driven

Build a diversified medical complex platform that integrates various healthcare services to meet the evolving needs of patients. We are driven by medical demand, ensuring that our services are tailored to address the most pressing healthcare challenges. We aim to provide comprehensive, accessible, and high-quality care that improves the health and well-being of our communities.

Corpora e Go ernance Repor

T B

Board Composi ion

A L R D B D D D D T D D S S M T B C ' T F B D T J 9, 2023 F B D T

A L R D B R 3.10 3.10A H K L R C D D B .

T C D H K L R T C D R 3.13 H K L R .

A D D B B ' I D A C N C R C S R M C .

T CG C D C T D C .

T C B T C D C C C ' B T B B .

Corpora e Go ernance Repor

R F D B

T B C . I - C D C B . T B .

T B C ( ), D . F A .

I , B A C , N C , R C S R . M C C . F

A D C S . T C D .

C C E

D R P , M . GUAN W D B , M . WANG L D C .

R D C E

A L P D , M . GUAN W M . WANG L . S B .

R F S M

T C B . A L P D C . D D , S S M . T B . T B . T C . T B C ,

Corpora e Go ernance Repor

C D, S S M

A L P D D, S C .

C D', S ' C E', B D

S D', S ' R P L P D, R 13.51B H K L R :

Name	Members of he Gro p	Posi ions held a members of he Gro p	Term of office
GUAN W	Q K H C., L.	E	F A 2011 D 2024
	Q K H C., L.	D	F D 2024
WANG L	W G F H C., L.	E, M	F M 2024
	B Y H C., L.	D	F M 2019 J 2024
	B Y H C., L.	E	F J 2024
	Q K P M C., L.	M	F N 2024
WANG J	Y G H M C., L.	E	F A 2024
	B Y H C., L.	D, M	F F 2023 J 2024
	B Y H C., L.	M	F J 2024
	Y G H S C., L.	D, M	F A 2024

S C D', S ' R 13.51B H K L R .

I C P D D

D R P, C D, A B H K L R . T B . T D :

D R P, D C , M . GUAN W , M . WANG L , M . WANG J , M . QIN H , M . LI C , M . HONG W , M . JIN L M . CHAN S K H D'

Corpora e Go ernance Repor

C M C

T C M C C D' S' . H D S D S M C R P . T C . A C S S . T C C' I C

C G

T C . T C C G C . T D C C G C T C C G C .

S C D S

E D (D) S C .

T A . N D S C C .

A S

T C C A S B E 2017, C O (C 622 H K) (**Companies Ordinance**).

Corpora e Go ernance Repor

A P

Acco n ing Policies

T A S B E B S , M F F 15, 2006 (he Acco n ing S andards for B siness En erprises).

T . T H K C O M 3, 2014. C H K C O .

Changes of Significan Acco n ing Policies

T N III F S C

A B M G M

T C B C.5.1 CG C . N B D C.5.3 CG C .

D R P , C 8 B D B :

Name of Direc ors	Nu mber of Board mee ings con ened/a ended
E ec i e Direc ors	
M . GUAN W *(C)*	8/8
M . WANG L	8/8
M . WANG J	8/8
Non-e ec i e Direc ors	
M . QIN H	8/8
M . LI C	8/8

Corpora e Go ernance Repor

Name of Direc ors	N mber of Board mee ings con ened/a ended
Independen non-e ec i e Direc ors	
M . HONG W	8/8
M . JIN	8/8
M . CHAN S K H	8/8

A D . T C C ,

M B D M B D . D B D . T B D .

D R P D :

Name of Direc ors	N mber of general mee ings con ened/a ended
E ec i e Direc ors	
M . GUAN W *(C)*	2/2
M . WANG L	2/2
M . WANG J	2/2
Non-e ec i e Direc ors	
M . QIN H	2/2
M . LI C	2/2
Independen non-e ec i e Direc ors	
M . HONG W	2/2
M . JIN	2/2
M . CHAN S K H	2/2

Corpora e Go ernance Repor

B C

T B , A C , N C , R C S R M C , B C A B C H K S E C ,

A C

T C A C R 3.21 R 3.22 H K L R , CG C A C B . T A C C ; C ; C ; B .

A A C D , M . HONG W (A C) M . JIN , D , M . LI C . F A C R P , 2023 2024 G .

T D A C R P :

Direc ors	N mber of mee ings con ened/a ended
M . HONG W (C)	4/4
M . JIN	4/4
M . LI C	4/4

Corpora e Go ernance Repor

R C

T C R C CG C
R C B . T
R C D
D
D
D
/ C 17 H K L R ;
D ;
C ;
B .

A R C D , M . JIN
L ( ), M . HONG W M . CHAN S K H . T R C
E.1.2( ) CG C (. B
D). T R C
R P , C
2023 H- I T P .

T D R C R P
:

Direc ors	N mber of mee ings con ened/a ended
M . JIN L *(C)*	2/2
M . HONG W	2/2
M . CHAN S K H	2/2

T G ' D C
D . T
/ . T
D D D '
B .

T D D 31, 2024 N F S
R .

Corpora e Go ernance Repor

S R M C

T C S R M C S R M C B T S R M C C ' C ; C '

A S R M C D , M . GUAN W ( ), D , M . QIN H , D , M . HONG W . T S R M C R P , G 2023 B T S R M C G ' s

T D S R M C R P :

Direc ors	N mber of mee ings con ened/a ended
M . GUAN W *(C)*	2/2
M . HONG W	2/2
M . QIN H	2/2

B D P

T B B . T C B I B C ' . T T B B . A :

Corpora e Go ernance Repor

The G rren Composi ion of he Board

Age	Gender	Years of ser ice as Direc or
30 49 (4)	F (37.5%)	1 5 (6)
50 (4)	M (62.5%)	6 10 (2)

T B 3 D 5 D . T B C B B B . T N C B D 31, 2024, B

G D W .

A D 31, 2024, G 4,869 ( ), 67.1% 32.9% . T G B ( ) G . T G R M M 《招錄管理辦法》. D G . D R P B

C G F

T B :

( ) C , CG C ;

( ) C , ;

( ) D ;

( ) D , S ;

( ) C ,

D R P B : (1) D ; (2) D , S ; (3) ; (4)

Corpora e Go ernance Repor

D ' A ' R F R R F S

T D D 31, 2024, C G G ' T D G T C B B C ' B T C B C ' .

T D G ' .

T C A ' R .

R M I C

T B S .

T C . A C T ' T A C W G ' A .

Corpora e Go ernance Repor

Corporate Governance Report

Senior Management's Remuneration

The Company's senior management, including Directors, Supervisors and senior management of the Company, whose remuneration for the year ended December 31, 2024 is set out below:

Remuneration band (RMB)	Number of individuals
0-700,000	5
700,001-1,400,000	8

Auditor's Remuneration

For the year ended December 31, 2024, the Company's auditor, BDO, provided the following services to the Company during the year ended December 31, 2024, and the remuneration paid to the Company's auditor is as follows:

Audit services	RMB2,438,000
Non-audit services (mainly consulting services for the preparation of the 2024 Interim Report)	RMB381,600

Joint Company Secretaries

Mr. WANG Jun and Mr. WONG Wai Chung Francis of the Company's joint company secretaries are responsible for the daily management of the Company's secretarial affairs. Mr. WONG Wai Chung Francis is a Chartered Secretary of The Chartered Governance Institute (formerly known as The Institute of Chartered Secretaries and Administrators) and The Hong Kong Chartered Governance Institute (formerly known as The Hong Kong Institute of Chartered Secretaries). The primary contact person of the Company is Mr. WONG Wai Chung Francis and Mr. WANG Jun (Secretary to the Board of Directors).

During the Reporting Period, the joint company secretaries have taken no less than 15 hours of relevant professional training in accordance with Rule 3.29 of the Hong Kong Listing Rules.

Corpora e Go ernance Repor

C S I R

T B T G

T C S ' C P S S P S ' C P , C

T C B S . C B B B , B

D R P , C . P C ' . I C @

T B S ' C P S ' C P C

S ' R

Proced res for Shareholder(s) o Con ene an E raordinar General Mee ing (EGM–)

S EGM :

S , 10% S B EGM . A , A , B EGM

I B EGM , B . C S .

I B EGM S 10% S S C EGM .

Corpora e Go ernance Repor

I S C EGM , C S .

I S C EGM S C . S 10% S 90 EGM . N S C S C .

P S ( ) P F P G M

W C , B , S C S 3% S C .

S 3% S 10 EGM. T 2 . T :

A :
N .1 S R
H R D
W , .
PRC
F : (86) 577 8878 9117
E : @

Corpora e Go ernance Repor

C C D

D R P C A

T C CSRC A 26, 2024 2,500,000 D S C H S . S A 23, 2024. F , T C B H S 2023 , 2024 H ' 2024 ' M 30, 2024. T B H S

B B A . T A O 30, 2024 S E C . F C O 30, 2024.

D P

T C . W C , 10% C ' . T C C ' 50% C ' S C ' C , ' . A C . A C S A S S C . N S C C .

T C ( ):

(I) ;

(II) ;

(III) ( )

T C RMB S . S C S RMB HKD. S HKD C ' S

Direc ors, S per isors and Senior Managemen

D

E ec i e Direc ors

Mr. GUAN Weili (管偉立), 55, B D C . H C . H C F 1996 D . M . G B D S 2014 C . P C , M . G W M H (溫州市精神病院), W , A 1987 D 1993,

M . G W M U (溫州醫科大學) (W M C (溫州醫學院)) W A 1987, . M . G W M B P (溫州市人事局) D 2007. M . G M . WANG L - M . XU Y .

Ms. WANG Lian e (王蓮月), 56, D C . S C . S . C J 1998 S 2011 D A 2013. M . W D S 2014 C . P C , A 1988 D 1997, W M H (溫州市精神病院),

M . W W M U (溫州醫科大學) (W M C (溫州醫學院)) W J 2004 P S W M C C P C (中共温州市委黨校) W J 2002, . S O E C X' J U (西安交通大學網絡教育學院), , J 2007. S C E I B S (中歐國際工商學院) S S 2006. S (二級心理諮詢師) M H R S S C (人力資源和社會保障部) D 2004. M . W M . GUAN W - M . XU Y .

Direc ors, S per isors and Senior Managemen

Mr. WANG Jian (王健), 40, D B C . H . M . W C J 2014 B C . M . W B C S 2014 C . H D C J 2023. P . C , J 2009 J 2014, (科員) (副主任科員) X R B C S R C (中國證券監督管理委員會廈門監管局) X . F F 2008 M 2009, F & Y H M LLP (安永華明會計師事務所(特殊普通合夥)), . F A 2005 F 2008, P C C P A L ,

M . W ' G S M P U (北京大學光華管理學院) B J 2005, . M . W (註冊會計師非執業會員) . C I C P A A 2010 M J PRC M 2014.

Direc ors, S per isors and Senior Managemen

Non-e eo i e Direc ors

Mr. QIN Hao (秦浩), 34,. G J 2021. H S L V I M C ., L (上海正心谷投資管理有限公司), J 2022. H S L V I M C ., L J 2017 D 2021.

M . Q P. U J 2014 . H F U J 2017 .

Mr. LI Changhao (李昌浩), 34,. G O 2021. H SDIC C . I F M C ., L . (國投創益產業基金管理有限公司) J 2022, . M . L N Y X E C ., L . (S S. E : 000862,) O 2023. S A 2023, W G C ., L . (S S. E : 601069,). H SDIC C . I F M C ., L . M 2014 D 2021. S J 2021, Y A C ., L . (S S. E : 000807.S ,). S A 2021, J . (L) L S T C ., L . (S S. E : 301509,).

M . L B. U P T S 2012. H Q M U L D 2013. M . L (CFA) C F A I A 2017, M H R S S P R C D 2017, (FRM) G A R P A 2018.

Direc ors, S per isors and Senior Managemen

Independen Non-e ec i e Direc ors

Ms. ZHONG Wen ang (鐘文堂), 35, G J 2020. S D C C , S I C C ., L . (上海信公企業管理諮詢有限公司), F 2019, . F F 2016 F 2019, M . S I C C ., L ., . F O 2012 F 2016, P C T CPA L C ,

M . F U S ' J 2012. S M B A F U J 2022.

Ms. JIN Ling (金玲), 66, G J 2023. M . J C A X F P ' H (蕭山第一人民醫院) J 2022. M . J C A P ' H P (浙江省人民醫院) M 2000 D 2008; C A A C ' H U S M (浙江大學醫學院附屬兒童醫院) J 2009 J 2013; C A S A H U S M (浙江大學醫學院附屬第二醫院) J 2013 D 2018; C F O S (H) H (樹蘭(杭州)醫院) J 2019 M 2022. M . J B. N A I (北京國家會計學院) U S M (浙江大學管理學院).

M . J H I E E (杭州電子工業學院) J 1996; ' T Q U H K (. H K M U) J 2005. I D 2010, M . J H R S S D P (浙江省人力資源和社會保障廳).

Mr. CHAN Sai Ke ng H go (陳世強), 69, G J 2023. M . C L , H & C (廖何陳律師行), H K , A 1986, & C . M . C F V P H K P S E A (香港專業及資深行政人員協會) S 2006. F O 2006 O 2011, C E E C H K . H C P ' P C C S , C 2006 2010. H OR & PARTNERS S (柯廣輝律師行) J 2011, B T O R U , U S N 2016.

M . C U S , U K ' A 1978. H O N U , U S M 2010.

Direc ors, S per isors and Senior Managemen

S

Mr. XU Ning (許寧), 51, S C . H . M . X C M 2016, C . H C . M . X M 2016 O 2016, . F N 2016 D 2017, . H C J 2018 J 2022. H J 2022 J 2022. H M 2023. P . C , . W TV S (溫州電視台) W N (《溫州新聞聯播》), S 1998 F 2016,

M . X B B I (北京廣播學院) (. C U C (中國傳媒大學)) J 1998 ' . H (一級人力資源管理師) M H R S S P ' R C F 2018.

Mr. XU Yongjiu (徐永久), 47, S . H . C O 2021 . S A 2023, S J J E I M C ., L . (上海金浦健服股權投資管理有限公司) . S J 2021, W J E I P (L P) (溫州金寧股權投資合夥企業(有限合夥)). F J 2004 D 2007, D R H S I G . F D 2007 M 2009, I B . H A P C . F M 2009 S 2011, S I G S I H S T . F O 2011 O 2015, M . X GP C C ., L . (金浦產業投資基金管理有限公司). F A 2016 M 2023, S J J E I M C ., L . (上海金浦健服股權投資管理有限公司)

Direc ors, S per isors and Senior Managemen

M . X S U F E J 2000. H F U J 2004. S J 2015, S L S F U , . H C E I B S EMBA (E M B A) N 2022.

Mr. QIAN Chengliang (錢成良), 74, S . H . M . Q C J 2017 S . P C , M 2007 M 2012, S C W M P C (溫州市人大常委會). F F 2003 A 2007, W . F O 1996 J 2003, S C L (麗水市委常委). F N 1995 S 1996, C P W .

Mr. XIE Tiefan (謝鐵凡), 45, S . H . M . X . C M 2000 . F M 2000 A 2017, C . H S S 2014 C . H S 2017.

M . X . Q U C (中央廣播電視大學) B . D 2004. H J U J P J 2016, . M . X A E W M B H R D 2007. H D H R S S P S 2024.

Ms. ZHANG Ye (張玥), 30, S . S . C J 2023 . S S Y C C ., L ., O 2021 /

M . J U J 2017 U S , A J 2020.

Direc ors, S per isors and Senior Managemen

S M

Mr. ZHOU Chao i (周朝毅), 62, H C . M . C F 2005 . H S 2014 C . P C , N 1995 D 2004, M . W C H (溫州心血管醫院) W , . F M 1990 O 1995, M . (科長) W T C M H (溫州市中醫院) W , . F J 1986 A 1990, M . W Q S (溫州市氣功療養院) W , .

M . W M H R S S B N 2015.

Mr. YE Minjie (葉敏捷), 51, H . C . H . C O 2013 . M . Y S 2014 C . P C , J 1994 S 2013, (科長) W M H (溫州市精神病院), W , .

M . Y X M C (新鄉醫學院) , X , H P J 2007. H H R S S B P (浙江省人力資源和社會保障廳) J 2014.

Direc ors, S per isors and Senior Managemen

Mr. XU Yi (

Direc ors, S per isors and Senior Managemen

Mr. Wang Jian (王健), 40, C . F M . W D , S S M E D .

Mr. JIN Weig ang (金偉光), 56, . H C , H . M . J C M 2015 S Y H M 2015 、 M 2017, M . J C M 2017 、 F 2022 H C F 2022. H C N 2018. P . C , A 1987 、 A 2015, W M H B (溫州市衛生局), W M H B A 2009 、 A 2015. F M 2002 、 M 2009, W M H B .

M . J C C P S C C CPC (中央黨校函授學院) D 1997, . H N U (浙江師範大學區域經濟研究生課程進修班) A 2002. H A T C H A (M Q M) (澳大利亞衛生行政管理(醫療質量管理)培訓班) N 2003. H P A S U (浙江大學公共管理研修班) N 2004.

Mr. JIN H i (金輝), 38, . H H . C J 2022 . P C , H C P A C L (浙江華明會計師事務所有限公司) F 2012 、 D 2021, . H W ; ; , . H W M P , C N 2018, . P H C P A C L , W L C P A C L (溫州立德會計師事務所有限公司) F 2009 、 J 2012.

Direc ors, S per isors and Senior Managemen

M . J U F & E (浙江財經大學) J 2008. H P D F M 2013. H M J P R C M 2024.

S R P D, S C G :

Direc ors/Senior Managemen	Members of he Gro p	Posi ions Held a Members of he Gro p	Term of Office
GUAN W	Q K H C ., L .	E	F A 2011 D 2024
	Q K H C ., L .	D	F D 2024
	C K H C ., L .	E	F J 2012
	Y K H C ., L .	E	F D 2012
	Y K H C ., L .	E	F S 2013
	B Y H C ., L .	C	F A 2015 J 2024
	W Y G H C ., L .	E	F N 2015
	P K H C ., L .	E	F N 2015
	W L Y H C ., L .	C , G	F A 2020
	W Y N H C ., L .	D	F A 2024
	Q K P M C ., L .	D	F N 2024

Direc ors, S per isors and Senior Managemen

Direc ors/Senior Managemen	Posi ions Held a Members of he Gro p		Term of Office
WANG L	Y K H M C ., L .	E , M	J 2017
	Q K H C ., L .	M	D 2018
	B. Y H C ., L .	D	M 2019 J 2024
	B. Y H C ., L .	E	J 2024
	H Y N S C ., L .	E , G	D 2020
	Y H T C ., L .	E	S 2022
	D P C ., L .	C	S 2022
	C ' K H H C ., L .	D	N 2022
	C K P H C ., L .	C	M 2023
	W G F H C ., L .	E , M	M 2024
	Q K M C ., L .	M	N 2024

Direc ors, S per isors and Senior Managemen

Direc ors/Senior Managemen	Posi ions Held a Members of he Gro p		Term of Office
XU Y	Q K H C., L.	S	Fr A 2011
	Y. K H C., L.	S	Fr S 2013
	S Y H C., L.	S	Fr S 2014
	W Y G H C., L.	S	Fr N 2015
	B. Y H C., L.	S	Fr A 2015 J 2024
	T K H C., L.	E G	Fr J 2016
	K H M (G) C., L.	E G, G	Fr J 2016
	T L C H C., L.	E G, M	Fr D 2016
	H K H C., L.	C	Fr J 2018
	H C H C., L.	E G, G	Fr N 2017
	W T TCM C C., L.	E G	Fr J 2018
	J H T C., L.	E G, G	Fr D 2018
	W L Y H C., L.	D	Fr A 2020
	W J J T C., L.	E G, G	Fr D 2021 N 2024
	Q K M C., L.	S	Fr N 2024
	W Y N H C., L.	S	Fr A 2024

Direc ors, S per isors and Senior Managemen

Direc ors/Senior Managemen	Members of he Gro p	Posi ions Held a Members of he Gro p	Term of Office
HOU C	Y K H M C., L.	S	F J 2017
	Q Y H C., L.	D	F N 2022
	C ' Q L. K H C., L	E G	F M 2021 M 2024
WANG J	Q Y H C., L.	D	F N 2015
	W N P S H C., L.	C , M	F J 2019
	H K H C., L.	D	F J 2019
	H Y P H C., L.	D	F M 2020
	W L Y H C., L.	D	F A 2020
	Y H T C., L.	M	F M 2020
	Y P I H (W) C., L.	E G	F M 2020
	H Y M E R&D C., L.	E G	F A 2021
	J S H C., L.	C	F O 2022
	B Y H C., L.	D, M	F F 2023 J 2024
	B Y H C., L.	M	F J 2024
	C K P H C., L.	D	F M 2023
	L K H C., L.	E G	F F 2023
	C J Y P H C., L.	C	F D 2023
	Y G H S C., L.	D, M	F A 2024

Direc ors, S per isors and Senior Managemen

Direc ors/Senior Managemen	Members of he Gro p	Posi ions Held a Members of he Gro p	Term of Office
HANG F	L K H C ., L .	E , M	F J 2018
	W N P S H C ., L .	D	F J 2019
	L C H C ., L .	E , M	F D 2020
JIN W	H Y P H C ., L .	D	F D 2018
	P C Y H C ., L .	E	F S 2021
XU N	G Y H C ., L .	E	F J 2019
	H Y P H C ., L .	C	F M 2020
JIN H	W Q Y E H C ., L .	S	F S 2022
	C Y N C C ., L .	S	F S 2022
	P C Y H C ., L .	S	F J 2023
	J S H C ., L .	D	F M 2024

A di or's Repor

X K S B 2025 N . A10505

T S W K H C ., L .,

I. O

W W K H C ., L . (K H), 31 D 2024, , , ,

Au di or's Repor

III. K A M

K

W

Ke Au di Ma ers	Ho e addressed he ke au di ma er
(I) I R R I P	
P N 3.24 I N 5.41 O F S .	T : 1. O ; 2. O , ; 3. R K H , C , ; 4. A C ; 5. C ,
K H . I , K H D R A I P - S P . A , . A ,	

A di or's Repor

III. K A M ( )

Ke A di Ma ers	Ho e addressed he ke a di ma er

(II) Good ill impairmen

R N 3.18 I , N 3.31 C N 5.16 G

A . M . A 31 D 2024, RMB144,445,442.66, RMB30,287,008.74

M . S , : . S , . U

T :

1. U ( ).
2. B K H ,
3. B ,
4. R

A di or's Repor

III. K A M ( )

Ke A di Ma ers	Ho e addressed he ke a di ma er
	5. T ( ). S
	6. C

IV. O

M K H ( ) . T 2024 K H

O

I

I , . H ,

Auditor's Report

V. Review of Financial Status, Financial Performance and Risk Management

A di or's Repor

VI. A ' R A F S ( )

(4) C C
K H I
O
H
K H

(5) E ( ),

(6) O
K H W
W

W

W

F
W

BDO CHINA S L P
(C P A LLP)

C P A C :
(E)

C P A C :

S , C
28 M 2025

Consolida ed Balance Shee

A 31 D 2024

(A RMB)

Asse s	N 5	Balance as a 31 December 2024	B 31 D 2023
G rren asse s:			
C	5.1	261,749,010.62	418,861,721.39
B			
L			
F	5.2	7,938,322.41	7,350,298.53
D			
N	5.3	663,798.83	
A	5.4	571,812,956.97	420,441,069.56
R			
A	5.5	14,713,963.24	9,830,552.98
P			
R			
R			
O	5.6	81,354,941.59	69,705,728.98
F			
I	5.7	50,629,131.38	60,600,180.25
I :			
C			
A			
N			
O	5.8	5,859,353.91	858,020.39
To al o rren asse s		994,721,478.95	987,647,572.08
Non-o rren asse s:			
D			
D			
O			
L	5.9	14,000,000.00	14,000,000.00
L	5.10	99,413,985.20	139,071,987.05
O			
O	5.11	36,755,116.10	65,099,055.34
I			
F	5.12	889,544,442.13	794,856,342.94
C	5.13	185,164,227.10	186,980,240.67
B			
O			
R	5.14	161,821,444.56	189,054,506.68
I	5.15	291,535,792.26	320,321,705.16
I :			
D			
I :			
G	5.16	114,158,433.92	119,909,089.24
L	5.17	150,407,031.48	175,910,626.14
D	5.18	56,197,544.77	45,146,270.60
O	5.19	11,233,664.34	9,689,210.94
To al non-o rren asse s		2,010,231,681.86	2,060,039,034.76
To al asse s		3,004,953,160.81	3,047,686,606.84

Consolida ed Balance Shee

A 31 D 2024
(A RMB)

Liabili ies and o ners' eq i	N 5	Balance as a 31 December 2024	B 31 D 2023
G rren liabili ies:			
S	5.21	91,000,000.00	127,001,700.00
B			
L			
F	5.22	14,000,000.00	12,400,000.00
D			
N	5.23		1,545,021.09
A	5.24	131,936,379.98	110,060,007.67
A	5.25	21,319,198.39	26,563,603.06
C	5.26	49,771.35	
F			
A			
R			
R			
E	5.27	85,747,296.61	84,324,006.40
T	5.28	39,128,083.85	38,553,746.47
O	5.29	81,287,433.15	150,270,575.15
H			
R			
L			
N	5.30	229,270,444.13	250,411,756.99
O	5.31	615,218.00	
To al o rren liabili ies		694,353,825.46	801,130,416.83
Non-o rren liabili ies:			
R			
L	5.32	691,017,337.44	557,719,214.69
B			
I			
P			
L	5.33	151,300,062.80	163,239,532.76
L	5.34	76,236,878.60	61,351,340.53
L			
R			
D	5.35	8,430,307.00	8,734,099.00
D	5.18	40,313,058.68	47,306,056.21
O			
To al non-o rren liabili ies		967,297,644.52	838,350,243.19
To al liabili ies		1,661,651,469.98	1,639,480,660.02

Consolida ed Balance Shee

A 31 D 2024
(A RMB)

Liabili ies and o ners' eq i	N 5	Balance as a 31 December 2024	B 31 D 2023
O ner's eq i :			
S	5.36	72,670,000.00	74,600,300.00
O			
I :			
P			
C	5.37	790,024,238.03	852,695,601.69
L :	5.38	22,366,848.64	12,587,011.74
O			
S			
S	5.39	38,399,577.13	38,399,577.13
G			
R	5.40	344,285,828.01	311,956,229.16
To al eq i a rib able o o ners of he paren compan		1,223,012,794.53	1,265,064,696.24
Minori eq i		120,288,896.30	143,141,250.58
To al o ners' eq i		1,343,301,690.83	1,408,205,946.82
To al liabili ies and o ners' eq i		3,004,953,160.81	3,047,686,606.84

T

C P :	A P :	H A D :
GUAN W	JIN H	WANG M

Paren Compan 's Balance Shee

A 31 D 2024
(A RMB)

Asse s	N 17	Balance as a 31 December 2024	B 31 D 2023
G rren asse s:			
C		112,152,552.80	186,837,559.21
F			
D			
N			
A	17.1	69,696,752.09	48,066,557.69
R			
A		2,264,057.74	228,131.12
O	17.2	616,875,722.47	600,448,325.58
I		10,162,306.19	11,181,002.59
I			
C			
A			
N			
O		355,000.00	330,000.00
To al o rren asse s		811,506,391.29	847,091,576.19
Non-o rren asse s:			
D			
O			
L			
L	17.3	834,837,987.87	785,983,439.17
O			
O		36,755,116.10	65,099,055.34
I			
F		280,273,134.88	288,701,322.35
C		622,132.50	113,600.00
R			
O			
R			
I		23,603,766.55	23,680,002.23
I			
D			
I			
G			
L		18,701,115.49	18,459,271.72
D		17,876,806.13	14,608,690.36
O		6,010,995.66	6,320,388.26
To al non-o rren asse s		1,218,681,055.18	1,202,965,769.43
To al asse s		2,030,187,446.47	2,050,057,345.62

T

C R : A R : H A D :
GUAN W JIN H WANG M

Paren Compan 's Balance Shee

A 31 D 2024
(A RMB)

Liabili ies and o ners' eq i	N 17	Balance as a 31 December 2024	B 31 D 2023
G rren liabili ies:			
S		75,000,000.00	125,000,000.00
F			
D			
N			
A		50,885,691.57	33,774,329.53
A		4,828,444.68	4,172,410.35
C			
E		20,234,697.93	20,572,854.31
T		3,208,892.78	1,603,746.33
O		51,395,823.13	38,919,608.73
L			
N		172,880,144.00	173,615,500.00
O			
To al o rren liabili ies		**378,433,694.09**	397,658,449.25
Non-o rren liabili ies:			
L		399,350,000.00	362,042,127.25
B			
I P			
L			
L		34,016,324.10	25,855,234.63
L			
R			
D		8,430,307.00	8,734,099.00
D			
O			
To al non-o rren liabili ies		**441,796,631.10**	396,631,460.88
To al liabili ies		**820,230,325.19**	794,289,910.13

Paren Compan 's Balance Shee

A 31 D 2024
(A RMB)

Liabili ies and o ners' eq i	N 17	Balance as a 31 December 2024	B 31 D 2023
O ner's eq i :			
S		72,670,000.00	74,600,300.00
O			
I :			
P			
C		832,320,975.11	871,230,628.64
L :		22,366,848.64	12,587,011.74
O			
S			
S		38,399,577.13	38,399,577.13
R		288,933,417.68	284,123,941.46
To al o ners' eq i		1,209,957,121.28	1,255,767,435.49
To al liabili ies and o ners' eq i		2,030,187,446.47	2,050,057,345.62

T

C P : GUAN W

A P : JIN H

H A D : WANG M

Consolida ed Income S a emen

F Y E 31 D 2024
(A RMB)

I em		N 5	Year 2024	Y 2023
I.	To al opera ing income		1,654,289,413.23	1,596,265,532.13
	I :	5.41	1,654,289,413.23	1,596,265,532.13
	I			
	B			
	I			
II.	To al opera ing cos s		1,549,653,898.69	1,495,651,128.76
	I :	5.41	1,215,885,485.62	1,185,129,954.78
	I			
	H			
	S			
	N			
	N			
	P			
	R			
	T	5.42	12,336,885.73	6,474,904.42
	S	5.43	9,972,500.41	17,102,355.09
	G	5.44	227,346,205.41	213,025,707.14
	R	5.45	36,519,661.16	32,466,196.15
	F	5.46	47,593,160.36	41,452,011.18
	I :		41,601,182.38	39,936,115.20
	I		3,122,805.73	5,265,571.27
	P :	5.47	13,253,818.83	15,976,715.23
	I ( )	5.48	754,876.93	-6,067,197.23
	I :		-1,089,495.22	-6,465,278.89
	G			
	G ( )			
	G ( )			
	G ( )	5.49	-269,736.39	214,405.20
	L ( )	5.50	-26,454,997.91	-9,354,735.55
	L ( )	5.51	-16,495,929.58	
	G ( )	5.52	-69,932.29	68,088.99

Consolida ed Income S a emen

F Y E 31 D 2024
(A RMB)

I em	N 5	Year 2024	Y 2023
III. Opera ing profi s (-- for losses)		75,353,614.13	101,451,680.01
P : -	5.53	1,528,901.03	9,545,446.16
L : -	5.54	8,783,028.50	11,815,508.86
IV. To al profi s (-- for o al losses)		68,099,486.66	99,181,617.31
L :	5.55	17,701,775.29	12,250,009.49
V. Ne profi (-- for ne loss)		50,397,711.37	86,931,607.82
(I) C			
1. N ( )		50,397,711.37	86,931,607.82
2. N ( )			
(II) C			
1. N ( )		65,610,188.85	85,947,806.64
2. M ( )		-15,212,477.48	983,801.18
VI. O her comprehensi e income, ne of a			
O C			
(I) O			
1. C			
2. O			
3. C			
4. C C			

Consolida ed Income S a emen

F Y E 31 D 2024
(A RMB)

I em	N 5	Year 2024	Y 2023
(II) O			
1. O			
2. C			
3. A			
4. R			
5. C			
6. D			
7. O			
O			
VII. To al comprehensi e income		50,397,711.37	86,931,607.82
T		65,610,188.85	85,947,806.64
T		-15,212,477.48	983,801.18
VIII. Earnings per share:			
(I) B (RMB/)	5.56	0.88	1.15
(II) D (RMB/)	5.56	0.88	1.15

T

C R : GUAN W

A R : JIN H

H A D : WANG M

Compan 's Income S a emen

F Y E 31 D 2024
(A RMB)

I em		N 17	Year 2024	Y 2023
I.	Opera ing income	17.4	382,203,291.48	387,325,861.90
	L :	17.4	265,234,884.25	269,941,680.92
	T		4,316,465.04	455,531.13
	S		631,732.91	954,503.04
	G		68,141,320.83	76,405,750.06
	R		25,088,282.82	20,551,838.32
	F		15,534,037.93	13,355,222.49
	I :		27,155,993.77	24,083,867.34
	I		15,686,764.05	15,119,285.04
	P :		4,410,314.14	2,686,378.93
	I ( )	17.5	49,133,712.65	34,292,572.00
	I :		1,695,251.38	1,538,932.70
	G			
	G ( )			
	G ( )		742,239.73	1,982,203.29
	L ( )		4,015,631.88	-2,576,210.65
	L ( )			
	G ( )			39,085.15
II.	Opera ing profi s (— for losses)		61,558,466.10	42,085,364.66
	P :		338,053.84	8,106,945.59
	L :		27,039,569.49	1,844,670.16
III.	To al profi (— for o al loss)		34,856,950.45	48,347,640.09
	L :		-3,233,115.77	-1,370,722.10
IV.	Ne profi (— for ne loss)		38,090,066.22	49,718,362.19
	(I) N ( )			
	(II) N ( )			

Compan 's Income S a emen

F Y E 31 D 2024

(A RMB)

I em	N 17	Year 2024	Y 2023
V. O her comprehensi e income, ne of a			
(I) O			
1. C			
2. O			
3. C			
4. C C '			
(II) O her comprehensi e income ha ill be reclassified in o profi or loss			
1. O			
2. C			
3. A			
4. R			
5. C			
6. D			
7. O			
VI. To al comprehensi e income		38,090,066.22	49,718,362.19
VII. Earnings per share:			
(I) B (RMB/)			
(II) D (RMB/)			

T

C R :
GUAN W

A R :
JIN H

H A D :
WANG M

Consolida ed S a emen of Cash Flo s

F Y E 31 D 2024
(A RMB)

I em	N 5	Year 2024	Y 2023
I. Cash flo s from opera ing ac i i ies			
C		1,387,505,397.99	1,563,715,823.56
N			
N			
N			
C			
N			
N			
C			
N			
N			
N			
R			
C	5.57	46,542,855.34	215,257,897.46
S b- o al of cash inflo s from opera ing ac i i ies		1,434,048,253.33	1,778,973,721.02
C		536,137,778.74	534,160,766.19
N			
N			
C			
N			
C			
C			
C		642,555,983.44	588,242,659.36
C		63,003,045.02	54,415,007.31
C	5.57	92,712,942.45	337,122,050.70
S b- o al of cash o flo s from opera ing ac i i ies		1,334,409,749.65	1,513,940,483.56
Ne cash flo s from opera ing ac i i ies		99,638,503.68	265,033,237.46

Consolida ed S a emen of Cash Flo s

F Y E 31 D 2024

(A RMB)

I em	N 5	Year 2024	Y 2023
II. Cash flo s from in es ing ac i i ies			
C		34,242,178.97	8,279,457.77
C			
N		1,844,120.17	2,924,936.67
N		2,000,000.00	
C	5.57		1,248,000.00
S b- o al of cash inflo s from in es ing ac i i ies		38,086,299.14	12,452,394.44
C		192,178,988.86	179,732,393.77
C		17,020,000.00	2,447,872.75
N			
N			31,289,153.32
C	5.57	942,428.37	14,000,059.94
S b- o al of cash o flo s from in es ing ac i i ies		210,141,417.23	227,469,479.78
Ne cash flo s from in es ing ac i i ies		-172,055,118.09	-215,017,085.34

Consolida ed S a emen of Cash Flo s

F Y E 31 D 2024
(A RMB)

I em	N 5	Year 2024	Y 2023
III. Cash flo s from financing ac i i ies			
C		7,210,500.00	2,999,500.00
I			
		7,210,500.00	2,999,500.00
C		448,460,250.00	605,774,669.65
C	5.57	60,000,000.00	55,900,000.00
S b- o al of cash inflo s from financing ac i i ies		515,670,750.00	664,674,169.65
C		367,013,827.25	357,677,872.75
C		74,654,124.22	35,398,808.90
I		2,923,034.00	3,001,920.88
C	5.57	150,919,616.84	175,490,616.99
S b- o al of cash o flo s from financing ac i i ies		592,587,568.31	568,567,298.64
Ne cash flo s from financing ac i i ies		-76,916,818.31	96,106,871.01
IV. Impac of fl c a ion in e change ra e on cash and cash eq i alen s		-157,162.49	4,325.27
V. Ne increase in cash and cash eq i alen s		-149,490,595.21	146,127,348.40
P :	5.58	404,723,339.37	258,595,990.97
VI. Ending balance of cash and cash eq i alen s	5.58	255,232,744.16	404,723,339.37

T

C P : GUAN W

A P : JIN H

H A D : WANG M

Compan 's S a emen of Cash Flo s

F Y E 31 D 2024

(A RMB)

I em	N	Year 2024	Y 2023
I. Cash flo s from opera ing ac i i ies			
C		355,123,462.58	388,171,338.58
R			
C		563,112,957.82	677,755,040.34
S b- o al of cash inflo s from opera ing ac i i ies		918,236,420.40	1,065,926,378.92
C		135,345,404.98	132,581,733.32
C		163,048,839.70	155,983,637.05
C		3,350,063.92	1,125,964.24
C		535,927,923.31	662,158,585.72
S b- o al of cash o flo s from opera ing ac i i ies		837,672,231.91	951,849,920.33
Ne cash flo s from opera ing ac i i ies		80,564,188.49	114,076,458.59
II. Cash flo s from in es ing ac i i ies			
C		139,899,934.13	16,657,744.50
C		18,438,461.27	45,000,000.00
N		21,024.00	714,238.30
N			
C			108,521,408.71
S b- o al of cash inflo s from in es ing ac i i ies		158,359,419.40	170,893,391.51
C		12,562,107.39	6,217,731.13
C		184,882,800.00	54,194,772.75
N			
C			164,426,250.04
S b- o al of cash o flo s from in es ing ac i i ies		197,444,907.39	224,838,753.92
Ne cash flo s from in es ing ac i i ies		-39,085,487.99	-53,945,362.41

Consolida ed S a emen of Changes in O ners' Eq i

F Y E 31 D 2024

(A RMB)

Year 2024

Eq i a rib able o o ners of he paren compan

Item	Share capi al	Other eq i ins n men s: Preferred s ocks	Other eq i ins n men s: Perpe al bonds	Other eq i ins n men s: O hers	Capi al reser es	Less: reas r s ocks	O her comprehensi e income	Special reser es	S rpl s reser es	General risk reser es	Re ained earnings	S b- o al	Minori eq i	To al o ners' eq i
I. Balance as a 31 December 2023	74,600,300.00				852,695,601.69	12,587,011.74			38,399,577.13		311,956,229.16	1,265,064,696.24	143,141,250.58	1,408,205,946.82
P i														
C														
B														
O														
II. Balance as a 1 Jan ar 2024	74,600,300.00				852,695,601.69	12,587,011.74			38,399,577.13		311,956,229.16	1,265,064,696.24	143,141,250.58	1,408,205,946.82
III. Increases/decreases in 2024 (- for decreases)	-1,930,300.00				-62,671,363.66	9,779,836.90					32,329,598.85	-42,051,901.71	-22,852,354.28	-64,904,255.99
(I) T											65,610,188.85	65,610,188.85	-15,212,477.48	50,397,711.37
(II) C					-27,437,604.59	9,779,836.90						-39,147,741.49	-4,748,359.80	-43,896,101.29
1. C	-1,930,300.00											-41,214,951.27	-4,748,359.80	-45,963,311.07
2. C					-31,435,114.37	9,779,836.90								
3. A												3,997,509.78		3,997,509.78
4. O					3,997,509.78							-1,930,300.00		-1,930,300.00
(III) D	-1,930,300.00										-33,280,590.00	-33,280,590.00	-2,891,517.00	-36,172,107.00
1. W														
2. W														
3. D											-33,280,590.00	-33,280,590.00	-2,891,517.00	-36,172,107.00
4. O														

Consolida ed S a emen of Changes in O ners' Eq i

F Y E 31 D 2024

(A RMB)

Item	Equi a rib able o o ners of he paren compan												Minori eq i	To al o ners' eq i
	Year 2024													
	O her eq i ins n men s						O her							
	Share capi al	Preferred s ocks	Perpe al bonds	O hers	Capi al reser es	Less: reas r s ocks	comprehensi e income	Special reser es	S rpl s reser es	General risk reser es	Re ained earnings	S b- o al		
(IV) I -														
1. C														
2. C														
3. S														
4. C -														
5. C -														
6. O														
(V) S														
1. A 2024														
2. A 2024														
(VI) O														
					-35,233,759.07							-35,233,759.07		-35,233,759.07
IV. Balance as a 31 December 2024	72,670,000.00				790,124,238.03	22,366,848.64			38,399,577.13		344,285,828.01	1,223,012,794.53	120,288,896.30	1,343,301,690.83

T

C P

GUAN W

A P

JIN H

H A D

WANG M

Consolida ed S a emen of Changes in O ners' Eq i

F Y E 31 D 2024

(A RMB)

Y 2023

Items	Equity attributable to owners of the parent company								Minority interests	Total owners' equity
	Share capital	Preference shares	Perpetual bonds	Other equity instruments	Capital reserve	Less: Treasury shares	Other comprehensive income	Surplus reserve	General risk reserve	Retained earnings		
I. Balance as at 31 December 2022	74,600,300.00				855,078,533.30			38,399,577.13		233,506,534.43	1,201,584,944.86	124,317,673.97	1,325,902,618.83
Plus: Changes in accounting policies													
Corrections of prior period errors													
Business combinations under common control													
Others													
II. Balance as at 1 January 2023	74,600,300.00				855,078,533.30			38,399,577.13		233,506,534.43	1,201,584,944.86	124,317,673.97	1,325,902,618.83
III. Increases/decreases in 2023 (- for decreases)					-2,382,931.61	12,587,011.74				78,449,694.73	63,479,751.38	18,823,576.61	82,303,327.99
(I) Total comprehensive income										85,947,806.64	85,947,806.64	983,801.18	86,931,607.82
(II) Capital contributed or reduced by owners						12,587,011.74					-12,587,011.74	20,730,696.31	8,143,684.57
1. Capital contributed by owners						12,587,011.74					-12,587,011.74	20,730,696.31	8,143,684.57
2. Capital contributed by holders of other equity instruments													
3. Amount of share-based payments recognized in owners' equity													
4. Others													
(III) Profit distribution										-7,498,111.91	-7,498,111.91	-2,890,920.88	-10,389,032.79
1. Withdrawal of surplus reserve													
2. Withdrawal of general risk reserve													
3. Distributions to owners (or shareholders)										-7,498,111.91	-7,498,111.91	-2,890,920.88	-10,389,032.79
4. Others													

Consolida ed S a emen of Changes in O ners' Eq i

F Y E 31 D 2024

(A RMB)

L.	Equity attributable to owners of the Company										Minority Interests	Total Equity
	Share Capital	Preference Shares	Perpetual Bonds	Other	Capital Reserve	Less: Treasury Shares	Other Comprehensive Income	Special Reserve	Surplus Reserve	Retained Earnings		
(IV) I												
1. C												
2. C												
3. S												
4. C												
5. C												
6. O												
(V) S												
1. A 2023												
2. A 2023												
(VI) O										-2,382,931.61	-2,382,931.61	-2,382,931.61
IV. Balance as a 31 December 2023	74,600,300.00				852,695,601.69	12,587,011.74			38,399,577.13		311,956,229.16	1,265,064,696.24
											143,141,250.58	1,408,205,946.82

T

C P
GUAN W

A P
JIN H

H A
WANG M

D

Paren Compan 's S a emen of Changes in O ners' Eq i

F Y E 31 D 2024

(A RMB)

Item	Year 2024											
	Share capi al	Other eq i ins n men s			Capi al reser es	Less: reas r s ocks	O her comprehensi e income	Special reser es	S rpl s reser es	Re ained earnings	To al o ners' eq i
		Preferred s ocks	Perpe al bonds	O hers							
I. Balance as a 31 December 2023	74,600,300.00				871,230,628.64	12,587,011.74			38,399,377.13	284,123,941.46	1,255,767,435.49
P i i											
C , ,											
, , ,											
O ,											
II. Balance as a 1 Jan ar 2023	74,600,300.00				871,230,628.64	12,587,011.74			38,399,377.13	284,123,941.46	1,255,767,435.49
III. Increases/decreases in 2023 (- for decreases)	-1,930,300.00				-38,909,633.53	9,779,836.90				4,809,476.22	-45,810,314.21
(1) T , ,										38,090,066.22	38,090,066.22

Paren Compan 's S a emen of Changes in O ners' Eq i

F Y E 31 D 2024
(A RMB)

Notes to the Financial Statements

For the Year Ended 31 December 2024
(All amounts are expressed in RMB unless otherwise stated)

1 General information

Wenzhou Kangning Hospital Co., Ltd. (the "Company") was established in Wenzhou City, Zhejiang Province, the PRC on 1996. The Company's registered address is No. 1, Shuangrui Road, Hi-tech Development Zone, Wenzhou, Zhejiang, PRC.

On 15 October 2014, the Company was converted into a joint stock limited company named Wenzhou Kangning Hospital Co., Ltd.

The Company's H shares were listed on the Stock Exchange of Hong Kong Limited on 20 November 2015. The Company's shares are mainly engaged in medical services.

As at 31 December 2024, the Company's registered capital was 72.67 million shares with a par value of RMB72.67 million; the registered address is No. 1, Shuangrui Road, Hi-tech Development Zone, Wenzhou, Zhejiang, PRC, and the headquarters address is No. 1, Shuangrui Road, Hi-tech Development Zone, Wenzhou, Zhejiang, PRC.

The principal activities of the Company and its subsidiaries (collectively referred to as the "Group") are mainly engaged in medical services.

The ultimate controlling shareholder of the Company is Guangwen Wenzhou Investment Limited.

These financial statements were approved by the Board of Directors of the Company on 28 March 2025.

2 Basis of preparation of financial statements

2.1 Basis of preparation

These financial statements have been prepared in accordance with the Accounting Standards for Business Enterprises issued by the Ministry of Finance of the PRC, and the disclosure requirements of the Hong Kong Companies Ordinance (Cap. 622) and the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the "Hong Kong Listing Rules"). In addition, the Group has also prepared financial statements in accordance with International Financial Reporting Standards ("IFRS") and the disclosure requirements of the Hong Kong Companies Ordinance (Cap. 622) and the Hong Kong Listing Rules (the "Hong Kong Financial Statements"). The Company's financial statements are prepared in accordance with the Accounting Standards for Business Enterprises issued by the Ministry of Finance of the PRC, and the disclosure requirements of the Hong Kong Companies Ordinance (Cap. 622) and the Hong Kong Listing Rules.

2.2 Going concern

The Group has assessed its ability to continue as a going concern for the twelve months from the end of the reporting period.

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S

1. F G

2. T G

3. T G T G T G

3.1 S a emen on compliance i h Acco n ing S andards for B siness En erprises

T A S B E M F , C 31 D 2024, ,

3.2 Acco n ing period

T , 1 J 31 D .

3.3 Opera ing c cle

T C , 12 .

3.4 F nc ional c rrenc

T C RMB .

3.5 Acco n ing rea men me hods for b siness combina ion nder common con rol and b siness combina ion no nder common con rol

B : F ( ) S ( ). I

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.5 Acco n ing rea men me hods for b siness combina ion nder common con rol and b siness combina ion no nder common con rol ( )

B : T . T C . T C . T

D T

3.6 J dgemen cri eria for con rol and prepara ion me hod of consolida ed financial s a emen s

3.6.1 J

T T C . C C

3.6.2 B

T C . I C C . I . I C C .

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.6 J dgemen cri eria for con rol and prepara ion me hod of consolida ed financial s a emen s ( )

3.6.2 B ( )

T ’ ’ I

(1) I

D C A

D C

No es o he Financial S a emen s

F Y E 31 D 2024

(A RMB)

3 S ( )

3.6 J dgemen cri eria for con rol and prepara ion me hod of consolida ed financial s a emen s ( )

3.6.2 B ( )

(2) D

① G

F C T O

② D

I

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.6 J dgemen cri eria for con rol and prepara ion me hod of consolida ed financial s a emen s ( )

3.6.2 B ( )

(2) D ( )

② D ( )

. T ;

. T ;

. T ;

. A

W

W

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.6 J dgemen cri eria for con rol and prepara ion me hod of consolida ed financial s a emen s ( )

3.6.2 B ( )

(3) P

T C ( ) W

(4) P

T ;

3.7 Classifica ion of join en re arrangemen s and acco n ing rea men me hods of join opera ion

J

J

T C :

(1) A ;

(2) L ;

(3) I ;

(4) I ;

(5) S

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.8 Recogni ion cri eria for cash and cash eq i alen s

C C C

3.9 Foreign o rrenc ransac ions and ransla ion of foreign o rrenc s a emen s

F RMB

T T

3.10 Financial ins n men s

W C

3.10.1 C

A G

T C

T ;

T

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.10 Financial ins n men s ( )

3.10.1 C ( )

F ( ) :

T ;

T

A C ( ) . T ,

E C A C

A :

A :

1) T

2) A

3) T

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.10 Financial ins n men s ( )

3.10.1 C ( )

A C :
( )

3.10.2 R

(1) F

F C

D

A

(2) F

F ( ) T
C

W

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.10 Financial ins n men s ( )

3.10.2 R ( )

(3) F ( )

F ( ) T D

W

(4) F

F T C

(5) F

F T C

D

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.10 Financial ins n men s ( )

3.10.2 R ( )

(6) F

F

D

D

3.10.3 D

W C :

T ;

T ;

T C

I C

A

I

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.10 Financial ins n men s ( )

3.10.3 D ( )

T C W :

(1) T ;

(2) T (( )).

W :

(1) T ;

(2) T (( )).

W

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

3 Significant accounting policies and accounting estimates (continued)

3.10 Financial instruments (continued)

3.10.4 Derecognition

The Group derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the financial asset to the transferee. The Group does not derecognise a financial asset when it retains substantially all the risks and rewards of ownership of the financial asset.

The Group derecognises a financial liability when the current obligation is discharged, cancelled or expires. When the Group enters into an agreement with a creditor to replace the original financial liability by assuming a new financial liability, and the contractual terms of the new financial liability are substantially different from those of the original financial liability, the Group derecognises the original financial liability and recognises the new financial liability. When the Group makes substantial modifications to the contractual terms of the original financial liability (or part of it), it derecognises the original financial liability (or part of it) and recognises the modified financial liability as a new financial liability.

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.10 Financial ins n men s ( )

3.10.6 T

T C ( )

B C

F A S B E N . 14 I , C

F A S B E N . 21 L , C

F C

B C G. , C 30

I C

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.10 Financial ins n men s ( )

3.10.6 T ( )

I
C
C
12
A
. F
( ), C

I C

E C
T C ,
:

I em	Por folio pe	De ermining basis
N	P	S
	P	S
A	P	S
	P	S
O	P	S
	P	S
	P	S
	P	S
	O	S

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.11 In en ories

3.11.1 C

I

I

3.11.2 M

I

3.11.3 I

P

3.11.4 A

L

3.11.5 D

O W T

N N N

W

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.12 Long- erm eq i in es men s

3.12.1 J

C W C C

S W C C

3.12.2 D

(1) L

F

6

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.12 Long- erm eq i in es men s ( )

3.12.2 D ( )

(2) L

F

F

3.13.3 S

(1) L

L C E C C

(2) L

L C I

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.12 Long- erm eq i in es men s ( )

3.13.3 S ( )

(2) L ( )

T C T C A (O C O ' E), C '

W ' ' C C C C '

T C C W C

T C ' W C

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.12 Long- erm eq i in es men s ( )

3.13.3 S ( )

(3) D ( )

W I

3.13 In es men proper ies

I . E ,( ).

S C

T C . F C ,

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.14 Fi ed asse s

3.14.1 R

F . F :

(1) I C ;

(2) T

F

T C ;

3.14.2 D

T F W C

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S

3.14 Fi ed asse s ( )

3.14.2 D ( )

T :

Ca egor	Deprecia ion me hod	Deprecia ion life (ear)	Resid al al e ra e (%)	Ann al deprecia ion ra e (%)
B	S	35	5	2.71
M	S	3 -10	0-5	9.50-33.33
T	S	4 -10	5	9.50-23.75
E	S	3 -10	0-5	9.50-33.33

3.14.3 D

W T

3.15 Cons n c ion in progress

A C T W

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.15 Cons n c ion in progress ( )

G :

Ca egor	Cri eria and ime poin for carr ing for ard cons n c ion in progress in o fi ed asse s
B	(1) T ;
	(2) T
M	(1) T ;
	(2) T ;
	(3) T

3.16 Borro ing cos s

3.16.1 R

T C ;

A , , ,

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.16 Borro ing cos s ( )

3.16.2 C

C

B

(1) A ;

(2) B ;

(3) T

C

3.16.3 P

I ; B

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

3 Significant accounting policies and accounting estimates (continued)

3.16 Borrowing costs (continued)

3.16.4 Measurement of borrowing costs for qualifying assets

A qualifying asset refers to a fixed asset, investment property, inventory, etc. that can reach the intended usable or saleable state after a relatively long period of purchase and construction or production activities.

An asset can reach the intended usable or saleable state after a relatively long period of purchase and construction or production activities, which means that the asset can reach the intended usable or saleable state after a relatively long period of purchase and construction or production activities. The

During the period of capitalization, the amount of interest expenses capitalized in each accounting period shall be determined by the following methods: The interest expenses actually incurred in the current period of special borrowings shall be the amount after deducting the interest income obtained by depositing the unused borrowing funds in the bank or the investment income obtained by temporary investment. The

3.17 Intangible assets

3.17.1 Measurement of intangible assets

(1) The cost of

The

(2) Subsequent

The

For

C

C ;

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.17 In angible asse s ( )

3.17.2 E

I em	Es ima ed sef l life (ear)	Amor isa ion me hod	Basis
L	40-50	S	L
S	5	S	E
C	20-30	S	E
M	5-20	S	E
T	10	S	E

3.17.3 S

T C

R

D

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

3 Significant accounting policies and accounting estimates (continued)

3.17 Intangible assets (continued)

3.17.4 Specific criteria for the capitalization of expenditure during the development phase

The expenditure during the development phase is capitalized only if the Company can demonstrate all of the following:

(1) The technical feasibility of completing the intangible asset so that it will be available for use or sale;

(2) Its intention to complete the intangible asset and use or sell it;

(3) The ability to use or sell the intangible asset and how the asset will generate future economic benefits. Among other things, the Company should demonstrate the existence of a market for the output of the intangible asset or the intangible asset itself or, if it is to be used internally, the usefulness of the intangible asset;

(4) The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset;

(5) The ability to measure reliably the expenditure attributable to the intangible asset during its development.

When the Company cannot distinguish the research phase from the development phase of an internal project, the Company, C

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.18 Impairmen of long- erm asse s

T C I T P I C T

G

T C T R

A C T C

T

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

3 Significant accounting policies and accounting estimates (continued)

3.19 Long-term prepaid expenses

Long-term prepaid expenses are amortized on a straight-line basis over the expected benefit period. The amortization period is as follows:

Leasehold improvements	1

3.20 Contract liabilities

The Group's contract liabilities mainly include unearned revenue from membership services and prepayments received from customers for medical services. The Group's contract liabilities are presented as current liabilities or non-current liabilities in the balance sheet according to the expected timing of transfer of goods or services to customers.

3.21 Employee compensation

3.21.1 Accounting treatment of employee compensation

During the accounting period in which employees provide services to the Group, the Group recognizes the actual employee compensation payable as a liability, with corresponding amounts recognized in profit or loss or in the cost of related assets.

During the accounting period in which employees provide services to the Group, the Group recognizes the actual employee compensation payable as a liability, with corresponding amounts recognized in profit or loss or in the cost of related assets. Contributions made by the Group to basic pension insurance, unemployment insurance and annuity plans are calculated based on the prescribed bases and rates.

The Group's contributions to the above plans are recognized in profit or loss or in the cost of related assets.

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.21 Emplo ee compensa ion ( )

3.21.2 A

(1) D

T C D
C
I C
T C /

(2) D

T C
C

T
F C

T
12

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.21 Emplo ee compensa ion ( )

3.21.2 A ( )

(2) D ( )

T W

F

3.21.3 A

W C C C C

3.22 Pro isions

W C :

(1) T C ;

(2) T C ;

(3) T

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.22 Pro isions ( )

P

W C I

W C T

T C I

3.23 Share-based pa men s

T C C T C

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.23 Share-based pa men s ( )

3.23.1 E

T A T A

I C T H

3.23.2 C

A C T C F C C O

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.23 Share-based pa men s ( )

3.23.2 C ( )

T C ( ). I C

3.24 Income

3.24.1 A

T C O.

W C M. C

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.24 Income ( )

3.24.1 A ( )

T C . T C . T C . W G . I C :

- T C .
- T C ,
- T C C .

F C . T C . W C .

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.24 Income ( )

3.24.1 A ( )

F C T C :

- T C
- T C
- T C C
- T C
- T

T C I C C C

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.24 Income ( )

3.24.2 R

(1) I

I . T C . I C

(2) W

T C

(3) I

I C

(4) R

R

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

3 Significant accounting policies and accounting estimates (continued)

3.25 Government grants

3.25.1 Types

Government grants are monetary assets and non-monetary assets obtained by the Company from the government, including government grants related to assets and government grants related to income.

Government grants related to assets refer to government grants obtained by the Company for the purchase and construction or other long-term assets. Government grants related to income refer to government grants other than those related to assets.

3.25.2 Time of recognition

Government grants are recognized when the Company can meet the relevant conditions stipulated in the government grant policy and can receive the government grant.

3.25.3 Accounting treatment

Government grants related to assets are recognized as deferred income and evenly allocated to profit or loss over the useful life of the related assets.

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

3 Significant accounting policies and accounting estimates (continued)

3.25 Government grants (continued)

3.25.3 Accounting treatment (continued)

The Company adopts the following principles or methods to account for government grants:

(1) Government grants related to assets are recognized as deferred income if they are obtained before the Company receives the relevant assets. If they are obtained after the Company receives the relevant assets, they are recognized as deferred income at the amount of the actual amount received. Government grants related to assets are recognized as other income in installments over the useful life of the relevant assets.

(2) Government grants related to income are recognized as deferred income if they are obtained before the Company recognizes the relevant expenses. If they are obtained after the Company recognizes the relevant expenses, they are recognized as deferred income at the amount of the actual amount received.

3.26 Deferred income tax assets and deferred income tax liabilities

Income tax includes current income tax and deferred income tax. The Company recognizes the current income tax and deferred income tax as income tax expenses or benefits, except for those arising from transactions or events directly recognized in owner's equity (including other comprehensive income), or from business combinations.

The Company calculates the current income tax expenses (or benefits) for the current period based on the amount of taxable income for the current period calculated in accordance with the relevant tax laws.

Deferred income tax assets and deferred income tax liabilities are calculated and recognized for the temporary differences between the carrying amounts of assets and liabilities and their tax bases. For deductible losses and tax credits that can be carried forward to subsequent years, deferred income tax assets are recognized to the extent that it is probable that future taxable income will be available to offset the deductible losses and tax credits.

The Company does not recognize deferred income tax liabilities for temporary differences arising from the initial recognition of goodwill. For temporary differences arising from the initial recognition of assets or liabilities in transactions that are not business combinations and affect neither accounting profit nor taxable income (or deductible losses), the Company does not recognize deferred income tax assets or deferred income tax liabilities.

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.26 Deferred income a asse s and deferred income a liabili ies ( )

S :

– I ;

– T ( )

F C F

O C

O C I W

I C C

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.26 Deferred income a asse s and deferred income a liabili ies ( )

O :

- T ;
- D

3.27 Lease

L O C I

I C I

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.27 Lease ( )

3.27.1 T C

(1) R

O C R S :

– T ;

– I :

– T C ;

– T C

T C W C N 3.18 I .

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

3 Significant accounting policies and accounting estimates (continued)

3.27 Lease (continued)

3.27.1 The Company as lessee (continued)

(2) Lease liabilities

On the commencement date of the lease term, the Company recognizes lease liabilities at the present value of the lease payments that have not been paid. Lease payments include the following amounts for the right to use the leased asset during the lease term:

- Fixed payments (including substantial fixed payments), net of any lease incentives receivable;
- Variable lease payments that depend on an index or ratio;
- Amounts expected to be payable by the Company under residual value guarantees;
- The exercise price of purchase options, if the Company is reasonably certain to exercise the options;
- Payments for exercising termination options, if the lease term reflects the Company exercising the options to terminate.

The Company subsequently calculates the interest expense on lease liabilities at a constant periodic interest rate during the lease term and includes it in the cost of the relevant asset or profit or loss for the current period.

The Company includes the amount of lease liabilities that should be paid but not yet paid at the end of the period in current liabilities.

The Company recalculates the lease liabilities and adjusts the corresponding right-of-use assets when the following circumstances occur:

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.27 Lease ( )

3.27.1 T C ( )

(2) L ( )

A G I C :

– I C , C ;

– W C H ,

(3) S

T C S 12 . L

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

3 Significant accounting policies and accounting estimates (continued)

3.27 Lease (continued)

3.27.1 The Company as lessee (continued)

(4) Lease modification

When a lease modification occurs and the following conditions are met, the Company shall account for the lease modification as a separate lease:

– The lease modification increases the scope of the lease by adding the right to use one or more underlying assets;

– The increase in consideration for the lease is commensurate with the stand-alone price for the increase in scope and any appropriate adjustments to that stand-alone price to reflect the circumstances of the particular contract.

When a lease modification occurs and the above conditions are not met, the Company shall, at the effective date of the lease modification, reallocate the consideration in the modified contract, redetermine the lease term, and remeasure the lease liability by discounting the revised lease payments using a revised discount rate. The Company determines the revised discount rate as the interest rate implicit in the lease for the remainder of the lease term, if that rate can be readily determined, or the Company's incremental borrowing rate at the effective date of the lease modification if the interest rate implicit in the lease cannot be readily determined.

3.27.2 The Company as lessor

On the lease commencement date, the Company classifies leases that substantially transfer all risks and rewards incidental to ownership of the underlying asset as finance leases and classifies other leases that do not substantially transfer all risks and rewards incidental to ownership of the underlying asset as operating leases.

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.27 Lease ( )

3.27.2 T C ( )

(1) A

T . T C . V . I C

(2) A

O C W C T

T C . T 3.10 F

T

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

3 Significant accounting policies and accounting estimates (continued)

3.27 Lease (continued)

3.27.2 The Company as lessee (continued)

(2) Accounting treatment of operating lease (continued)

Income from sublease under operating lease shall be recognized by the Company as lessor:

- Where the Company subleases assets leased from other parties, the Company shall determine the classification of the sublease by reference to the underlying assets rather than the head lease;

- The Company shall account for the head lease and sublease separately.

Income from sublease under operating lease shall be recognized by the Company as lessor:

- If the Company has granted a sublease to the lessee of the head lease and has provided the head lease to the sublessee, the Company shall not derecognize the head lease, and shall account for the sublease in accordance with the provisions of Note 3.10 Financial Instruments.

3.27.3 Sale and leaseback transactions

The Company as the seller-lessee shall measure the sale and leaseback transactions in accordance with the provisions of Note 3.24 Income.

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.27 Lease ( )

3.27.3 S - ( )

(1) T C

I C ;

A 3.27 L 1. T C . I

I C , . P N 3.10 F

(2) T C

I C 2. T C ; C , . P N 3.10 F

No es o he Financial S a emen s

F Y E 31 D 2024

(A RMB)

3 S ( )

3.28 Rep rchase of he Compan 's shares

T C N 5.38.

3.29 De ermining me hod and selec ing basis of impor ance cri erion

I em	Impor ance cri erion
S :	A 10% RMB1,000,000;
R	A 10% RMB1,000,000;
S	A 10% RMB1,000,000;
S	A / 1 10% / RMB1,000,000;
S	T RMB5,000,000;
S - -	N 5% G 1% G RMB15,000,000;
I	A 10% RMB20,000,000;
S	T 5% G RMB20,000,000, / 10% G ;
S	N 5% G 10% G .

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.30 Significan acco n ing es ima es and j dgemen s

T C

1. *E*

A N 3.24, C

T

2. *E*

A N 3.18, C

. T

(N 5.16)

I EBIT

EBIT

C I

EBIT

C

3. *E*

T

C T

( ) . T

4. *M*

I 2022, C H Y H C ., L .,

. A

N 10.2.

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S ( )

3.31 Changes in significan acco n ing policies and acco n ing es ima es

3.31.1 C

(1) I I N . 17 A S B E

O 25 O 2023, M F I N . 17 A S B E (CK 2023 N . 21, I N . 17).

① D

I 17 :

I

F ( ). W

T ( ) ’ I A S B E N . 37 B F I

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

3 S

3.31 Changes in significan acco n ing policies and acco n ing es ima es ( )

3.31.1 C ( )

(1) I I N . 17 A S B E

O 25 O 2023, M F I N . 17 A S B E (CK 2023 N . 21, I N . 17). ( )

② D

I N . 17 . T . T . A : T , B C ,

T B

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

3 Significant accounting policies and accounting estimates (continued)

3.31 Changes in significant accounting policies and accounting estimates (continued)

3.31.1 Changes in significant accounting policies (continued)

(2) Implementation of Interpretation No. 18 of Accounting Standards for Business Enterprises (continued)

According to Interpretation No. 18, the Group shall not recognize deferred income tax liabilities and deferred income tax assets for temporary differences arising from the initial recognition of assets and liabilities in transactions that are not business combinations and affect neither accounting profit nor taxable income (or deductible losses) at the time of transaction, and shall not apply the exemption or initial recognition exemption specified in paragraphs 11 and 13 of Accounting Standards for Business Enterprises No. 18 – Income Tax. For lease transactions and decommissioning obligations in which the Group is the lessee, the Group recognizes deferred income tax liabilities and deferred income tax assets for the taxable temporary differences and deductible temporary differences arising from the initial recognition of the lease liabilities and the right-of-use assets on the commencement date of the lease, and the decommissioning obligations and the corresponding amounts recognized as part of the cost of the related assets, respectively, and the taxable temporary differences and deductible temporary differences arising from subsequent changes in the lease liabilities and the right-of-use assets, and the decommissioning obligations and the corresponding amounts recognized as part of the cost of the related assets, respectively, shall be applied to the transactions occurring between the beginning of the earliest comparative financial statement period presented in the financial statements and the date of implementation of the Interpretation.

The Group has adjusted the relevant financial statement items for the earliest comparative financial statement period presented in the financial statements for the cumulative impact of the first implementation of the Interpretation on the date of implementation of the Interpretation.

3.31.2 Changes in significant accounting estimates

The Group has no significant changes in accounting estimates during the reporting period.

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

4 T

4.1 Major a pes and a ra es

Ta pe	Basis of a assessmen	Ta ra e
V	O VAT VAT, VAT VAT	3%, 6%,13%
U	L VAT	7%
E	L VAT,	5%
E	L	15%, 20%, 25%

N

Ta pa er	Income a ra e
W K H C ., L .	15%
J H T C ., L	15%
Y K H M C ., L .	20%

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

4 T ( )

4.2 Preferen ial a rea men

1. P C O B P B L VAT P B T (CS 2016 N . 36). M F S T A C A M M I (O S C N . 149) S C I M A M M I (O M H N . 35) M H M I P L

2. P R P W K J F C , C , VAT 3%

3. P M I P P L VAT P B T C O B P B L VAT P B T (CS 2016 N . 36). M F S T A , R P C VAT 6% 3%.

4. T C C H N T E (N . GR202133010023) D S T P 3 . U A 28 E I T L P ' R C , C 15%.

5. O 8 D 2023, J H T C ., L ., C , C H N T E (N . GR202333001809) S T D P 3 . U A 28 E I T L P ' R C , C 15% 1 J 2023 31 D 2026.

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to items of the consolidated financial statements

5.1 Cash at bank and on hand

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Cash on hand	192,804.35	371,623.69
Cash at bank	255,642,342.05	416,980,298.98
Other cash balances	5,913,864.22	1,509,798.72
Total	261,749,010.62	418,861,721.39

Other explanations:

As at the end of the period, the Company's cash at bank and on hand amounted to RMB6,516,266.46, which was pledged or restricted, see Note 5.20.

5.2 Financial assets held for trading

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Financial assets at fair value through profit or loss		
Including: Investments in equity instruments	7,938,322.41	7,350,298.53
Including:	7,938,322.41	7,350,298.53
Total	7,938,322.41	7,350,298.53

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.3 Notes receivable

5.3.1 Presentation of notes receivable

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Bank acceptance bills	663,798.83	
Total	663,798.83	

5.3.2 Disclosure by method of bad debt provision

	Balance as at 31 December 2024					Balance as at 31 December 2023				
	Book balance		Provision for bad debts			Book balance		Provision for bad debts		
Category	Amount	Proportion (%)	Amount	Proportion of provision (%)	Book value	Amount	Proportion (%)	Amount	Proportion (%)	Book value
Provision for bad debts made on an individual basis										
Including:										
Provision for bad debts made on an individual basis for notes receivable	663,798.83	100.00			663,798.83					
Total	663,798.83	100.00			663,798.83					

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

5 N

5.4 Acco n s recei able

5.4.1 D

A	Balance as a 31 December 2024	B 31 D 2023
W 1	576,106,513.42	425,833,221.01
1 2	20,258,896.20	6,696,709.84
2 3	4,413,821.89	4,480,032.80
O 3	4,766,339.71	7,780,009.57
S	605,545,571.22	444,789,973.22
L	33,732,614.25	24,348,903.66
T	571,812,956.97	420,441,069.56

T C T

5.4.2 D

	Balance as a 31 December 2024					B 31 D 2023				
	Book balance		Pro ision for bad deb s			B				
T	Amo n	Propor ion (%)	Amo n	Propor ion of pro ision (%)	Book al e	A	(%)	A	(%)	B
I :										
M	12,375,105.95	2.04	12,337,791.47	99.70	37,314.48	19,507,030.88	4.39	12,854,582.28	65.90	6,652,448.60
I :	12,375,105.95	2.04	12,337,791.47	99.70	37,314.48	19,507,030.88	4.39	12,854,582.28	65.90	6,652,448.60
P	593,170,465.27	97.96	21,394,822.78	3.61	571,775,642.49	425,282,942.34	95.61	11,494,321.38	2.70	413,788,620.96
I :	593,170,465.27	97.96	21,394,822.78	3.61	571,775,642.49	425,282,942.34	95.61	11,494,321.38	2.70	413,788,620.96
T	605,545,571.22	100.00	33,732,614.25	/	571,812,956.97	444,789,973.22	100.00	24,348,903.66	/	420,441,069.56

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise indicated)

5 Notes to items of the financial statements (continued)

5.4 Accounts receivable (continued)

5.4.2 Disclosure by method of provision for bad debts (continued)

Specific provision for bad debts:

Name	Balance as at 31 December 2024				Balance as at 31 December 2023	
	Book balance	Provision for bad debts	Proportion of provision (%)	Basis of provision	Book balance	Provision for bad debts
Medical insurance receivables	12,375,105.95	12,337,791.47	99.70	Provision for bad debts for lifetime expected credit loss	19,507,030.88	12,854,582.28
Total	12,375,105.95	12,337,791.47	/	/	19,507,030.88	12,854,582.28

Note: For the basis of determining the combination, see Note 3.10.

Provision for bad debts made, recovered or reversed during the reporting period:

Important write-offs during the reporting period:

Name	Balance as at 31 December 2024		
	Accounts receivable	Provision for bad debts	Proportion of provision (%)
Public medical insurance	593,170,465.27	21,394,822.78	3.61
Total	593,170,465.27	21,394,822.78	/

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise indicated)

5 Notes to items of the financial statements (continued)

5.4 Accounts receivable (continued)

5.4.3 Provision for bad debts for the year 2024

Type	Balance as at 31 December 2023	Provision	Recovery or reversal	Write-off	Other changes	Balance as at 31 December 2024
Provision for bad debts assessed individually	12,854,582.28		516,790.81			12,337,791.47
Provision for bad debts assessed by portfolio	11,494,321.38	19,632,862.48		9,732,361.08		21,394,822.78
Total	24,348,903.66	19,632,862.48	516,790.81	9,732,361.08		33,732,614.25

5.4.4 Accounts receivable written off for the year 2024

Item	Write-off amount
Accounts receivable written off	9,732,361.08

Significant accounts receivable written off:

Enterprise name	Nature of accounts receivable	Write-off amount	Reason for write-off	Write-off procedures performed	Whether it is due to related-party transaction
Medical insurance fund	Receivables	9,732,361.08	Aged over 3 years	Unable to recover	No
Total	/	9,732,361.08	/	/	/

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.5 Advances to suppliers

By aging

Aging	Balance as at 31 December 2024 Amount	Proportion (%)	Balance as at 31 December 2023 Amount	(%)
Within 1 year	14,660,777.90	99.64	9,048,941.18	92.05
1 to 2 years	53,185.34	0.36	742,811.80	7.56
2 to 3 years			6,000.00	0.06
Over 3 years			32,800.00	0.33
Total	14,713,963.24	100.00	9,830,552.98	100.00

5.6 Other receivables

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Interest receivable	787,500.00	
Dividends receivable		
Other receivables	80,567,441.59	69,705,728.98
Total	81,354,941.59	69,705,728.98

5.6.1 Interest receivable

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Time deposits	787,500.00	
Subtotal	787,500.00	
Less: Provision for bad debts		
Total	787,500.00	

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to items of the consolidated balance sheet (continued)

5.6 Other receivables (continued)

5.6.2 Other receivables

(1) Details

Aging	Balance as at 31 December 2024	Balance as at 31 December 2023
Within 1 year	25,849,875.86	53,412,990.26
1 to 2 years	49,150,437.26	29,894,811.69
2 to 3 years	12,039,651.89	8,912,677.15
3 to 4 years	8,603,521.35	5,404,423.07
4 to 5 years	4,769,598.96	742,744.83
Over 5 years	4,306,969.79	3,885,239.68
Subtotal	104,720,055.11	102,252,886.68
Less: Provision for bad debts	24,152,613.52	32,547,157.70
Total	80,567,441.59	69,705,728.98

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.6 Other receivables (continued)

5.6.2 Other receivables (continued)

(2) Classification by nature of amounts

	Balance as at 31 December 2024					Balance as at 31 December 2023				
	Book balance		Provision for bad debts			Book balance		Provision for bad debts		
Category	Amount	Proportion (%)	Amount	Proportion of provision (%)	Book value	Amount	Proportion (%)	Amount	Proportion (%)	Book value
Receivables with significant individual amounts and individually assessed for provision for bad debts	21,694,758.77	20.72	21,694,758.77	100.00		37,404,736.41	36.58	30,697,494.28	82.07	6,707,242.13
Including:										
Hubei Yuanchuang Medical Management Co., Ltd.	8,000,000.00	7.64	8,000,000.00	100.00		23,709,977.64	23.19	17,002,735.51	71.71	6,707,242.13
Shanghai Huiyi Property Management Co., Ltd.	10,204,311.69	9.74	10,204,311.69	100.00		10,204,311.69	9.98	10,204,311.69	100.00	
Wuhan Chuangyi Medical Technology Co., Ltd.	3,490,447.08	3.33	3,490,447.08	100.00		3,490,447.08	3.41	3,490,447.08	100.00	
Receivables with insignificant individual amounts but individually assessed for provision for bad debts	83,025,296.34	79.28	2,457,854.75	2.96	80,567,441.59	64,848,150.27	63.42	1,849,663.42	2.85	62,998,486.85
Including:										
Provision for bad debts on receivables with insignificant individual amounts but individually assessed for provision for bad debts	83,025,296.34	79.28	2,457,854.75	2.96	80,567,441.59	64,848,150.27	63.42	1,849,663.42	2.85	62,998,486.85
Total	104,720,055.11	100.00	24,152,613.52	/	80,567,441.59	102,252,886.68	100.00	32,547,157.70	/	69,705,728.98

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.6 Other receivables (continued)

5.6.2 Other receivables (continued)

(3) Disclosure by provision for bad debts

Provision for bad debts	Stage I 12-Month expected credit loss	Stage II Lifetime expected credit loss (without credit impairment)	Stage III Lifetime expected credit loss (with credit impairment)	Total
Balance as at 31 December 2023	1,849,663.42		30,697,494.28	32,547,157.70
In 2024, balance as at 31 December 2023				
—Transferred to Stage II				
—Transferred to Stage III				
—Reversed to Stage II				
—Reversed to Stage I				
Provision for the year 2024	631,733.40		6,707,242.13	7,338,975.53
Reversal for the year 2024	49.29			49.29
Write-off for the year 2024	270.48		15,709,977.64	15,710,248.12
Closing for the year 2024	23,222.30			23,222.30
Other changes				
Balance as at 31 December 2024	2,457,854.75		21,694,758.77	24,152,613.52

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

5 N

5.6 O her recei ables ( )

5.6.2 O ( )

(3) D ( )

C :

Book balance	S age I 12-Mon h e pec ed credi loss	S age II Life ime e pec ed credi loss (i ho credi impairmen)	S age III Life ime e pec ed credi loss (i h credi impairmen)	To al
B 31 D 2023	64,848,150.27		37,404,736.41	102,252,886.68
I 2024, 31 D 2023				
—To S II				
—To S III				
—R S II				
—R S I				
I 2024	18,177,146.07			18,177,146.07
D 2024			15,709,977.64	15,709,977.64
O				
B 31 D 2024	83,025,296.34		21,694,758.77	104,720,055.11

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.6 Other receivables (continued)

5.6.2 Other receivables (continued)

(4) Provision for bad debts in 2024

Category	Balance as at 31 December 2023	Provision	Recovery or reversal	Write-off	Other changes	Balance as at 31 December 2024
Provision for bad debts on other receivables with significant amount and provided for bad debts individually	30,697,494.28	6,707,242.13		15,709,977.64		21,694,758.77
Provision for bad debts on other receivables with insignificant amount but provided for bad debts individually	1,849,663.42	631,733.40	49.29	23,492.78		2,457,854.75
Total	32,547,157.70	7,338,975.53	49.29	15,733,470.42		24,152,613.52

(5) Other receivables written off in 2024

Item	Amount
Other receivables written off	15,733,470.42

Significant other receivables written off:

Enterprise name	Nature of other receivables	Charge-off amount	Reason for charge-off	Charge-off procedures performed	Whether it is due to other related-party transaction
Hainan Yihai Hospital Co., Ltd.	Receivables	15,709,977.64	Difficult to recover	Under the approval of the Board of Directors	No
Total	/	15,709,977.64	/	/	/

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.6 Other receivables (continued)

5.6.2 Other receivables (continued)

(6) Classified by nature of payments

Nature of payments	Book balance as at 31 December 2024	Book balance as at 31 December 2023
Deposits	**19,433,847.49**	22,266,761.49
Subsidies	**38,067,000.00**	19,150,000.00
Loans	**3,878,281.89**	4,818,862.51
Advances	**256,914.93**	51,045.33
Receivables from employees	**39,121,016.95**	52,887,698.31
Others	**3,962,993.85**	3,078,519.04
Total	**104,720,055.11**	102,252,886.68

5.7 Inventories

	Balance as at 31 December 2024		Balance as at 31 December 2023	
Category	Book balance	Provision for impairment of inventories	Book balance	Provision for impairment of inventories

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.8 Other current assets

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Input VAT to be deducted	3,761,468.41	205,753.33
Estimated input VAT		4,368.35
Deferred expenses	2,097,885.50	647,898.71
Total	5,859,353.91	858,020.39

5.9 Long-term receivables

Item	Balance as at 31 December 2024			Balance as at 31 December 2023		
	Book balance	Provision for bad debts	Book value	Book balance	Provision for bad debts	Book value
Receivables from sales of goods	14,000,000.00		14,000,000.00	14,000,000.00		14,000,000.00
Total	14,000,000.00		14,000,000.00	14,000,000.00		14,000,000.00

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.10 Long-term equity investments

5.10.1 Details

Investee	Balance as at 31 December 2023	Balance as at 31 December 2023	Additions	Reductions	Investment income recognised under equity method	Adjustments to other comprehensive income	Other changes in equity	Declaration of cash dividends or profits	Provision for impairment	Balance as at 31 December 2024	Balance of provision for impairment as at 31 December 2024
Associates											
Hangzhou Anmeitang Medical Technology Co., Ltd.	16,018,884.98			2,505,129.87	-11,654,848.94					6,869,165.91	
Wenzhou Lvyuan Yuhang Hospital Co., Ltd.	56,841,432.86			-416,654.25						56,424,778.61	
Zhejiang Huimei Medical Management Co., Ltd.	21,561,607.67		21,168,383.43	-393,224.24							
Shaoxing Shangyu Huimei Medical Management Co., Ltd.	22,287,534.75			-297,898.00						21,989,636.75	
Changsha Hexing Kangning Hospital Co., Ltd.	18,649,398.65			-1,656,814.62			10,745,274.26			16,992,584.03	10,745,274.26
Zhejiang Fuyang Nuotai Medical Management Co., Ltd.	3,713,128.14	2,000,000.00		-801,867.70						4,911,260.44	
Wenzhou Ouhai Huimei Medical Management Co., Ltd.		3,000,000.00		-28,166.28						2,971,833.72	
Total	139,071,987.05	5,000,000.00	21,168,383.43	-1,089,495.22	-11,654,848.94		10,745,274.26			110,159,259.46	10,745,274.26

Other explanations: During the reporting period, Hangzhou Anmeitang Medical Technology Co., Ltd., Zhejiang Huimei Medical Management Co., Ltd., Shaoxing Shangyu Huimei Medical Management Co., Ltd., Changsha Hexing Kangning Hospital Co., Ltd., Zhejiang Fuyang Nuotai Medical Management Co., Ltd., and Wenzhou Ouhai Huimei Medical Management Co., Ltd. (collectively, the "Target Companies") underwent equity transfers, and the Company acquired equity interests in the Target Companies at a total consideration of RMB37,828,137.78, thereby increasing its shareholding ratio to 30.81%, and the Company recognized investment income under the equity method of RMB11,654,848.94.

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise indicated)

5 Notes to items of the financial statements (continued)

5.10 Long-term equity investments (continued)

5.10.2 Investments in associates

Investment in Chongqing Kangning Hospital Co., Ltd. ("Kangning Hospital"), an associate of the Company, with a carrying amount of RMB10,745,274.26.

5.11 Other non-current financial assets

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Financial assets measured at fair value through profit or loss	36,755,116.10	65,099,055.34
Including: Investments in equity instruments	36,755,116.10	65,099,055.34
Total	36,755,116.10	65,099,055.34

5.12 Fixed assets

5.12.1 Fixed assets

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Fixed assets	889,544,442.13	794,856,342.94
Disposal of fixed assets		
Total	889,544,442.13	794,856,342.94

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts in the notes are denominated in RMB unless otherwise stated)

5 Notes to items of the consolidated financial statements (continued)

5.12 Fixed assets (continued)

5.12.2 Details

Item	Buildings	Machinery equipment	Transportation vehicles	Electronic equipment	Furniture and fixtures	Total
1. Original carrying amount						
(1) Balance as at 31 December 2023	870,189,179.09	80,978,235.73	13,585,774.73	62,896,115.93	101,426,794.17	1,129,076,099.65
(2) Increase in 2024	124,565,215.63	48,924,243.57	2,410,744.43	22,459,780.35	41,808,828.13	240,168,812.11
Purchase		14,832,296.07	601,138.00	8,495,394.60		23,928,828.67
Transfer from construction in progress	124,565,215.63					124,565,215.63
Others		34,091,947.50	1,809,606.43	13,964,385.75	41,808,828.13	91,674,767.81
(3) Decrease in 2024	14,774,979.80	43,549,422.37	2,871,189.42	8,435,811.22	50,303,149.68	119,934,552.49
Disposal or retirement	1,655,502.10	18,575,217.78	376,100.33	7,202,754.47	450,210.00	28,259,784.68
Others	13,119,477.70	24,974,204.59	2,495,089.09	1,233,056.75	49,852,939.68	91,674,767.81
(4) Balance as at 31 December 2024	979,979,414.92	86,353,056.93	13,125,329.74	76,920,085.06	92,932,472.62	1,249,310,359.27
2. Accumulated depreciation						
(1) Balance as at 31 December 2023	141,204,440.95	58,760,403.20	8,132,499.35	44,567,939.35	81,554,473.86	334,219,756.71
(2) Increase in 2024	26,197,404.98	39,762,947.88	2,854,394.31	20,167,893.04	25,382,890.09	114,365,530.30
Provision	25,567,157.03	9,093,050.81	1,100,638.61	7,623,139.61	5,856,333.57	49,240,319.63
Others	630,247.95	30,669,897.07	1,753,755.70	12,544,753.43	19,526,556.52	65,125,210.67
(3) Decrease in 2024	3,514,055.87	31,997,812.70	1,360,534.73	5,981,199.78	45,965,766.79	88,819,369.87
Disposal or retirement	512,174.44	16,675,956.08	424,953.49	5,713,962.55	367,112.64	23,694,159.20
Others	3,001,881.43	15,321,856.62	935,581.24	267,237.23	45,598,654.15	65,125,210.67
(4) Balance as at 31 December 2024	163,887,790.06	66,525,538.38	9,626,358.93	58,754,632.61	60,971,597.16	359,765,917.14

5 N

5.12 Fixed assets

5.12.2 D

Item	Buildings	Machinery equipment	Transportation vehicles	Electronic equipment and other equipment	Fixtures	Total
3. Balance at the end of the period						
(1) Balance at 31 December 2023						
(2) Increase in 2024						
(3) Decrease in 2024						
(4) Balance at 31 December 2024						
4. Book value						
(1) Book value at 31 December 2024	816,091,624.86	19,827,518.55	3,498,970.81	18,165,452.45	31,960,875.46	889,544,442.13
(2) Book value at 31 December 2023	728,984,738.14	22,217,832.53	5,453,275.38	18,328,176.58	19,872,320.31	794,856,342.94

Other notes:

As at 31 December 2024, [illegible] RMB277,405,475.89 [illegible]. See Note 5.20 [illegible].

5.13 Construction in progress

5.13.1 C

Item	Balance as at 31 December 2024			Balance as at 31 December 2023		
	Book balance	Provision for impairment	Book value	Book balance	Provision for impairment	Book value
Construction in progress	185,164,227.10		185,164,227.10	186,980,240.67		186,980,240.67
Total	185,164,227.10		185,164,227.10	186,980,240.67		186,980,240.67

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

5 N ( )

5.13 Cons n c ion in progress ( )

5.13.2 B

	Balance as a 31 December 2024			B 31 D 2023		
I em	Book balance	Pro ision for impairmen	Book al e	B	P	B
T L Y H	159,409,044.58		159,409,044.58	101,029,929.74		101,029,929.74
T L K H	24,326,199.34		24,326,199.34			
T L C H				85,174,600.41		85,174,600.41
T C Y H	867,174.00		867,174.00			
O	561,809.18		561,809.18	775,710.52		775,710.52
T	185,164,227.10		185,164,227.10	186,980,240.67		186,980,240.67

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

5 Notes to the consolidated financial statements (continued)

5.13 Construction in progress

5.13.3 Changes in significant construction in progress for the year 2024

Item	Budget (RMB'0,000)	Balance at 31 December 2023	Increase in 2024	Transfer to fixed assets in 2024	Other decrease in 2024	Balance at 31 December 2024	Project progress (%)	Accumulated capitalised interest	Including: capitalised interest for the year	Interest capitalisation rate for the year (%)	Source of funds
Tianhe Kangning Hospital Phase Y	18,412.19	101,029,929.74	58,379,114.84			159,409,044.58	86.58	4,021,943.50	3.03	Specific borrowings and self-raised funds	
Tianhe Kangning Hospital LK	8,754.00	24,326,199.34				24,326,199.34	27.78				
Tianhe Kangning Hospital LC	11,585.67	85,174,600.41	30,682,051.40	115,856,651.81			100.00	2,547,378.83	1,764,381.63	1.83	Specific borrowings and self-raised funds
Total		186,204,330.15	113,387,365.58	115,856,651.81		183,735,243.92	/	10,771,395.75	5,786,325.13	/	/

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts in RMB unless otherwise stated)

5 Notes to items of the consolidated financial statements (continued)

5.14 Right-of-use assets

Item	Buildings and constructions	Total
1. Original carrying amount		
(1) Balance at 31 December 2023	301,405,111.73	301,405,111.73
(2) Increase in 2024	10,312,567.96	10,312,567.96
New lease	10,949,778.85	10,949,778.85
Reassessment	-637,210.89	-637,210.89
(3) Decrease in 2024	4,307,078.05	4,307,078.05
Disposal	3,221,361.59	3,221,361.59
Other decrease	1,085,716.46	1,085,716.46
(4) Balance at 31 December 2024	307,410,601.64	307,410,601.64
2. Accumulated depreciation		
(1) Balance at 31 December 2023	112,350,605.05	112,350,605.05
(2) Increase in 2024	36,130,781.58	36,130,781.58
Provision	36,130,781.58	36,130,781.58
(3) Decrease in 2024	2,892,229.55	2,892,229.55
Disposal	2,590,641.64	2,590,641.64
Other decrease	301,587.91	301,587.91
(4) Balance at 31 December 2024	145,589,157.08	145,589,157.08
3. Provision for impairment		
(1) Balance at 31 December 2023		
(2) Increase in 2024		
(3) Decrease in 2024		
(4) Balance at 31 December 2024		
4. Book value		
(1) Book value at 31 December 2024	161,821,444.56	161,821,444.56
(2) Book value at 31 December 2023	189,054,506.68	189,054,506.68

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts in RMB unless otherwise stated)

5 Notes to items of the consolidated financial statements

5.15 Intangible assets

Item	Land use right	Trademark right	Software	Medical practicing qualification	Contractual right to provide management services	Total
1. Original carrying amount						
(1) Balance as at 31 December 2023	154,962,176.05	3,061,637.13	16,215,218.87	216,837,000.00	32,400,000.00	423,476,032.05
(2) Increase in 2024	3,784,472.43					3,784,472.43
Purchase	3,784,472.43					3,784,472.43
(3) Decrease in 2024			177,500.00			177,500.00
Disposal			177,500.00			177,500.00
(4) Balance as at 31 December 2024	158,746,648.48	3,061,637.13	16,037,718.87	216,837,000.00	32,400,000.00	427,083,004.48
2. Accumulated amortization						
(1) Balance as at 31 December 2023	20,300,242.06	1,077,654.89	8,107,861.28	62,972,140.09	10,696,428.57	103,154,326.89
(2) Increase in 2024	3,424,969.95	327,240.30	2,044,286.86	24,896,233.30	1,728,571.43	32,421,301.84
Provision	3,424,969.95	327,240.30	2,044,286.86	24,896,233.30	1,728,571.43	32,421,301.84
(3) Decrease in 2024			28,416.51			28,416.51
Disposal			28,416.51			28,416.51
(4) Balance as at 31 December 2024	23,725,212.01	1,404,895.19	10,123,731.63	87,868,373.39	12,425,000.00	135,547,212.22
3. Provision for impairment						
(1) Balance as at 31 December 2023						
(2) Increase in 2024						
(3) Decrease in 2024						
(4) Balance as at 31 December 2024						
4. Book value						
(1) Balance as at 31 December 2024	135,021,436.47	1,656,741.94	5,913,987.24	128,968,626.61	19,975,000.00	291,535,792.26
(2) Balance as at 31 December 2023	134,661,933.99	1,983,982.24	8,107,357.59	153,864,859.91	21,703,571.43	320,321,705.16

Other explanations:

As at 31 December 2024, the Group's intangible assets with a net value of RMB60,484,716.91 were pledged as collateral for bank loans, see Note 5.20.

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to items of the consolidated financial statements (continued)

5.16 Goodwill

5.16.1 Cost

Name of the investees or matters forming goodwill	Balance as at 31 December 2023	Increase in 2024		Decrease in 2024		Balance as at 31 December 2024
		Arising from business combinations	Others	Disposal	Others	
Ordinary partnerships						
Ningyang Hengkang Clinic Co., Ltd.	9,271,800.00					9,271,800.00
Heyang Puhua Hengkang Clinic Co., Ltd.	690,331.47					690,331.47
Guoyang Hengkang Clinic Co., Ltd.	1,549,022.38					1,549,022.38
Wuning Puhua Specialty Hospital Co., Ltd.	7,784,850.00					7,784,850.00
Bozhou Yaohua Hengkang Clinic Co., Ltd.	22,987,331.04					22,987,331.04
Wuhu Yijiahe Tangji Clinic Co., Ltd.	151,048.40					151,048.40
Huaikang Hengkang Clinic Co., Ltd.	5,068,959.78					5,068,959.78
Changkang Puhua Hengkang Clinic Co., Ltd.	6,843,288.91					6,843,288.91
Wuhu Chuangyi Hengkang Clinic Co., Ltd.	19,416,285.97					19,416,285.97
Puchang Yihua Hengkang Clinic Co., Ltd.	51,770,194.67					51,770,194.67
Huaiyuan Yinuo Surgery Clinic Co., Ltd.	1,272,643.00					1,272,643.00
Jinshan Hengkang Clinic Co., Ltd.	5,060,323.85					5,060,323.85
Lingchuankang Hengkang Clinic Co., Ltd.	283,528.10					283,528.10
Dingli Hengkang Clinic Co., Ltd.	2,502,854.13					2,502,854.13
Changjiang Puhua Hengkang Clinic Co., Ltd.	9,564,442.65					9,564,442.65
Wuhu Aiyi Puhua Clinic Co., Ltd.	228,538.31					228,538.31
Subtotal	144,445,442.66					144,445,442.66
Partnerships						
Bozhou Yaohua Hengkang Clinic Co., Ltd.	22,987,331.04					22,987,331.04
Guoyang Hengkang Clinic Co., Ltd.	1,549,022.38					1,549,022.38
Jinshan Hengkang Clinic Co., Ltd.			5,060,323.85			5,060,323.85
Heyang Puhua Hengkang Clinic Co., Ltd.			690,331.47			690,331.47
Subtotal	24,536,353.42		5,750,655.32			30,287,008.74
Balance	119,909,089.24		-5,750,655.32			114,158,433.92

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

5 N ( )

5.16 Good ill ( )

5.16.2 C

Name of good ill asse gro ps or combina ion of asse gro ps	Composi ion and basis of asse gro p or combina ion of asse gro ps	Balance as a 31 December 2024	Whe her o be consis en i h ha adop ed in he pre io s ear
N Y H C ., L .	I	12,150,376.50	Y
H Y P H C ., L .	I	13,495,922.29	Y
G Y H C ., L .	I	9,996,916.53	Y
W N P S H C ., L .	I	7,090,912.39	Y
B Y H C ., L .	I	36,448,619.04	Y
W Y H T C ., L .	I	132,927.06	Y
H K H C ., L .	I	4,755,450.75	Y
C K P H C ., L .	I	10,581,447.23	Y

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

5 Notes to items of the consolidated financial statements (continued)

5.16 Goodwill (continued)

5.16.2 Cash-generating units or groups of cash-generating units to which goodwill is allocated (continued)

Name of goodwill asset groups or combination of asset groups	Composition and basis of asset group or combination of asset groups	Balance as at 31 December 2024	Whether to be consistent with that adopted in the previous year
Wuhan Chuhe Clinic Co., Ltd.	Income from medical services	37,279,360.06	Yes
Puyang Clinic Hospital Co., Ltd.	Income from medical services	119,434,663.26	Yes
Henan Yuning Surgical Clinic Co., Ltd.	Income from medical services	1,676,147.20	Yes
Jiaozuo Shuguang Clinic Co., Ltd.	Income from medical services	69,582,706.16	Yes
Luoyang Clinic Kangkang Hospital Co., Ltd.	Income from medical services	23,336,471.96	Yes
Dengzhou Longhu Clinic Co., Ltd.	Income from medical services	21,590,721.67	Yes
Changjiang Yuyang Pediatric Clinic Co., Ltd.	Income from medical services	27,599,391.81	Yes
Wuhan Aiyuan Pediatric Clinic Co., Ltd.	Income from medical services	18,597.98	Yes

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to the items of the consolidated financial statements (continued)

5.16 Goodwill

5.16.3 Goodwill

Tested for impairment

Item	Beginning balance	Increase in the current period	Decrease in the current period	Ending balance
Name of investee or groups of assets	30,330,376.50	32,000,000.00		
Name of investee or groups of assets	14,849,513.41	13,700,000.00	1,149,513.41	
Name of investee or groups of assets	22,355,324.15	69,000,000.00		
Name of investee or groups of assets	12,553,850.41	35,000,000.00		
Name of investee or groups of assets	21,182,979.24	71,000,000.00		
Name of investee or groups of assets	56,695,646.03	106,000,000.00		
Name of investee or groups of assets	2,948,790.20	5,000,000.00		
Name of investee or groups of assets	171,204,857.93	172,000,000.00		
Name of investee or groups of assets	79,504,909.79	69,000,000.00	10,504,909.79	
Name of investee or groups of assets	26,273,137.48	28,000,000.00		
Name of investee or groups of assets	46,988,085.61	47,000,000.00		
Total	484,887,470.74	647,700,000.00	11,654,423.20	/ /

Item	Basis for determining the existence of impairment	Provision for impairment	Key parameters for the current impairment test (if applicable)	Key parameters for the previous impairment test (if applicable)	Description of the impairment test process and method
Name of investee or groups of assets	Name of investee or groups of assets		Name of investee or groups of assets	Name of investee or groups of assets	Name of investee or groups of assets
Name of investee or groups of assets	Name of investee or groups of assets		Name of investee or groups of assets	Name of investee or groups of assets	Name of investee or groups of assets
Name of investee or groups of assets	Name of investee or groups of assets		Name of investee or groups of assets	Name of investee or groups of assets	Name of investee or groups of assets
Name of investee or groups of assets	Name of investee or groups of assets		Name of investee or groups of assets	Name of investee or groups of assets	Name of investee or groups of assets
Name of investee or groups of assets	Name of investee or groups of assets		Name of investee or groups of assets	Name of investee or groups of assets	Name of investee or groups of assets
Name of investee or groups of assets	Name of investee or groups of assets		Name of investee or groups of assets	Name of investee or groups of assets	Name of investee or groups of assets
Name of investee or groups of assets	Name of investee or groups of assets		Name of investee or groups of assets	Name of investee or groups of assets	Name of investee or groups of assets
Name of investee or groups of assets	Name of investee or groups of assets		Name of investee or groups of assets	Name of investee or groups of assets	Name of investee or groups of assets
Name of investee or groups of assets	Name of investee or groups of assets		Name of investee or groups of assets	Name of investee or groups of assets	Name of investee or groups of assets
Name of investee or groups of assets	Name of investee or groups of assets		Name of investee or groups of assets	Name of investee or groups of assets	Name of investee or groups of assets
Name of investee or groups of assets	Name of investee or groups of assets		Name of investee or groups of assets	Name of investee or groups of assets	Name of investee or groups of assets

Note: Name of investee or groups of assets RMB5,750,655.32 Name of investee or groups of assets.

No es o he Financial S a emen s

F . . Y. E 31 D. 2024
(A RMB.)

5 N ( )

5.16 Good ill ( )

5.16.4 K

Asse gro p or combina ion of asse gro p	A erage n mber of beds in opera ion	Ke parame ers d ring he forecas period A erage dail e pendi re per bed for inpa ien s (bed/da /RMB)	Ne profi margin on sales	Pre- a disco n ra e
N Y H C., L.	162	319	14.08%	12.70%
H. Y P H C., L.	300	191	7.47%	12.70%
W. N P S H C., L.	330	228	11.07%	12.70%
H K H C., L.	220	201	24.40%	12.70%
C . K P H C., L.	360	225	21.60%	12.70%
W. C H C., L.	388	582	11.82%	12.70%
P C Y H C., L.	691	530	6.20%	12.70%
H . Y N S C., L.	200	126	8.16%	12.70%
J. S. H C., L.	404	274	11.66%	12.70%
D . L. H C., L.	320	143	8.54%	12.70%
C . J. Y P H C., L.	356	207	9.62%	12.70%

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise indicated)

5 Notes to items of the financial statements (continued)

5.17 Long-term prepaid expenses

Item	Balance as at 31 December 2023	Increase in 2024	Amortization in 2024	Other decrease	Balance as at 31 December 2024
Renovation	175,706,029.27	11,573,213.90	36,908,485.09	120,071.30	150,250,686.78
Rent	178,292.93	38,000.00	71,618.95		144,673.98
Other	26,303.94		14,633.22		11,670.72
Total	175,910,626.14	11,611,213.90	36,994,737.26	120,071.30	150,407,031.48

5.18 Deferred income tax assets and deferred income tax liabilities

5.18.1 Details of unoffset deferred income tax assets and deferred income tax liabilities

Item	Balance as at 31 December 2024		Balance as at 31 December 2023	
	Deductible temporary differences	Deferred income tax assets	Deductible temporary differences	Deferred income tax assets
Provision for impairment of assets	26,538,427.87	5,287,300.54	25,318,013.56	5,221,670.24
Unrealized profit from internal transactions	40,937,273.96	10,234,318.49	12,292,271.17	3,073,067.80
Deductible losses	149,112,887.66	30,900,227.31	126,627,704.89	26,623,506.01
Lease liabilities	177,260,490.33	44,473,733.97	181,046,756.88	45,261,689.23
Salary payable	58,128,415.43	8,720,971.12	54,688,502.33	8,203,275.35
Total	451,977,495.25	99,616,551.43	399,973,248.83	88,383,208.63

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

5 N ( )

5.18 Deferred income a asse s and deferred income a liabili ies ( )

5.18.2 D

I em	Balance as a 31 December 2024 Ta able emporar differences	Deferred income T a liabili ies	B 31 D	D
A C	162,308,548.18	40,577,137.06	175,124,829.41	43,659,778.78

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to items of the consolidated financial statements (continued)

5.18 Deferred income tax assets and deferred income tax liabilities (continued)

5.18.4 Details of unrecognized deductible temporary differences and deductible losses

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Deductible temporary differences	8,368,159.52	1,081,752.53
Deductible losses	58,354,984.35	43,468,613.13
Total	66,723,143.87	44,550,365.66

5.18.5 Deductible losses not recognized as deferred income tax assets will expire in the following years

Year	Balance as at 31 December 2024	Balance as at 31 December 2023	Remarks
2025	11,276,025.44	11,276,025.44	
2026	7,834,515.76	7,834,515.76	
2027	7,112,174.17	7,112,174.17	
2028	11,574,030.72	17,245,897.76	
2029	20,558,238.26		
Total	58,354,984.35	43,468,613.13	

5.19 Other non-current assets

Item	Balance as at 31 December 2024			Balance as at 31 December 2023		
	Book balance	Provision for impairment	Book value	Book balance	Provision for impairment	Book value
Prepayments for equipment	7,764,995.66		7,764,995.66	6,034,588.26		6,034,588.26
Prepayments for intangible assets	3,468,668.68		3,468,668.68	3,654,622.68		3,654,622.68
Total	11,233,664.34		11,233,664.34	9,689,210.94		9,689,210.94

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

5 N

5.20 Asse s i h res ric ed o nership or righ -of- se

	As a 31 December 2024				A 31 D 2023			
I em	Book balance	Book al e	T pe of res ric ion	Si a ion of res ric ion	B	B	T	S
C	150,009.00	150,009.00	Fre ing	Bank accep ance bill deposi	772,510.54	772,510.54	Fi	B
	5,000,000.00	5,000,000.00	Fre ing	Performance bond	12,000,000.00	12,000,000.00	Fi	P
	1,364,131.55	1,364,131.55	Fre ing	Foreign e change s per ision acco n	1,361,750.73	1,361,750.73	Fi	F
	2,125.91	2,125.91	Fre ing	La s i	2,120.75	2,120.75	Fi	L
			Fre ing	O hers	2,000.00	2,000.00	Fi	O
L	208,244,700.00	208,244,700.00	Pledge	Pledged borro ings	208,244,700.00	208,244,700.00	P	P
F	92,932,472.62	31,960,875.46	Mor gage	Sale and leaseback	101,426,794.17	19,872,320.31	M	S
	308,835,922.00	277,405,475.89	Mor gage	Mor gaged borro ings	161,856,152.45	156,403,844.80	M	M
I	69,872,967.58	60,484,716.91	Mor gage	Mor gaged borro ings	59,523,538.00	52,511,079.33	M	M
T	686,402,328.66	584,612,034.72	/	/	545,189,566.64	451,170,326.46	/	/

5.21 Shor - erm borro ings

I em	Balance as a 31 December 2024	B 31 D 2023
M	75,000,000.00	125,000,000.00
G	16,000,000.00	2,001,700.00
T	91,000,000.00	127,001,700.00

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

5 N

5.22 Financial liabili ies held for rading

I em	Balance as a 31 December 2024	B 31 D 2023
F	14,000,000.00	12,400,000.00
T	14,000,000.00	12,400,000.00

5.23 No es pa able

Ca egor	Balance as a 31 December 2024	B 31 D 2023
B		1,545,021.09
T		1,545,021.09

5.24 Acco n s pa able

A :

I em	Balance as a 31 December 2024	B 31 D 2023
W 1	127,861,415.20	107,790,034.53
1 2	3,124,361.77	1,815,169.24
2 3	751,141.60	85,740.32
O 3	199,461.41	369,063.58
T	131,936,379.98	110,060,007.67

A 31 D 2024, 1 (31 D 2023:).

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.25 Advances from customers

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Advances from customers	**21,319,198.39**	26,563,603.06
Total	**21,319,198.39**	26,563,603.06

Significant advances from customers with ageing over 1 year as at 31 December 2024 (31 December 2023: Nil)

5.26 Contract liabilities

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Contract liabilities	**49,771.35**	
Total	**49,771.35**	

Other notes:

Contract liabilities mainly represent the amounts received in advance from customers for the sale of goods and the provision of services.

5.27 Employee compensation payable

5.27.1 Presentation

Item	Balance as at 31 December 2023	Increase in 2024	Decrease in 2024	Balance as at 31 December 2024
Short-term compensation	80,039,461.84	603,318,873.74	600,750,003.58	**82,608,332.00**
Post-employment benefits – defined contribution plans	4,284,544.56	40,793,129.19	41,938,709.14	**3,138,964.61**
Total	84,324,006.40	644,112,002.93	642,688,712.72	**85,747,296.61**

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.27 Employee compensation payable (continued)

5.27.2 Presentation by deferred and short-term compensation (continued)

Item	Balance as at 31 December 2023	Increase in 2024	Decrease in 2024	Balance as at 31 December 2024
(1) Salaries, bonuses, allowances and subsidies	77,925,215.48	536,966,304.46	534,703,446.46	80,188,073.48
(2) Employee welfare	268,889.28	20,296,719.20	20,105,720.82	459,887.66
(3) Social insurance	1,639,752.64	22,037,176.74	21,945,683.06	1,731,246.32
Including: Medical insurance	1,551,473.36	20,458,117.63	20,379,955.04	1,629,635.95
Work injury insurance	87,568.78	1,513,750.04	1,500,418.95	100,899.87
Maternity insurance		65,309.07	65,309.07	
Others	710.50			710.50
(4) Housing fund	205,604.44	23,784,329.37	23,784,333.37	205,600.44
(5) Labor union fund and employee education fund		234,343.97	210,819.87	23,524.10
Total	80,039,461.84	603,318,873.74	600,750,003.58	82,608,332.00

5.27.3 Presentation by defined contribution plans

Item	Balance as at 31 December 2023	Increase in 2024	Decrease in 2024	Balance as at 31 December 2024
Basic pension insurance	4,142,491.99	39,545,166.43	40,639,845.45	3,047,812.97
Unemployment insurance	142,052.57	1,247,962.76	1,298,863.69	91,151.64
Total	4,284,544.56	40,793,129.19	41,938,709.14	3,138,964.61

According to the relevant regulations of the People's Republic of China, the Company participates in the pension insurance plan organized by the local government. According to the plan, the Company pays pension insurance premiums to the local labor and social security bureau at a certain proportion every month. In addition to the monthly payment of pension insurance premiums, the Company has no other material payment obligations. The corresponding expenses are included in the current profit or loss or the cost of related assets when incurred. The Group

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.28 Taxes and surcharges payable

Taxes and surcharges	Balance as at 31 December 2024	Balance as at 31 December 2023
Value-added tax	1,253,541.90	3,056,261.74
Enterprise income tax	28,623,585.71	30,600,774.99
Individual income tax	1,280,818.51	1,148,089.23
Urban maintenance and construction tax	128,273.19	134,739.29
Housing property tax	6,799,424.03	2,960,159.04
Education surcharge	65,721.04	96,590.18
Land use tax	778,342.55	523,438.18
Stamp duty	195,717.23	31,053.22
Environmental protection tax	2,121.00	1,869.00
Water conservancy fund	538.69	771.60
Total	39,128,083.85	38,553,746.47

5.29 Other payables

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Interest payable	1,919,729.45	35,313.43
Dividends payable	1,090,000.00	624,000.00
Other payables	78,277,703.70	149,611,261.72
Total	81,287,433.15	150,270,575.15

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise indicated)

5 Notes to items of the financial statements (continued)

5.29 Other payables (continued)

5.29.1 Information

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Interest payable on borrowings and bonds payable	1,919,729.45	35,313.43
Total	1,919,729.45	35,313.43

5.29.2 Dividends payable

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Dividends payable for ordinary shares	1,090,000.00	624,000.00
Total	1,090,000.00	624,000.00

5.29.3 Other payables

(1) By nature

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Payables for equipment and engineering	25,610,062.45	62,637,634.31
Equity incentive	1,313,457.77	1,313,457.77
Accrued expenses	6,681,680.88	6,766,360.73
Deposits	1,136,955.18	1,663,762.95
Current accounts	24,729,158.13	38,542,529.94
Loans	8,748,024.96	9,845,641.28
Payables for purchases	9,416,830.18	28,481,495.22
Others	641,534.15	360,379.52
Total	78,277,703.70	149,611,261.72

As at 31 December 2024, [illegible] 1 [illegible].

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

5 N ( )

5.30 Non-c rren liabili ies ma ring i hin one ear

I em	Balance as a 31 December 2024	B 31 D 2023
L	164,170,000.00	180,020,000.00
L	38,367,421.50	41,747,868.00
L	26,733,022.63	28,643,888.99
T	229,270,444.13	250,411,756.99

5.31 O her c rren liabili ies

I em	Balance as a 31 December 2024	B 31 D 2023
A	615,218.00	
T	615,218.00	

5.32 Long- erm borro ings

I em	Balance as a 31 December 2024	B 31 D 2023
P	78,500,000.00	212,842,127.25
G	222,130,000.00	252,010,000.00
M	554,557,337.44	272,887,087.44
L :	164,170,000.00	180,020,000.00
T	691,017,337.44	557,719,214.69

5.33 Lease liabili ies

I em	Balance as a 31 December 2024	B 31 D 2023
L	151,300,062.80	163,239,532.76
T	151,300,062.80	163,239,532.76

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise indicated)

5 Notes to items of the financial statements (continued)

5.34 Long-term payables

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Long-term payables	71,916,878.60	61,351,340.53
Special payables	4,320,000.00	
Total	76,236,878.60	61,351,340.53

5.34.1 Long-term payables

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Amounts payable for purchase of fixed assets	110,284,300.10	103,099,208.53
Interest payable for long-term payables	16,422,565.39	15,109,210.13
Long-term payables due within 1 year	38,367,421.50	41,747,868.00
Total	71,916,878.60	61,351,340.53

5.34.2 Special payables

Item	Balance as at 31 December 2023	Increase in 2024	Decrease in 2024	Balance as at 31 December 2024	Formation
Government grants		4,320,000.00		4,320,000.00	Government grants for Luzhou Kangning Hospital
Total		4,320,000.00		4,320,000.00	/

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

5 N

5.35 Deferred income

I em	B 31 D 2023	I 2024	D 2024	Balance as a 31 December 2024	F
G	8,734,099.00		303,792.00	8,430,307.00	A
T	8,734,099.00		303,792.00	8,430,307.00	

5.36 Share capi al

I em	B 31 D 2023	N	C 2024 ( ) S	C O	S	Balance as a 31 December 2024
T	74,600,300.00			-1,930,300.00	-1,930,300.00	72,670,000.00

O :

D C 1,930,300 H .

5.37 Capi al reser es

I em	B 31 D 2023	I 2024	D 2024	Balance as a 31 December 2024
S	781,037,804.26		55,014,024.50	726,023,779.76
O				
S	44,857,374.20	3,997,509.78		48,854,883.98
O	26,800,423.23		11,654,848.94	15,145,574.29
T	852,695,601.69	3,997,509.78	66,668,873.44	790,024,238.03

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

5 N ( )

5.37 Capi al reser es ( )

O 2024 :

(1) T RMB23,578,910.13 C N 7. 2

(2) T C TRE H S A T. S RMB9,334,383.19.

(3) A P A B D R P H S A G M 2023, F H S C M 2024, F D S C M 2024 C M 30, 2024, C 1,930,300 H . T RMB22,100,731.18.

(4) I C ' H S A T. S, RMB3,997,509.78 N 12.

(5) D H A M T C., L C ' RMB11,654,848.94

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts in RMB unless otherwise stated)

5 Notes to items of the consolidated financial statements (continued)

5.38 Treasury stocks

Item	Balance as at 31 December 2023	Increase in 2024	Decrease in 2024	Balance as at 31 December 2024
Shares repurchased for the purpose of equity incentive	12,587,011.74	25,253,220.09	15,473,383.19	22,366,848.64
Shares repurchased for the purpose of cancellation		24,031,031.18	24,031,031.18	
Total	12,587,011.74	49,284,251.27	39,504,414.37	22,366,848.64

Other explanations, including changes during the year and reasons for changes, for treasury stocks in 2024:

(1) Pursuant to the Company's H Share Restricted Share Incentive Scheme, 1,991,600 restricted H shares were repurchased by the Company, with a total amount of RMB25,253,220.09, at an average price of HKD1,240,100.00 per share. During the year, RMB15,473,383.19 was transferred out from treasury stocks for the vesting of restricted shares.

(2) The Company repurchased 1,930,300 H shares through centralized bidding transactions, with a total amount of RMB24,031,031.18.

5.39 Surplus reserves

Item	Balance as at 31 December 2023	Increase in 2024	Decrease in 2024	Balance as at 31 December 2024
Statutory surplus reserves	38,399,577.13			38,399,577.13
Total	38,399,577.13			38,399,577.13

Description, including changes during the year and reasons for changes, for surplus reserves in 2024:

According to the Company Law and the Articles of Association of the Company, the Company is required to appropriate 10% of its net profit to statutory surplus reserves until the balance reaches 50% of the registered capital. The appropriation to statutory surplus reserves must be made before distribution of dividends to shareholders.

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.40 Retained earnings

Item	Year 2024	Year 2023
Retained earnings at the end of last year	**311,956,229.16**	233,506,534.43
Total retained earnings at the beginning of the year (+ or -)		
Retained earnings at the beginning of the year	**311,956,229.16**	233,506,534.43
Plus: Net profit attributable to owners of the parent company	**65,610,188.85**	85,947,806.64
Less: Withdrawal of statutory surplus reserve		
Withdrawal of discretionary surplus reserve		
Common stock dividends payable	**33,280,590.00**	7,498,111.91
Common stock dividends converted to share capital		
Retained earnings at the end of the year	**344,285,828.01**	311,956,229.16

(1) According to the Company's 2023 profit distribution plan reviewed and approved at the 26 April 2024 Annual General Meeting, the Company declared cash dividends to all shareholders registered on the record date of 31 May 2024: 74,600,300 shares of the Company as at 31 December 2023, RMB3 (tax inclusive) per 10 shares of the Company, totaling RMB22,380,090 (tax inclusive). The Company completed the payment on 28 June 2024. (The exchange rate for Hong Kong dollars is HKD 0.9103)

(2) According to the Company's First Extraordinary General Meeting on 14 October 2024, the Proposal on Distribution of Profits for the First Half of 2024 was reviewed and approved: Based on the total number of shares of the Company registered on the equity distribution record date in 2024 (74,600,300 shares), a cash dividend of RMB1.50 (tax inclusive) per 10 shares was distributed to all shareholders, totaling RMB11,025,045 (tax inclusive). The Company completed the payment on 18 November 2024 (The exchange rate for Hong Kong dollars is HKD 0.9097).

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.41 Operating income and operating cost

5.41.1 Details

Item	Year 2024		Year 2023	
	Income	Cost	Income	Cost
Main business	1,517,773,042.05	1,125,416,714.47	1,485,160,594.55	1,107,920,076.52
Other business	136,516,371.18	90,468,771.15	111,104,937.58	77,209,878.26
Total	1,654,289,413.23			

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.42 Taxes and surcharges

Item	Year 2024	Year 2023
Housing property tax	**8,739,992.84**	3,840,629.56
Urban maintenance and construction tax	**1,053,941.94**	999,802.54
Education surcharge	**737,327.87**	715,238.61
Land use tax	**917,801.34**	591,575.87
Stamp duty	**546,353.47**	236,151.41
Others	**341,468.27**	91,506.43
Total	**12,336,885.73**	6,474,904.42

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

5 N ( )

5.44 General and adminis ra i e e penses

I em	Year 2024	Y 2023
E	129,004,061.40	117,426,249.41
C	6,011,242.51	14,340,685.87
D	17,850,551.80	16,053,053.39
M	10,919,254.63	11,808,114.41
A	8,751,064.86	9,295,943.53
A	2,819,600.00	5,512,000.00
O	5,031,789.54	5,352,023.47
A	4,190,150.74	3,751,610.40
B	5,713,396.43	5,412,016.04
E	3,997,509.78	
T	4,977,716.48	4,724,842.42
R	6,849,479.49	4,210,351.64
H	3,732,284.42	2,276,807.42
D	349,803.81	336,383.83
D	3,012,235.08	2,862,423.39
O	3,490,839.71	2,356,838.11
W	977,577.12	1,038,793.97
D	3,316,647.39	1,818,421.94
S	3,084,988.50	2,325,816.39
O	3,266,011.72	2,123,331.51
T	227,346,205.41	213,025,707.14

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise indicated)

5 Notes to items of the financial statements (continued)

5.45 Research and development expenses

Item	Year 2024	Year 2023
Employee compensation	35,534,458.87	30,617,367.73
Office expenses	97,145.66	418,828.66
Depreciation expenses	285,738.36	624,385.94
Depreciation of right-of-use assets	74,158.46	152,451.48
Amortization of intangible assets	915.32	
Travel expenses	16,281.28	18,963.20
Consulting fees		47,787.71
Property management fees	28,826.00	21,880.00
Technical service fees	11,422.21	7,034.07
Water and electricity fees	9,622.22	6,591.50
Conference fees	23,000.00	13,781.04
Others	438,092.78	537,124.82
Total	36,519,661.16	32,466,196.15

5.46 Financial expenses

Item	Year 2024	Year 2023
Interest expenses	41,601,182.38	39,936,115.20
Interest income: Interest income from bank deposits	8,458,214.13	9,755,131.70
Less: Interest capitalized	3,122,805.73	5,265,571.27
Gain on exchange	157,162.49	-4,325.27
Handling charges	1,057,179.95	1,091,522.53
Interest on lease liabilities	7,900,441.27	5,694,269.99
Total	47,593,160.36	41,452,011.18

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.47 Other income

Item	Year 2024	Year 2023
Government grants	13,058,565.88	15,747,206.89
Additional deduction for input VAT	45.41	37,292.41
Handling fee refund	195,207.54	192,215.93
Total	13,253,818.83	15,976,715.23

5.48 Investment income

Item	Year 2024	Year 2023
Investment income from long-term equity investments accounted for using the equity method	-1,089,495.22	-6,465,278.89
Investment income from disposal of financial assets at fair value through profit or loss	1,844,372.15	697,750.03
Investment income from disposal of long-term equity investments		-299,668.37
Total	754,876.93	-6,067,197.23

5.49 Gains from changes in fair value

Sources of the gains from changes in fair value	Year 2024	Year 2023
Financial assets at fair value through profit or loss	588,023.88	-3,290,727.47
Financial liabilities at fair value through profit or loss	-1,600,000.00	1,522,929.38
Other non-current financial assets	742,239.73	1,982,203.29
Total	-269,736.39	214,405.20

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise indicated)

5 Notes to items of the financial statements (continued)

5.50 Losses from credit impairment

Item	Year 2024	Year 2023
Loss from credit impairment of other receivables	19,116,071.67	7,172,896.37
Loss from credit impairment of accounts receivable	7,338,926.24	2,181,839.18
Total	26,454,997.91	9,354,735.55

5.51 Losses from impairment of assets

Item	Year 2024	Year 2023
Loss from impairment of contract assets	10,745,274.26	
Impairment loss of inventories	5,750,655.32	
Total	16,495,929.58	

5.52 Gains from disposal of assets

Item	Year 2024	Year 2023	Amount recognized in non-recurring profit or loss for the year
Gains from disposal of fixed assets (losses are listed with "-")	-69,932.29	68,088.99	-69,932.29
Including: Gains from disposal of fixed assets (losses are listed with "-")	-69,932.29	68,088.99	-69,932.29
Total	-69,932.29	68,088.99	-69,932.29

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.53 Non-operating income

Item	Year 2024	Year 2023	Amount recognized in non-recurring profit or loss for the year
Government grants	157,773.18	32,855.87	157,773.18
Including:	157,773.18	32,855.87	157,773.18
Asset disposal gains	46,960.37	5,974,990.37	46,960.37
Gains from changes in fair value of financial assets held for trading, derivative financial assets, derivative financial liabilities, and investments in other equity instruments	86,363.28	566,120.96	86,363.28
Gains from debt restructuring		129,185.58	
Penalty income		1,000.00	
Liquidated damages		1,754,952.00	
Value-added tax refunds	89,700.00		89,700.00
Unpayable accounts	86,864.89	162,522.85	86,864.89
Others	1,061,239.31	923,818.53	1,061,239.31
Total	1,528,901.03	9,545,446.16	1,528,901.03

5.54 Non-operating expenses

Item	Year 2024	Year 2023	Amount recognized in non-recurring profit or loss for the year
Losses from damage and retirement of non-current assets	1,117,414.85	291,184.61	1,117,414.85
Including:	1,117,414.85	291,184.61	1,117,414.85
External donations	2,697,864.84	4,494,074.74	2,697,864.84
Asset disposal losses	20,094.09	264,009.83	20,094.09
Inventory losses	49,092.37	41,926.44	49,092.37
Administrative penalties	1,606,766.04	2,183,827.02	1,606,766.04
Expenses from debt restructuring	2,668,838.80	4,111,097.80	2,668,838.80
Others	622,957.51	429,388.42	622,957.51
Total	8,783,028.50	11,815,508.86	8,783,028.50

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.55 Income and expenses

5.55.1 Lease expenses

Item	Year 2024	Year 2023
Current lease expenses	35,746,101.09	36,259,411.49
Depreciation of right-of-use assets	-18,044,325.80	-24,009,402.00
Total	17,701,775.29	12,250,009.49

5.55.2 Analysis of expenses by nature

Item	Year 2024
Total	68,099,486.66
Interest income from financial assets measured at amortised cost	13,700,455.42
Interest expenses	-43,610.88
Interest income from financial assets measured at fair value through profit or loss	1,468,471.33
Interest income from financial assets measured at fair value through other comprehensive income	6,053,711.27
Interest income from financial assets measured at fair value through profit or loss and financial assets measured at fair value through other comprehensive income	-12,352,475.38
Interest income from financial assets measured at amortised cost and financial assets measured at fair value through other comprehensive income	16,429,654.98
Cash flow hedge transferred from other comprehensive income	-245,058.36
Interest income from financial assets measured at fair value through profit or loss	-1,693,157.90
Interest income from financial assets measured at fair value through profit or loss R&D	-5,605,853.02
Interest income from financial assets measured at fair value through profit or loss	-10,362.17
Interest income from financial assets measured at fair value through profit or loss	17,701,775.29

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

5 N

5.56 Earnings per share

5.56.1 B

T C :

I em	Year 2024	Y 2023
C	65,610,188.85	85,947,806.64
W C	74,278,583.33	74,600,300.00
B	0.88	1.15
I : B	0.88	1.15

5.56.2 D

T C ( ):

I em	Year 2024	Y 2023
C ( )	65,610,188.85	85,947,806.64
W C ( )	74,278,583.33	74,600,300.00
D	0.88	1.15
I : D	0.88	1.15

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.57 Items of statement of cash flows

5.57.1 Cash

(1) Cash

Item	Year 2024	Year 2023
Rental income	14,760,401.02	14,853,235.92
Interest income	17,327,632.97	16,214,614.27
Refund of deposits	3,921,615.94	5,348,551.23
Interest income	46,960.37	8,222,606.16
Interest income	2,335,305.73	3,014,649.40
Net [illegible]	1,150,939.31	2,808,105.11
Refund [illegible]	7,000,000.00	
Refund [illegible]		164,796,135.37
Total	46,542,855.34	215,257,897.46

(2) Cash

Item	Year 2024	Year 2023
Cash [illegible]	10,369,957.83	67,255,904.20
Cash [illegible]	69,909,138.48	80,394,069.79
Deposit	2,697,864.84	6,741,690.53
Net [illegible]	4,898,562.35	3,747,445.03
Fee [illegible]	1,250,922.69	1,111,874.54
Refund [illegible]		1,635,289.27
Other [illegible]	3,586,496.26	10,320,319.28
Refund [illegible]		165,915,458.06
Total	92,712,942.45	337,122,050.70

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise indicated)

5 Notes to items of the financial statements (continued)

5.57 Items of statement of cash flows (continued)

5.57.2 Cash flow information (continued)

(1) Cash flow information (continued)

Item	Year 2024	Year 2023
Interest income		276,383.95
Interest expense		971,616.05
Total		1,248,000.00

(2) Cash flow information (continued)

Item	Year 2024	Year 2023
Net amount of cash and cash equivalents	**942,428.37**	500,059.94
Interest income		13,500,000.00
Total	**942,428.37**	14,000,059.94

Other explanations:

The cash and cash equivalents at the end of the Year amounted to RMB432,733.42. Other monetary funds at the end of the Year amounted to RMB1,375,161.79. The total amount of RMB942,428.37 is presented in Note 5.58.2.

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.57 Items of statement of cash flows (continued)

5.57.3 Cash

(1) Cash

Item	Year 2024	Year 2023
Cash on hand	60,000,000.00	55,000,000.00
Interest receivable		900,000.00
Total	60,000,000.00	55,900,000.00

(2) Cash

Item	Year 2024	Year 2023
Cash on hand	61,246,345.17	100,045,828.93
Cash	31,637,451.28	49,299,788.06
Cash	48,214,658.67	
Cash	9,821,161.72	2,656,500.00
Cash		4,866,900.00
Payments for HS and Tax		18,621,600.00
Total	150,919,616.84	175,490,616.99

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

5 N

5.58 S pplemen ar informa ion o he s a emen s of cash flo s

5.58.1 S

S pplemen ar informa ion	Year 2024	Y 2023
1. N		
N	50,397,711.37	86,931,607.82
P :	26,454,997.91	9,354,735.55
P	16,495,929.58	
D	49,240,319.63	47,460,771.26
D		
D		
D	36,130,781.58	40,597,483.20
A	40,516,786.29	25,492,057.82
A	28,899,252.81	45,839,280.77
L ( )	69,932.29	297,499.85
L ( )	959,641.67	258,328.74
L ( )	269,736.39	-214,405.20
F ( )	42,602,761.73	40,800,972.44
I ( )	-754,876.93	6,067,197.24
D ( )	-11,051,274.17	-18,371,099.67
I ( )	-6,992,997.53	-5,638,302.33
D ( )	9,971,048.87	4,376,940.05
D ( )	-66,194,329.87	-53,549,066.70
I ( )	-121,374,427.72	35,329,236.62
O	3,997,509.78	
N	99,638,503.68	265,033,237.46

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to items in the financial statements (continued)

5.58 Supplementary information to the statement of cash flows (continued)

5.58.1 Supplementary information (continued)

Supplementary information	Year 2024	Year 2023
2. Supplementary information on cash flows:		
Cash		
Cash equivalents		
Restricted cash and cash equivalents		
3. Net increase in cash and cash equivalents		
Ending balance of cash	255,232,744.16	404,723,339.37
Less: Beginning balance of cash	404,723,339.37	258,595,990.97
Plus: Ending balance of cash equivalents		
Less: Beginning balance of cash equivalents		
Net increase in cash and cash equivalents	-149,490,595.21	146,127,348.40

5.58.2 Net cash paid for the acquisition of subsidiaries in 2024

	Amount
Cash and cash equivalents paid for the acquisition of subsidiaries in this period	432,733.42
Including: Wuhan Yuhua Hospital Co., Ltd.	432,733.42
Less: Cash and cash equivalents held by subsidiaries on the acquisition date	1,375,161.79
Including: Wuhan Yuhua Hospital Co., Ltd.	1,375,161.79
Plus: Cash paid for the acquisition of subsidiaries in previous periods	
Net cash paid for the acquisition of subsidiaries	-942,428.37

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts in RMB unless otherwise stated)

5 Notes to items of financial statements (continued)

5.58 Supplementary information to the statement of cash flows (continued)

5.58.3 Bala

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
I. Cash	255,232,744.16	404,723,339.37
Including: Bank deposits available for payment at any time	192,804.35	371,623.69
Unrestricted bank deposits	254,276,084.59	402,841,916.96
Other monetary funds available for payment at any time	763,855.22	1,509,798.72
II. Cash equivalents		
Including: Investments with maturity of three months or less		
III. Ending balance of cash and cash equivalents	255,232,744.16	404,723,339.37
Including: Restricted cash and cash equivalents used by the parent company or subsidiaries within the Group		

Cash and cash equivalents not held by the Company and subject to restrictions on use:

Item	Balance as at 31 December 2024	Balance as at 31 December 2023	Reason
Pledged deposits	5,000,000.00	12,000,000.00	Restricted
Frozen deposits	1,364,131.55	1,361,750.73	Restricted
Deposits with restricted withdrawal	150,009.00	772,510.54	Restricted
Housing maintenance fund	2,125.91	2,120.75	Restricted
Other		2,000.00	Restricted
Total	6,516,266.46	14,138,382.02	

5.59 Notes to items of statement of changes in owners' equity

None

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

5 Notes to items of the financial statements (continued)

5.60 Foreign currency monetary items

Item	Balance in foreign currency at 31 December 2024	Exchange rate	Balance in RMB at 31 December 2024
Cash at bank			333,606.27
Including: USD	40,004.67	7.1884	287,569.57
EUR			
HKD	49,713.51	0.9260	46,036.70

5.61 Lease

5.61.1 As lessee

Item	Year 2024	Year 2023
Interest on lease liabilities	**8,458,214.13**	9,755,131.70
Total cash outflow for leases	**92,883,796.45**	49,299,788.06
Lease liabilities increased	**7,884,721.10**	5,694,269.99
Carrying amount of right-of-use assets increased	**60,000,000.00**	55,000,000.00
Carrying amount of right-of-use assets decreased	**61,246,345.17**	100,045,828.93

The maturity analysis of lease liabilities is presented below:

Remaining lease term	Lease payments undiscounted
Within 1 year	**65,100,444.13**
1 to 2 years	**76,866,885.90**
2 to 3 years	**116,008,440.39**
Over 3 years	**86,707,676.25**
Total	**344,683,446.67**

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts in RMB unless otherwise stated)

6 Changes in consolidation scope

6.1 Disposal of subsidiaries

6.1.1 Transactions or other circumstances in which the Company loses control over subsidiaries in 2024

Name of subsidiary	Disposal price at the time of loss of control	Proportion of disposal at the time of loss of control (%)	Disposal method of loss of control	Timing of loss of control	Determination basis of time point of loss of control	Difference between the disposal price and the share in net assets of the subsidiary in consolidated financial statements corresponding to the investment disposed	Proportion of the residual equity on the date of losing control right	Book value of remaining equity at the consolidated financial statements on the date of loss of control	Fair value of remaining equity at the consolidated financial statements on the date of loss of control	Gains or losses arising from the re-measurement

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

6 Changes in the consolidation scope

6.2 Other reasons for the change of the consolidation scope

Company name	Reason	Date of loss of control
Wenzhou Yongjian Hospital Co., Ltd.	Non-wholly-owned subsidiary	April 2024
Quzhou Kangning Maternity and Child Care Hospital Co., Ltd.	Non-wholly-owned subsidiary	November 2024
Wenzhou Gaofu Hospital Co., Ltd.	Non-wholly-owned subsidiary	May 2024
Cangnan Qianlong Kangning Hospital Co., Ltd.	Investment relationship no longer exists	May 2024
Wenzhou Jiajia Tianyuan Co., Ltd.	Investment relationship no longer exists	November 2024
Wenzhou Yuhang Tianyuan Co., Ltd.	Investment relationship no longer exists	July 2024

No es o he Financial S a emen s

F . . Y . E . . 31 D . . . 2024
(A . . . . RMB . . . .)

7 E . . . .

7.1 Eq i in he s bsidiaries

7.1.1 S . . . . .

N . . .	T . . .	R . . B . . . R . .	N . . .	S . . (%) D . . I . .	W . .
. K H . .					
M . . (G . .) C . L .	L . . .	20,000.00 N .	N .	H . . . 100.00	E . .
P K H . .					
C . L .	L . . .	600.00 P	P	M . . .	100.00 E . .
W . Y G . .					
H . . C . L .	L . . .	3,000.00 W .	W .	M . . .	100.00 E . .
Q . Y H . . C . L .	L . . .	3,000.00 Q .	Q .	M . . .	60.00 E . .
T . L C H . .					
C . L .	L . . .	1,000.00 T .	T .	M . . .	51.00 E . .
Y . K H . .					
M . . C . L .	L . . .	3,000.00 Y .	Y .	H . . .	100.00 E . .
T . K H . . C . L .	L . . .	1,000.00 T .	T .	M . . .	51.00 C . . .
H . C H . . C . L .	L . . .	100.00 H .	H .	M . . .	100.00 E . .
W . T . . TCM					
C . C . L .	L . . .	500.00 W .	W .	M . . .	100.00 E . .
. J . H .					
T . . C . L .	L . . .	1,000.00 H .	H .	T . . .	100.00 E . .
N . Y H . . C . L .	L . . .	1,000.00 N .	N .	M . . .	85.65 C . . .
H . Y P . . H . .					
C . L .	L . . .	3,000.00 H .	H .	M . . .	51.00 C . . .
G Y H . . C . L .	L . . .	1,000.00 G	G	M . . .	C . . .
W . N P . .					
S . . H . . C . L .	L . . .	753.00 T .	T .	M . . .	68.80 C . . .
B . Y H . . C . L .	L . . .	4,653.67 B .	B .	M . . .	51.00 E . .
W . Y H .					
T . . C . L .	L . . .	50.00 W .	W .	T . . .	100.00 C . . .
H K H . . C . L .	L . . .	1,000.00 H	H	M . . .	95.00 C . . .
. Y H .					
T . . C . L .	L . . .	2,040.82 H .	H .	T . . .	98.00 E . .
W . Y D . . C . L .	L . . .	50.00 W .	W .	D . . .	100.00 E . .
Y P . . I .					
H . . (W . .) C . L .	L . . .	500.00 W .	W .	H . . .	100.00 E . .

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

7 Equity in other entities (continued)

7.1 Equity in subsidiaries (continued)

7.1.1 Structure of the Group (continued)

Name	Type	Registered capital	Business nature	Nature	Shareholding (%)	Investment way
Direct Participation						
Changle Kangning Hospital Co., Ltd.	Limited liability company	1,000.00	Wholly-owned	Public welfare	80.00	Establishment
Changle Kangning Hospital						
Huaxi Changle Kangning Hospital Co., Ltd.	Limited liability company	1,500.00	Controlling	Medical	64.55	Combination under common control
Hongyi Medical						
Enshi R&D Changle Kangning Hospital Co., Ltd.	Limited liability company	500.00	Holding	Technology	100.00	Establishment
Hongyi Nursing Service						
Changle Kangning Hospital Co., Ltd.	Limited liability company	100.00	Holding	Nursing	100.00	Establishment
Lichuan Changle Kangning Hospital Co., Ltd.	Limited liability company	5,000.00	Trading	Medical	100.00	Establishment
Shizhu Yihe Hospital	Limited liability company	6,000.00	Shizhu	Shizhu	55.00	Establishment
Pengshui Yihe Hospital						
Hongyi Changle Kangning Hospital Co., Ltd.	Limited liability company	1,400.00	Jiangjin	Medical	66.00	Establishment
Changjiang Kangning Hospital						
Hongyi Changle Kangning Hospital Co., Ltd.	Limited liability company	1,000.00	Holding	Medical	60.00	Establishment
Changle Kangning Hospital Co., Ltd.	Limited liability company	5,000.00	Chongqing	Medical	100.00	Establishment
Changyuan Nursing Center						
Changle Kangning Hospital Co., Ltd.	Limited liability company	1,000.00	Chongqing	Medical	100.00	Establishment
Yuzhong Kangning Hospital Co., Ltd.	Limited liability company	100.00	Yuzhong	Medical	100.00	Establishment
Luzhou Kangning Hospital Co., Ltd.	Limited liability company	200.00	Trading	Medical	85.00	Establishment
Wanzhou Qiyi Elderly Care						
Hongyi Changle Kangning Hospital Co., Ltd.	Limited liability company	1,000.00	Wanzhou	Medical	100.00	Establishment
Qianjiang Kangning Hospital Co., Ltd.	Limited liability company	436.00	Liangping	Liangping	Medical	100.00	Establishment
Wanzhou Changle Kangning Hospital Co., Ltd.	Limited liability company	2,585.98	Wanzhou	Wanzhou	Medical	100.00	Combination under common control
Wanzhou Kangjian						
Fuling Changle Kangning Hospital Co., Ltd.	Joint stock limited company	50.00	Wanzhou	Wanzhou	Joint stock limited company	100.00	Establishment
Wanzhou Laoyi						
Hongyi Changle Kangning Hospital Co., Ltd.	Limited liability company	10,000.00	Wanzhou	Wanzhou	Medical	60.00	Establishment
Yuzhong Kangning Hospital Co., Ltd.	Limited liability company	2,700.00	Wanzhou	Wanzhou	Medical	100.00	Establishment
Pengcheng Yuan						
Hongyi Changle Kangning Hospital Co., Ltd.	Limited liability company	3,057.47	Wanzhou	Wanzhou	Medical	100.00	Combination under common control

No es o he Financial S a emen s

F . . Y . E . . 31 D . . . 2024
(A . . . . RMB . . . .)

7 E . . . . . (. . .)

7.1 Eq i in he s bsidiaries (. . .)

7.1.1 S . . . . . (. . .)

N . . .	T . . .	R . . .	B . . .	R . . .	N . . .	S . . . (%) D . . .	I . . .	W . . .
Y . Y . T . . . W . . .								
M . . H . . C . L .	L . . .	9,800.00	Y .	Y .	M . . .	100.00		C . . .
J . S . H . . C . L .	L . . .	2,398.26	J .	J .	M . . .	55.00		C . . .
L . C . K . K H . . C . L .	L . . .	2,040.00	L .	L .	M . . .	51.00		C . . .
L . K H . . C . L .	L . . .	3,000.00	L .	L .	M . . .		100.00	E . . .
W . A . . P . . C . L .	L . . .	100.00	W .	W .	D . . .		100.00	C . . .
D . . L H . . C . L .	L . . .	1,800.00	S	S	M . . .	51.00		C . . .
W . K P . . C . L .	L . . .	50.00	W .	W .	M . . .	100.00		E . . .
J . J . . E . I . . P . . (L . P . .)	L . . .	6,001.00	J	J	E . . .	66.60	33.30	E . . .
C . J . Y P . . H . . C . L .	L . . .	2,083.33	C .	C .	M . . .		49.33	C . . .
W . G . F . H . . C . L .	L . . .	1,000.00	W .	W .	M . . .		100.00	E . . .
. Y G . . H . . M . . C . L .	L . . .	20,000.00	W .	W .	H . . .	100.00		E . . .
Q . K H . . M . . C . L .	L . . .	2,764.00	L .	L .	H . . .	100.00		E . . .

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

7 Equity in other entities (continued)

7.1 Equity in subsidiaries (continued)

7.1.1 Structure of the Group (continued)

Note:

(a) As at 31 December 2024, Wenzhou Kangning Hospital Co., Ltd. directly holds 100% equity interest in Wenzhou Kangning Hospital Management Co., Ltd., Wenzhou Kangning Hospital Group Co., Ltd. directly holds 100% equity interest in Wenzhou Kangning Hospital Management Co., Ltd.

(b) Significant non-wholly-owned subsidiaries:

Changjiang Yangtze Pharmaceutical Co., Ltd. directly holds 49.33% equity interest in Changjiang Yangtze Pharmaceutical Co., Ltd. Changjiang Yangtze Pharmaceutical Co., Ltd. directly holds 100% equity interest in Changjiang Yangtze Pharmaceutical (Liaocheng) Co., Ltd.

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

7 E ( )

7.1 Eq i in he s bsidiaries ( )

7.1.2 M

Name of s bsidiaries	Shareholding ra io of minori shareholders (%)	Profi or loss a rib able o minori shareholders in 2024	Di idends declared o be dis rib ed o minori shareholders in 2024	Balance of minori eq i as a 31 December, 2024
W L Y H C ., L .	40.00	-244,591.66		32,122,348.71
J S. H C ., L .	45.00	-2,377,459.39		15,308,835.39
D. P C ., L .	20.00	130,964.19		21,457,805.69

7.1.3 M

	Balance as a 31 December 2024					
Name of s bsidiar	G rren asse s	Non-o rren asse s	To al asse s	G rren liabili ies	Non-o rren liabili ies	To al liabili ies
W L Y H C ., L .	11,954,272.04	184,644,954.86	196,599,226.90	699,355.11	115,594,000.00	116,293,355.11
J S. H C ., L .	12,386,739.26	70,370,750.35	82,757,489.61	19,680,759.72	27,801,932.47	47,482,692.19
D. P C ., L .	182,793,237.29	1,120,808.89	183,914,046.18	63,460,532.96	571,689.49	64,032,222.45

	B 31 D 2023					
N	C	N	T	C	N	T
W L Y H C ., L .	12,771,926.28	126,317,515.02	139,089,441.30	48,340.35	75,123,750.00	75,172,090.35
J S. H C ., L .	13,868,975.32	71,012,513.90	84,881,489.22	15,643,448.52	28,680,000.20	44,323,448.72
D. P C ., L .	116,361,981.18	775,471.82	117,137,453.00	58,483,676.92		58,483,676.92

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

7 Equity in other entities (continued)

7.2 Transactions with changes in the share of owners' equity in subsidiaries but still with control over the subsidiaries (continued)

7.2.2 Impact of transactions on non-controlling interests and owners' equity attributable to the parent company

	Pujiang Yining	Chun'an Kangning
Cash consideration for acquisition of non-controlling interests	14,686,521.08	10,545,862.35
Cash	5,220,000.00	4,000,000.00
Fair value of other consideration	9,466,521.08	6,545,862.35
Total consideration for acquisition of non-controlling interests	14,686,521.08	10,545,862.35
Less: Share of net assets of subsidiaries calculated based on the proportion of equity acquired	3,544,158.42	1,484,726.32
Difference	11,142,362.66	9,061,136.03
Including: Adjustment to capital reserve	11,142,362.66	9,061,136.03
Adjustment to surplus reserve		

7.3 Equity in joint ventures or associates

7.3.1 Significant

Name of joint venture or associate	Main business location	Registered address	Nature of business	Shareholding (%) Direct	Indirect	Accounting treatment for investments in joint ventures or associates	Whether there is a quoted market price
Hangzhou Anmei Tangqi Clinic Co., Ltd.	Hangzhou	Hangzhou	Healthcare		26.65	Equity method	Yes
Wenzhou Lvye Hospital Co., Ltd.	Wenzhou	Wenzhou	Medical service		45.00	Equity method	Yes

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

7 E ( )

7.3 Eq i in join en re arrangemen s or associa es ( )

7.3.2 M

I em	Balance as a 31 December 2024/Year 2024 Anken Medical	Long an Yining	B 31 D 2023/Y 2023 A M	L Y
C	45,907,773.26	196,852.44	53,708,669.65	46,656,767.88
N	66,672,211.67	219,142,045.33	46,709,884.95	152,199,429.22
T	112,579,984.93	219,338,897.77	100,418,554.60	198,856,197.10
C	97,851,535.78	38,926,869.26	54,935,249.19	37,541,901.86
N	17,305,931.19	55,023,631.60	15,050,976.27	35,000,000.00
T	115,157,466.97	93,950,500.86	69,986,225.46	72,541,901.86
M			4,751,694.63	
E	-2,577,482.04	125,388,396.91	25,680,634.51	126,314,295.24
N	-794,122.22	56,424,778.61	8,110,215.72	56,841,432.86
A				
G				
U				
O				
B				
F				
Q	169,056,106.91		140,281,463.89	
N	8,130,898.63	-925,898.33	6,903,036.00	-257,993.98
N				
O				
T	8,130,898.63	-925,898.33	6,903,036.00	-257,993.98

D

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

8 Government grants

8.1 Type or amount of and items listed in government grants

8.1.1 Government grants recognised according to the total amount

Applicable

Items listed on the balance sheet	Government grants	Amount included in the current profit or loss or used to offset the losses of related costs		Item included in the current profit or loss or used to offset the losses of related costs
		Year 2024	Year 2023	
Subsidy for Wen'an Fuxing Building	10,632,800.00	303,792.00	303,792.00	Other gains
Total	10,632,800.00	303,792.00	303,792.00	/

Inapplicable

Item included in the current profit or loss or used to offset the losses of related costs	Government grants	Amount included in the current profit or loss or used to offset the losses of related costs	
		Year 2024	Year 2023
Subsidy for Shijiazhuang Qiaoxi District Bureau of Industry and Information Technology	2,355,899.97	2,355,899.97	785,833.31
Subsidy for Shijiazhuang Qiaoxi District Bureau of Science and Technology	1,249,450.00	1,249,450.00	1,808,866.20
Energy Saving Subsidy for Renewable Energy Utilization Project of Wen'an Sanshang Building	1,086,469.80	1,086,469.80	133,469.31
Subsidy for Shijiazhuang R&D Platform	1,069,545.95	1,069,545.95	891,305.79
Medical Insurance Subsidy for Hengshui Branch	915,200.00	915,200.00	499,320.00
Tax Refund	904,765.91	904,765.91	1,607,644.57
Industrial Development Fund of Qiaoxi District Commerce and Trade Bureau	816,840.00	816,840.00	
Industrial Development Fund	625,000.00	625,000.00	
Industrial Development Fund of Qiaoxi District Commerce and Trade Bureau Qiaoxi Hengfeng Economic Development Zone	500,000.00	500,000.00	

No es o he Financial S a emen s

F Y E 31 D 2024

(A RMB)

8 G ( )

8.1 T pe or amo n of and i ems lis ed in go ernmen gran s ( )

8.1.1 G ( )

I ( )

I em incl ded in he o rren profi or loss or sed o offse he losses of rela ed cos s	Go ernmen gran s	Amo n incl ded in he o rren profi or loss or sed o offse he losses of rela ed cos s Year 2024	Y 2023
C Y P G	376,000.00	376,000.00	
M M E P S B M I	343,000.00	343,000.00	
VAT	315,666.54	315,666.54	
G H H I D (B) S T B B R&D C	300,000.00	300,000.00	
B H F P C	284,000.00	284,000.00	344,000.00
J E M C	249,470.10	249,470.10	
G C C F D P	217,779.00	217,779.00	
S	205,662.60	205,662.60	34,500.00
F C C H W B	200,890.00	200,890.00	
G H H I D (B) E I B S S D I	200,000.00	200,000.00	
O	129,138.01	129,138.01	78,742.36
M B M I	114,200.00	114,200.00	
G	100,000.00	100,000.00	

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

8 G ( )

8.1 T pe or amo n of and i ems lis ed in go ernmen gran s ( )

8.1.1 G ( )

I ( )

I em incl ded in he o rren profi or loss or sed o offse he losses of rela ed cos s	Go ernmen gran s	Amo n incl ded in he o rren profi or loss or sed o offse he losses of rela ed cos s Year 2024	Y 2023
120 P C H W B 2024	91,000.00	91,000.00	
P	35,443.12	35,443.12	
U H R S S B	35,246.16	35,246.16	
F M B F C C D C B	31,110.00	31,110.00	
S H F H C 2024 W -F C' I R W E E B	20,000.00	20,000.00	
O S	20,000.00	20,000.00	
S P M S C N ' D C F Y N A	20,000.00	20,000.00	
S	15,000.00	15,000.00	
S D P ' H	14,360.00	14,360.00	42,000.00
F C C P ' H 2022			203,186.30
F C C H W B			280,000.00
			154,811.73

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

8 Government grants (continued)

8.1 Type or amount of and items listed in government grants (continued)

8.1.1 Government grants recognised in current profit or loss or used to offset the losses of related costs (continued)

Items (continued)

Items included in the current profit or loss or used to offset the losses of related costs	Government grants	Amount included in the current profit or loss or used to offset the losses of related costs	
		Year 2024	Year 2023
Rural Key Practical Base			
Project Base			80,000.00
CDC Science Science Education Center			997,071.49
Education			167,287.64
Science			200,000.00
Research			
Annual			171,500.00
Talent			
Health Center			
Living Demonstration			29,900.00
Science			
Project Center Science			50,000.00
Education Talent Center			53,000.00
Talent Team			130,000.00
Science			
Base			
			38,900.00
Health			206,153.66
Quality Work Demonstration			
Education Center			
Total			6,174,393.49

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

Items included in the current profit or loss or used to offset the losses of related costs	Government grants	Amount included in the current profit or loss or used to offset the losses of related costs	
		Year 2024	Year 2023
Subsidy for Wenhou Old Hospital Building			53,200.00
Relocation Subsidy for Wenhou Elementary School			40,000.00
Wenhou Hospital Construction Subsidy			7,000.00
Wenhou Hospital Construction Subsidy			6,700.00
Total			710,750.00
Subsidy for Employment Stabilization			30,000.00
Total	12,841,137.16	**12,841,137.16**	16,009,535.85

8.1.2 Liabilities

Liabilities	31 December 2023	New	Amount	Other	Balance as at 31 December 2024	Asset/
Deferred						

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

9 Risks related to financial instruments

9.1 Various risks generated by financial instruments

The Company's activities expose it to various financial risks: credit risk, liquidity risk and market risk (including foreign exchange risk, interest rate risk and other price risk). The overall goal of the Company's risk management is to formulate risk management policies that minimize the adverse impact on the Company's financial performance while balancing the risk and benefit, and to determine the appropriate risk tolerance level and conduct risk management, timely and reliably monitor various risks faced by the Company, and control risks within the limited range.

The Board of Directors is responsible for planning and establishing the Company's risk management framework, formulating the Company's risk management policies and related guidelines, and monitoring the implementation of risk management measures. The Company has established risk management policies to identify and analyze the risks faced by the Company, and has set appropriate risk tolerance levels and designed corresponding internal control procedures to monitor the Company's risk levels. The Company regularly reviews these risk management policies and related internal control systems to adapt to changes in market conditions or the Company's activities. The Company's internal audit department regularly or irregularly checks the implementation of internal control systems and urges the management to take corresponding measures to address the risks that exceed the risk tolerance level.

The Company's risk management is carried out by the Finance Department under the policies approved by the Board of Directors. The Finance Department identifies, evaluates and avoids risks in close cooperation with other business departments of the Company. The Board of Directors has established written principles for overall risk management, as well as written guidelines covering specific risk areas such as foreign exchange risk, interest rate risk, credit risk, the use of derivative financial instruments and non-derivative financial instruments, and the investment of excess liquidity.

9.1.1 Credit risk

Credit risk refers to the risk that one party to a financial instrument fails to perform its obligations, causing financial loss to the other party. The Company's credit risk mainly arises from cash and cash equivalents, trade receivables, other receivables, etc.

The Company's cash and cash equivalents are mainly deposited in state-owned banks and other large and medium-sized listed banks. The Company believes that these banks have high reputation and good financial status, and there is no significant credit risk. The Company will not suffer significant losses due to bank default. The Company's trade receivables and other receivables are mainly from customers with good credit quality. The Company has established relevant policies to control the credit exposure to these customers. The Company evaluates the credit quality of customers based on their financial status, credit history and other factors, and sets corresponding credit limits. The Company regularly monitors the credit exposure to customers and the collection of receivables, and takes timely measures to reduce the risk of bad debts.

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

9 R ( )

9.1 Vario s risks genera ed b financial ins n men s ( )

9.1.1 G ( )

T C ’ A
C
T C
F C
F C
T
2-9 C
S
C A B D P ’ F T
C

9.1.2 L

T

T C
L C T
12 C
A C

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts in RMB unless otherwise stated)

9 Risks related to financial instruments

9.1 Various risks generated by financial instruments

9.1.2 Liquidity risk

The Company's liquidity risk management objective is to ensure sufficient liquidity to meet its financial obligations as they fall due. The Company's liquidity risk mainly arises from the mismatch between the maturity dates of financial assets and financial liabilities. The Company's liquidity risk management strategy is to ensure that it has sufficient liquidity to meet its financial obligations as they fall due, and to minimize the impact of liquidity risk on the Company's financial position and operating results.

Balance as at 31 December 2024

Item	Instalment repayment	Within 1 year	1-2 years	Between 2 to 5 years	Over 5 years	Total undiscounted contractual amount	Book value
Borrowings		295,897,567.90	231,446,702.05	332,391,684.58	258,553,226.86	1,118,289,181.39	946,187,337.44
Lease liabilities		26,733,022.63	45,988,901.90	58,725,671.39	86,707,676.25	218,155,272.17	178,033,085.43
Long-term payables		38,367,421.50	30,877,984.00	57,282,769.00		126,528,174.50	110,284,300.10
Accounts payable		127,861,415.20	3,124,361.77	950,603.01		131,936,379.98	131,936,379.98
Other payables		33,007,700.14	29,568,765.29	18,710,967.72		81,287,433.15	81,287,433.15
Total		521,867,127.37	341,006,715.01	468,061,695.70	345,260,903.11	1,676,196,441.19	1,447,728,536.10

Balance as at 31 December 2023

Item	Instalment repayment	Within 1 year	1-2 years	Between 2 to 5 years	Over 5 years	Total undiscounted contractual amount	Book value
Notes payable		1,545,021.09				1,545,021.09	1,545,021.09
Borrowings		340,005,699.32	270,474,264.25	228,670,426.19	158,782,942.13	997,933,331.89	864,740,914.69
Lease liabilities		28,643,888.99	44,408,365.80	71,261,748.80	69,158,488.54	213,472,492.13	191,883,421.75
Long-term payables		43,175,648.00	19,331,148.00	55,701,622.66		118,208,418.66	103,099,208.53
Accounts payable		110,060,007.67				110,060,007.67	110,060,007.67
Other payables		150,270,575.15				150,270,575.15	150,270,575.15
Total		673,700,840.22	334,213,778.05	355,633,797.65	227,941,430.67	1,591,489,846.59	1,421,599,148.88

Notes to the Financial Statements

For the Year Ended 31 December 2024
(All amounts are in RMB unless otherwise stated)

9 Risks related to financial instruments (continued)

9.1 Various risks generated by financial instruments (continued)

9.1.3 Market risk

Market risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in market prices, including interest rate risk, exchange rate risk and other price risk.

(1) Interest rate risk

Interest rate risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in market interest rates.

Floating-rate financial instruments expose the Company to cash flow interest rate risk. Fixed-rate financial instruments expose the Company to fair value interest rate risk. The Company determines the relative proportion of fixed-rate and floating-rate financial instruments based on the current market environment. The Company monitors the proportion of floating-rate financial instruments and may enter into interest rate swaps to hedge interest rate risk when necessary.

As at 31 December 2024, the Company's interest-bearing financial instruments were mainly RMB

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts in RMB unless otherwise stated)

9 Risks related to financial instruments

9.1 Various risks generated by financial instruments

9.1.3 Market risk

(2) Exchange rate risk

Exchange rate risk refers to the risk of loss arising from changes in exchange rates. The Company's main business is conducted in RMB, with only a small portion of transactions settled in USD. Foreign currency assets and liabilities are mainly denominated in USD. The exchange rate risk arising from foreign currency assets and liabilities may affect the Company's operating results. The following table sets out the foreign currency risk exposure of the Company, expressed in RMB:

	Balance as at 31 December 2024			Balance as at 31 December 2023		
Item	USD	HKD	Total	USD	Other currencies	Total
Cash and cash equivalents	287,569.57	46,036.70	333,606.27	81,905.11	52,061.43	133,966.54
Total	287,569.57	46,036.70	333,606.27	81,905.11	52,061.43	133,966.54

As at 31 December 2024, if the exchange rate of RMB against USD had increased or decreased by 3%, with all other variables held constant, the Company's net profit would have increased or decreased by approximately RMB10,008.19 (31 December 2023: RMB4,019.00). The analysis assumes that a 3% change in the exchange rate of RMB against USD occurred at the balance sheet date.

(3) Other price risk

Other price risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in market prices (other than those arising from interest rate risk or exchange rate risk), whether such changes are caused by factors specific to the individual financial instrument or its issuer, or by factors affecting all similar financial instruments traded in the market.

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

10 Disclosure of fair value

The following table presents the fair value of the Company's financial instruments measured at fair value on a recurring basis:

Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities. Such instruments typically include publicly traded equity securities and exchange-traded derivatives.

Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable inputs such as interest rates and yield curves.

Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Company's policy is to recognize transfers between different levels of the fair value hierarchy at the end of the reporting period in which the transfer occurs. There were no transfers between Level 1, Level 2 and Level 3 during the year.

10.1 Fair value of assets and liabilities measured at fair value as at 31 December 2024

	Fair value as at 31 December 2024			
Item	Measured at fair value Level 1	Measured at fair value Level 2	Measured at fair value Level 3	Total
I. C				
◆F			7,938,322.41	7,938,322.41
1. F				
			7,938,322.41	7,938,322.41
(1) I				
(2) E			7,938,322.41	7,938,322.41
2. F				
◆O			36,755,116.10	36,755,116.10
1. F				
			36,755,116.10	36,755,116.10
(1) I				
(2) E			36,755,116.10	36,755,116.10
2. F				
T			44,693,438.51	44,693,438.51

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

10 D ( )

10.1 Fair al e of asse s and liabili ies meas red a fair al e as a 31 December 2024 ( )

	Fair al e as a 31 December 2024			
I em	Meas red a fair al e a Le el 1	Meas red a fair al e a Le el 2	Meas red a fair al e a Le el 3	To al
◆F			14,000,000.00	14,000,000.00
1. F			14,000,000.00	14,000,000.00
(1) T				
(2) D				
(3) O			14,000,000.00	14,000,000.00
2. F				
T			14,000,000.00	14,000,000.00

10.2 Q ali a i e and q an i a i e informa ion on he al a ion echniq es and impor an parame ers adop ed for con in o s and non-con in o s meas remen s a Le el 3 fair al es

1. T C M P/B :

I em	Fair al e as a 31 December 2024	V	U	R
F	7,938,322.41	D	W	8%
O	36,755,116.10	M	P/B	1.97-4.31
			L	23.91_24.71
		D	W	9%-18%

2. T C H Y M

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

11 Related parties and related party transactions

11.1 Parent company of the Company

The parent company of the Company is Guangzhou Wenhou Kangning Medical Investment Co., Ltd.

11.2 Information on subsidiaries of the Company

See Note 7 Equity in other entities for details of subsidiaries of the Company.

11.3 Associates of the Company

See Note 7 Equity in other entities for details of associates of the Company.

Other associates of the Company that had balances or transactions during the year ended 2024 or 2023:

Name of joint venture or associate	Relationship with the Company
Huai'an Meitai Medical Co., Ltd.	Associate of the Company
Wuhan Liyuan Hospital Co., Ltd.	Associate of the Company
Xuzhou Huaihai Medical Co., Ltd.	Associate of the Company
Shanghai Shenkang Medical Clinic Co., Ltd.	Associate of the Company
Changzhou Huaikang Hospital Co., Ltd.	Associate of the Company
Fujian Nanping Tianhe Co., Ltd.	Associate of the Company

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

11 Related parties and related party transactions (continued)

11.4 Other related parties

Name of other related party	Relationship between other related parties and the Company
Ningbo Beilun Port Anke Investment Management Partnership (Limited Partnership)	Other entities controlled by the Company
Shanghai Fuhua Medical Management Co., Ltd.	Minority shareholder of subsidiary
Chongqing Wanzhou Kangning Hospital Co., Ltd.	Minority shareholder of subsidiary
Chongqing Gaoxin Kangning Hospital Co., Ltd.	Minority shareholder of subsidiary
Jiangsu Dingkang Hospital Co., Ltd.	Minority shareholder of subsidiary
Wuhan Lingkang Hospital Co., Ltd.	Minority shareholder of subsidiary
Wuhan Kangning Hospital Co., Ltd.	Minority shareholder of subsidiary
Xiangyang Xiangkang Hospital Co., Ltd.	Minority shareholder of subsidiary
Wuhan Chuangkang Hospital Co., Ltd.	Minority shareholder of subsidiary
Yichang Lingkang Hospital Co., Ltd.	Chongqing Kangning Hospital Co., Ltd. and its subsidiaries, Minority shareholder of subsidiary
Wuhan Hankang Hospital Co., Ltd.	Other entities controlled by the Company, Chongqing Kangning Hospital Co., Ltd. and its subsidiaries, Minority shareholder of subsidiary
Xiangyang Xiangkang Hospital Co., Ltd.	Shareholder with significant influence over the Company, Chongqing Kangning Hospital Co., Ltd. and its subsidiaries, Minority shareholder of subsidiary
Tianjin Tianyi Chuangkang Medical Co., Ltd.	Minority shareholder of subsidiary
Yichang Puren Medical Co., Ltd.	Minority shareholder of subsidiary
Lanzhou Shengrui Hospital Co., Ltd.	Shareholder with significant influence over the Company
Yunnan Mengzi Hongkang Clinic	Non-controlling shareholder of subsidiary

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

11 R ( )

11.5 Rela ed-par ransac ions ( )

11.5.2 R

T C :

G aran eed par	G aran ee amo n	Commencemen da e	E pir da e	Whe her he g aran ee has been f lfilled
Q Y H C ., L .	60,000,000.00	2023/10/9	2034/10/9	N
Y K H C ., L .	60,000,000.00	2019/8/20	2031/8/21	N
L C H C ., L .	68,440,000.00	2023/4/3	2032/3/2	N
J S. H C ., L .	6,000,000.00	2024/7/30	2025/7/30	N
H A. M T C ., L .	32,400,000.00	2024/7/1	2027/6/30	N
W L Y H C ., L .	8,400,000.00	2024/3/31	2027/3/31	N
W L Y H C ., L .	103,000,000.00	2023/10/12	2034/10/9	N
Y K H C ., L .	12,000,000.00	2024/7/18	2029/6/18	N
Y Y T W M H C ., L .	8,000,000.00	2024/7/18	2029/6/18	N
Q K H C ., L .	5,300,780.00	2024/1/1	2028/12/31	N
W Y G H C ., L .	4,337,088.00	2024/1/25	2028/12/25	N
W Y G H C ., L .	17,000,000.00	2022/10/25	2025/10/25	N
P C Y H C ., L .	26,000,000.00	2023/12/20	2031/12/20	N

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

11 R

11.5 Rela ed-par ransac ions ( )

11.5.2 R ( )

T C :

G aran eed par	G aran eed amo n	Commencemen da e	E pir da e	Whe her he g aran ee has been f lfilled
Y K H C ., L .	200,000,000.00	2021/12/24	2026/12/24	N
Y K H C ., L .	200,000,000.00	2021/12/24	2026/12/24	N
C K H C ., L .	200,000,000.00	2021/12/24	2026/12/24	N
W Y G H C ., L .	200,000,000.00	2021/12/24	2026/12/24	N
P K H C ., L .	200,000,000.00	2021/12/24	2026/12/24	N
W L Y H C ., L .	200,000,000.00	2021/12/24	2026/12/24	N
W C H C ., L .	200,000,000.00	2021/12/24	2026/12/24	N
C K H C ., L .	66,474,000.00	2021/12/24	2026/12/10	N
G W , W L	24,000,000.00	2020/6/30	2027/6/30	N
G W , W H , W L	79,642,127.25	2021/11/29	2028/11/29	N
G W , W H , W L , X Y	180,950,000.00	2020/10/26	2026/10/25	N
G W	70,000,000.00	2023/11/8	2026/11/15	N
G W , W L , W H	14,660,000.00	2019/9/10	2029/8/20	N
G W , W L , W H	10,280,000.00	2020/1/1	2029/8/20	N
G W , W L , W H	3,320,000.00	2020/12/22	2029/8/20	N
G W , W L , W H	2,200,000.00	2020/9/27	2029/8/20	N
G W , W L , W H	2,200,000.00	2020/9/27	2029/8/20	N
G W , W L , W H	3,050,000.00	2021/3/1	2029/8/20	N
G W , W L , W H	3,050,000.00	2021/3/1	2029/8/20	N
G W , W L , W H	45,000,000.00	2023/7/3	2037/12/31	N
G W , W L , W H	15,000,000.00	2023/7/31	2037/12/31	N
G W , W L , W H	10,116,550.00	2023/10/25	2037/12/31	N
G W , W L , W H	5,007,200.00	2023/11/24	2037/12/31	N
G W , T E C C ., L , Y P M C ., L .	60,000,000.00	2023/10/9	2031/10/9	N
W L	18,312,000.00	2023/12/20	2028/12/25	N
G W , W L	25,000,000.00	2024/12/10	2027/12/10	N
G W , W L	120,000,000.00	2024/3/27	2027/3/26	N

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

11 R ( )

11.5 Rela ed-par ransac ions ( )

11.5.3 L

Rela ed par	Lending/borro ing amo n	Commencemen da e	E pir da e	Remark
L				
C H K H C ., L .	800,000.00	2023/6/7	2024/6/7	N
C H K H C ., L .	28,000,000.00	2024/5/6	2025/5/6	
L S R H C ., L .	1,095,000.00	2023/9/29		N
Y M C ., L .	2,508,250.00	2022/6/13		N
X X.	2,000,000.00	2022/6/15	2023/6/14	N
L				
W L Y H C ., L .	13,500.000.00	2023/1/10	2026/1/9	
S H P C ., L .	10,204,311.69	2015/6/1		
W C	3,490,447.08	2015/9/1	N	

11.5.4 R

I em	Year 2024	Y 2023
S	8,625,385.30	8,642,653.48
S	1,863,108.72	

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

11 R ( )

11.6 Unse led i ems of recei ables from and pa ables o rela ed par ies

11.6.1 R

I em name	Rela ed par	Balance as a 31 December 2024 Book balance	Pro ision for bad deb s	B 31 D 2023 B	B
A					
	Y M H C	12,024,620.00	7,548,920.00	12,000,000.00	5,520,000.00
	H Y H C L	79,780.30	2,807.80	65,000.00	3,250.00
	H A M T C L			1,522.85	15.23
	L S R H C L			635,000.00	6,350.00
O					
	H Y H C L	8,000,000.00	8,000,000.00	23,709,977.64	17,002,735.51
	W L Y H C L	14,312,219.18	715,610.96	14,290,027.40	714,501.37
	S H P C L	10,204,311.69	10,204,311.69	10,204,311.69	10,204,311.69
	H A M T C L			16,836.66	841.83
	Y M H C	2,475,380.00	123,769.00		
	W C	3,490,447.08	3,490,447.08	3,490,447.08	3,490,447.08
	C G	100,000.00	1,000.00	100,000.00	1,000.00
	X X	80,004.00	800.04	80,004.00	800.04
	C W	45,187.50	2,259.38	105,187.50	5,259.38
	J D	383,467.50	19,173.38	479,707.50	23,985.38
	Y L	30,000.00	900.00		

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise indicated)

11 Receivables from and payables to related parties (continued)

11.6 Unsettled items of receivables from and payables to related parties (continued)

11.6.2 Payables

Item	Related party	Book balance as at 31 December 2024	Book balance as at 31 December 2023
Accounts payable	Hangzhou Aimeite Technology Co., Ltd.		167,677.40
	Zhejiang Fuyuan Network Technology Co., Ltd.	32,895.70	
	Yu Li	23,583.50	
Other payables	Wu Li		3,702,846.16
	Wu Xin		962,492.04
	Shanghai Fuyi Health Management Consulting Co., Ltd.		3,599,626.28
	Lishui Shengrui Health Industry Co., Ltd.	1,095,000.00	1,095,000.00
	Chengdu Huaxi Kangning Hospital Co., Ltd.	3,294,491.66	2,021,750.00
	Ningbo Meishan Bonded Port Area Kangning Investment Management Partnership (Limited Partnership)		6,347,133.33
	Gu Wei		16,997,627.91
	Zhejiang Yuanbo Health Management Consulting Co., Ltd.	2,508,250.00	3,108,250.00
	Cai Gang		94,276.16
	Xu Xin	2,405,961.75	2,261,567.19
	Ningbo Meishan Bonded Port Area Kangning Investment Management Partnership (Limited Partnership)		291,842.74
	Hangzhou Yuhang Hospital Co., Ltd.	93,142.79	93,142.79
	Zhejiang Huaxi Hospital Management Consulting Co., Ltd.	19,983.98	1,333,441.75

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

11 Related party relationships and transactions (continued)

11.7 Interests and equity of the directors

In 2024, the remuneration of the directors is as follows:

Name	Remunerations	Salaries and subsidies	Contributions to social security plans	Bonus	Other allowances and benefits	Equity incentive	Total
Executive director							
G W	100,000.00	404,160.00	82,725.65	99,967.00	5,300.00		692,152.65
W L	75,000.00	490,959.00	51.76	179,642.89	40,300.00	504,213.54	1,290,167.19
W J	75,000.00	730,000.00	77,348.70		59,300.00	366,824.67	1,308,473.37
Independent director							
J L	70,000.00						70,000.00
W	70,000.00						70,000.00
C S	70,000.00						70,000.00
Supervisor							
X N	219,960.00	71,060.00	148,298.65	80,900.00		118,427.19	638,645.84
X T	91,800.00	47,535.25	85,810.20	5,980.00		49,252.36	280,377.81
Total	771,760.00	1,743,714.25	394,234.96	366,489.89	104,900.00	1,038,717.76	4,419,816.86

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

11 R

11.7 In eres s and eq i of he direc ors ( )

I 2023, :

Name	Rem nera ions	Salaries and s bsidies	Con rib ions o social seo ri plans	Bon s	O her allo ances and benefi s	To al
E eo i e direc or						
G W		402,360.00	75,696.30	97,374.40	5,300.00	580,730.70
W L		468,584.00		131,416.00	58,800.00	658,800.00
W J		563,500.00	76,163.50	180,500.00	64,400.00	884,563.50
Non-e eo i e direc or						
Q H						
L C						
Independen direc or						
L N	35,000.00					35,000.00
W	70,000.00					70,000.00
X	35,000.00					35,000.00
J L	35,000.00					35,000.00
C S	35,000.00					35,000.00
S per isor						
Q C						
X Y						
S F						
X N		284,640.00	58,794.40	74,331.82	24,480.00	442,246.22
X T		90,720.00	43,605.90	84,131.20	6,500.00	224,957.10
T	210,000.00	1,809,804.00	254,260.10	567,753.42	159,480.00	3,001,297.52

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

11 Remuneration of directors, supervisors and senior management (continued)

11.8 Five individuals with the highest remunerations

In 2024, included in the Company's five highest paid individuals were 2 directors (2023: 1), whose remuneration is set out below:

Item	Year 2024	Year 2023
Basic salaries, housing allowances, other allowances and benefits in kind	2,422,542.70	3,789,230.21
Share-based payments	466,095.26	
Total	2,888,637.96	3,789,230.21

Scope of compensation	Persons in 2024	Persons in 2023
500,000-1,000,000.00	2	3
Over 1,000,000.00	1	1
Total	3	4

12 Share-based payments

12.1 General information of share-based payments

	Equity instruments granted in 2024		Equity instruments unlocked in 2024		Equity instruments exercised in 2024		Equity instruments expired in 2024	
Granting object	Quantity	Amount	Quantity	Amount	Quantity	Amount	Quantity	Amount
HS A Type S	1,240,100.00	12,345,912.02						
Total	1,240,100.00	12,345,912.02						

In H S A T S 2023 C 27 S 2023, C H S A T S T , C ' C ' H- T C ' C ' T H- H S A T S 5% C ' 3,730,015 .

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

12 S ( )

12.1 General informa ion of share-based pa men s ( )

O 12 A 2024, B D 363,100
35 RMB0/ H-
HKD11.20.

O 23 A 2024, B D 555,000
32 RMB7/ H-
HKD10.80.

O 18 J 2024, B D 322,000
50 RMB7/ H-
HKD11.94.

A H S A T S H-
:

Ves ing period	Ves ing da e	Ves ing ra io
F	F T 12	25%
S	F 12 T 24	25%
T	F 24 T 36	25%
F	F 36 T 48	25%

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

12 S ( )

12.2 Eq i -se led share-based pa men

De ermina ion me hod of fair al e of eq i ins n men s on gran da e	Marke me hod
S C	
D	
R 2024 2023	
A	48,854,883.98

12.3 Share-based pa men s

	Year 2024			Y 2023		
Gran ing objec	Eq i -se led share-based pa men s	Cash-se led share-based pa men s	To al	E	C	T
HS A Te S	3,997,509.78		3,997,509.78			
T	3,997,509.78		3,997,509.78			

13 C

13.1 Significan commi men s

13.1.1 C

T C :

I em	31 December 2024	31 D 2023
B	73,035,553.02	122,040,000.00
T	73,035,553.02	122,040,000.00

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

13 Commitments and contingencies

13.1 Significant commitments

13.1.2 Other significant commitments

As at 31 December 2024, the Company

13.2 Contingencies

The Company

14 Profit distribution

On 28 March 2025, the 18th meeting of the 4th Board of Directors of the Company approved the 2024 Profit Distribution Proposal of the Company, agreeing to distribute cash dividends of RMB3 (tax inclusive) for every 10 shares, totaling 72,670,000 shares, based on the total share capital of the Company as at the end of 2024, with a total cash dividend of RMB21,801,000 (tax inclusive). The 2024

14.2 Description of other events after the balance sheet date

None.

15 Other

The Company's

The Company's

The Company

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

15 Contingencies (continued)

The Company

As at the balance sheet date, the Company had the following contingencies:

	Balance as at 31 December 2024	Balance as at 31 December 2023
Debt guarantees	55.30%	53.93%

16 Other significant events

16.1 Segment information

Except for the Company's business in the Chinese Mainland, the Company's subsidiaries also operate businesses in Hong Kong, China. The Company's management regularly reviews the operating results of the Chinese Mainland and Hong Kong, China to make decisions about resource allocation and performance assessment. Therefore, the Company has identified the Chinese Mainland and Hong Kong, China as two operating segments.

As at December 31, 2024, the Company's non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets and rights arising from insurance contracts (hereinafter referred to as "Specified non-current assets") in the Chinese Mainland amounted to RMB 1,...

16.2 Other significant matters affecting decision-making of investors

None

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise stated)

17 Notes to items of the balance sheet

17.1 Accounts receivable

17.1.1 Disclosure by aging

Aging	Balance as at 31 December 2024	Balance as at 31 December 2023
Within 1 year	74,677,055.21	48,552,078.47
1 to 2 years	6,288,695.61	257,315.13
2 to 3 years	257,315.13	709,878.26
Over 3 years		3,906,521.87
Subtotal	81,223,065.95	53,425,793.73
Less: Provision for bad debts	11,526,313.86	5,359,236.04
Total	69,696,752.09	48,066,557.69

The Company's credit policy and the relevant information on the exposure to credit risk are disclosed in Note 12. The balance of accounts receivable due from shareholders with 5% or more voting shares is disclosed in Note 18.

17.1.2 Disclosure by method of provision for bad debts

	Balance as at 31 December 2024					Balance as at 31 December 2023				
	Book balance		Provision for bad debts			Book balance		Provision for bad debts		
Type	Amount	Proportion (%)	Amount	Proportion of provision (%)	Book value	Amount	Proportion (%)	Amount	Proportion (%)	Book value
Provision for bad debts made on an individual basis	10,763,194.65	13.25	10,725,880.17	99.65	37,314.48	4,873,715.26	9.12	4,873,715.26	100.00	
Including:										
Medical insurance receivables	10,763,194.65	13.25	10,725,880.17	99.65	37,314.48	4,873,715.26	9.12	4,873,715.26	100.00	
Provision for bad debts made on a portfolio basis	70,459,871.30	86.75	800,433.69	1.14	69,659,437.61	48,552,078.47	90.88	485,520.78	1.00	48,066,557.69
Including:										
Patient receivables	70,459,871.30	86.75	800,433.69	1.14	69,659,437.61	48,552,078.47	90.88	485,520.78	1.00	48,066,557.69
Total	81,223,065.95	100.00	11,526,313.86	/	69,696,752.09	53,425,793.73	100.00	5,359,236.04	/	48,066,557.69

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

17 Notes receivable and accounts receivable

17.1 Accounts receivable

17.1.2 Disclosed by method of bad debt provision for accounts receivable

Set out below is the information about the provision for bad debts of accounts receivable:

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

17 Notes to items of the balance sheet (continued)

17.2 Other receivables

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Interest receivable	787,500.00	
Dividends receivable	43,400,000.00	14,400,000.00
Other receivables	572,688,222.47	586,048,325.58
Total	616,875,722.47	600,448,325.58

17.2.1 Interest receivable

Item	Balance as at 31 December 2024	Balance as at 31 December 2023
Time deposits	787,500.00	
Subtotal	787,500.00	
Less: Provision for bad debts		
Total	787,500.00	

17.2.2 Dividends receivable

Investee	Balance as at 31 December 2024	Balance as at 31 December 2023
CK Hutchison Co., Ltd.	4,400,000.00	4,400,000.00
YK Hutchison Co., Ltd.	7,000,000.00	
QK Hutchison Co., Ltd.	16,000,000.00	10,000,000.00
YK Hutchison Co., Ltd.	16,000,000.00	
Subtotal	43,400,000.00	14,400,000.00
Less: Provision for bad debts		
Total	43,400,000.00	14,400,000.00

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts in RMB unless otherwise stated)

17 Notes to items of the balance sheet (continued)

17.2 Other receivables (continued)

17.2.3 Other receivables (continued)

(1) Disclosed by aging

Aging	Balance as at 31 December 2024	Balance as at 31 December 2023
Within 1 year	532,356,857.00	552,853,728.97
1 to 2 years	32,666,417.15	34,594,797.65
2 to 3 years	8,304,612.39	496,167.22
3 to 4 years	496,167.22	908,479.96
4 to 5 years	706,350.52	
Subtotal	574,530,404.28	588,853,173.80
Less: Provision for bad debts	1,842,181.81	2,804,848.22
Total	572,688,222.47	586,048,325.58

(2) Classification by method of provision for bad debts

	Balance as at 31 December 2024					Balance as at 31 December 2023				
	Book balance		Provision for bad debts			Book balance		Provision for bad debts		
Category	Amount	Proportion (%)	Amount	Proportion of provision (%)	Book value	Amount	Proportion (%)	Amount	Proportion (%)	Book value
By method of provision for bad debts										
By portfolio										
Including:										
Aging portfolio	65,297,554.50	11.37	1,842,181.81	2.82	63,455,372.69	75,462,768.59	12.82	2,804,848.22	3.72	72,657,920.37
Related party portfolio	509,232,849.78	88.63			509,232,849.78	513,390,405.21	87.18			513,390,405.21
Total	574,530,404.28	100.00	1,842,181.81		572,688,222.47	588,853,173.80	100.00	2,804,848.22		586,048,325.58

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are in RMB unless otherwise indicated)

17 Notes to items of the balance sheet (continued)

17.2 Other receivables (continued)

17.2.3 Other receivables (continued)

(2) Changes in the carrying amount of provision for bad debts (continued)

Basis for determining the stage and provision rate:

Impact of changes in the carrying amount of loss provision with significant changes in amount:

Name	Balance as at 31 December 2024		
	Other receivables	Provision for bad debts	Proportion of provision (%)
Amount	65,297,554.50	1,842,181.81	2.82
Receivables with low credit risk and not requiring provision for bad debts	509,232,849.78		
Total	574,530,404.28	1,842,181.81	/

(3) Disclosure by stage

Provision for bad debts	Stage I 12-Month expected credit loss	Stage II Lifetime expected credit loss (without credit impairment)	Stage III Lifetime expected credit loss (with credit impairment)	Total
Balance as at 31 December 2023	2,804,848.22			2,804,848.22
In 2024, balance as at 31 December 2023				
—Transfer to Stage II				
—Transfer to Stage III				
—Reversal to Stage II				
—Reversal to Stage I				
Provision for 2024	-962,666.41			-962,666.41
Reversal for 2024				
Write-off for 2024				
Cancellation for 2024				
Others				
Balance as at 31 December 2024	1,842,181.81			1,842,181.81

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

17 N ( )

17.2 O her recei ables ( )

17.2.3 O ( )

(3) D ( )

C :

B	S age I 12-Mon h e pec ed credi loss	S age II Life ime e pec ed credi loss (i ho credi impairmen)	S age III Life ime e pec ed credi loss (i h credi impairmen)	To al
B 31 D 2023	588,853,173.80			588,853,173.80
I 2024, 31 D 2023				
T S II				
T S III				
R S II				
R S I				
I 2024				
D 2024	14,322,769.52			14,322,769.52
O				
B 31 D 2024	574,530,404.28			574,530,404.28

(4) P 2024

Ca egor	B 31 D 2023	C 2024 R W		O	Balance as a 31 December 2024
		P			
O	2,804,848.22		962,666.41		1,842,181.81
T	2,804,848.22		962,666.41		1,842,181.81

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts in RMB unless otherwise stated)

17 Notes to items of the balance sheet (continued)

17.2 Other receivables (continued)

17.2.3 Other receivables (continued)

(5) Classification by nature of payments

Nature of payments	Book balance as at 31 December 2024	Book balance as at 31 December 2023
Other receivables from related parties	509,232,849.78	513,390,405.21
Security deposits	38,067,000.00	19,150,000.00
Cash advances	1,354,960.78	1,330,175.04
Deposits	1,891,780.00	5,920,030.00
Others	1,671,594.54	767,065.13
Receivables from equity transfer	22,312,219.18	48,295,498.42
Total	574,530,404.28	588,853,173.80

17.3 Long-term equity investments

Item	Balance as at 31 December 2024			Balance as at 31 December 2023	
	Book balance	Provision for impairment	Book value	Balance	Balance
Investments in subsidiaries	771,544,043.35		771,544,043.35	691,561,513.66	691,561,513.66
Investments in associates and joint ventures	63,293,944.52		63,293,944.52	94,421,925.51	94,421,925.51
Total	834,837,987.87		834,837,987.87	785,983,439.17	785,983,439.17

Notes to the Financial Statements

For the Year Ended 31 December 2024

(All amounts are expressed in RMB unless otherwise stated)

17 Non-current liabilities due within one year

No es o he Financial S a emen s

F Y E 31 D 2024

(A RMB)

17 N

17.3 Long- erm eq i in es men s ( )

17.3.1I ( )

O :

I P C Y H C L Y
I T W M H C L C M B W L S
S P D C B . C L W L S P S N 5.20 .

17.3.2I ( )

In es ee	31 D 2023	31 D 2023	R	I 2024	C	Balance of pro ision for impairmen	Balance as a 31 December 2024	Balance of pro ision for impairmen as a 31 December 2024
A H A M								
T C L	16,018,884.98		2,505,129.87	-11,654,848.94			6,869,165.91	
W L Y								
H C L	56,841,432.86		-416,654.25				56,424,778.61	
H H								
M C L	21,561,607.67	21,168,383.43	-393,224.24					
T	94,421,925.51	21,168,383.43	1,695,251.38	-11,654,848.94			63,293,944.52	

No es o he Financial S a emen s

F Y E 31 D 2024
(A RMB)

17 N

17.4 Opera ing income and opera ing cos s

17.4.1 B

I em	Year 2024 Income	Cos	Y 2023 I	C
M	376,394,574.38	265,148,203.02	380,358,202.27	269,941,680.92
O	5,808,717.10	86,681.23	6,967,659.63	
T	382,203,291.48	265,234,884.25	387,325,861.90	269,941,680.92

17.4.2 N

I em	Time for fulfillmen of obliga ions	Significan pa men erms	Na re of he Compan 's ransfer of he promised goods	Whe her he Compan is ac ing as principal	Amo n s ass med b he Compan ha are e pec ed o be ref nded o o s omer	T pes of q ali ass rance pro ided b he Compan and rele an obliga ions
T	A	M	D	Y	N	N

17.5 In es men income

I em	Year 2024	Y 2023
L	47,438,461.27	35,000,000.00
L	1,695,251.38	1,538,932.70
I		-1,946,692.33
I		-299,668.37
T	49,133,712.65	34,292,572.00

W K H C ., L .
(O)
28 M 2025

Defini ions

AGM	C 2024 J 30, 2025
A	C ,
A C	B
B Y H	B Y H C ., L . (北京怡寧醫院有限公司), PRC A 17, 2015, C '
B D B	C
C K H	C K H C ., L . (蒼南康寧醫院有限公司), PRC J 15, 2012, C '
CG C	C G C A C1 H K L R
C K P H	C K P H C ., L . (長春康林心理醫院有限公司), PRC F 16, 2016, C '
C Y H	C J Y P H C ., L . (C Y H C ., L .), C J 29, 2010,
C ' K H	C ' K H H C ., L . (淳安康寧黃鋒醫院有限公司), PRC A 16, 2020, C '
C W K H	W K H C ., L ., PRC, H S M B H K S E (S C : 2120)
C S	H K L R M . GUAN W M . WANG L

Defini ions

D ( )	( ) C
D S ( )	S ( ) C , RMB1.00 , , RMB S
D L H	D L H C ., L ., C J 5, 2018,
G H	W Y G H C ., L . (溫州怡寧老年醫院有限公司), PRC N 2, 2015, C ,
G	C
G Y H	G Y H C ., L . (冠縣怡寧醫院有限公司), PRC M 1, 2017, C ,
H S ( )	S ( ) C , RMB1.00 , M B H K S E
H Y H	H Y P H C ., L . (菏澤怡寧精神病醫院有限公司), PRC A 6, 2017, C ,
HK$ HKD	H K

Defini ions

H K	H K S A R PRC
H K L R	R G L S T S E H K
H K S E	T S E H K L
I S ( )	N D S E I S P , A E I S I S P , I S S S , C , I S
H K H	H K H C ., L . (淮南康寧醫院有限公司), PRC S 22, 2017, C , -
J S H	J S H C ., L . (縉雲舒寧醫院有限公司), PRC F 15, 2019, C , -
L P D	A 22, 2025,
L K H	L K H C ., L ., C F 6, 2023, -
L K H	L C K K H C ., L . (婁底市康樂康寧醫院有限責任公司), PRC A 28, 2017, C , -
L Y H	W L Y H C ., L . (溫州鹿城怡寧醫院有限公司), PRC A 2, 2020, C , -

Defini ions

L C H	L C H C ., L . (臨海慈寧醫院有限公司), PRC D 11, 2020, C '
M	M S A R PRC
M C	M C S T D L I A C3 H K L R
N C	B
N A	M 11, 2015 C C S
P C Y H	P C Y H C ., L ., C J 14, 2021,
P. Y H	P. Y H H C ., L . (浦江怡寧黃鋒醫院有限公司), PRC S 3, 2018, C '
PRC C	P ' R C , H K , M T
PRC C L	C L P ' R C (中華人民共和國公司法), S C T N P ' C PRC D 29, 2023 J 1, 2024 ( )
P F D	RMB3.0 S ( ) D 31, 2024 S AGM P F D
P	C N 10, 2015

Defini ions

Q K H	Q K H C ., L . (青田康寧醫院有限公司), PRC A 1, 2011, C
Q Y H	Q Y H C ., L . (衢州怡寧醫院有限公司), PRC N 20, 2015, C
R P	D 31, 2024
R C	B
RMB	PRC
SFO	S F O (C 571 L H K),
S ( )	S ( ) C , RMB1.00 D S ( ) H S ( )
S ( )	( ) S ( )
S Y H	S Y H (深圳怡寧醫院, S Y H C ., L . (深圳市怡寧醫院有限公司)), PRC S 22, 2014, C
S R M C	B
	C O (C 622 H K)
( )	H K L R
S ( )	S C
S C	C ' S C PRC C L

Defini ions

	H H K L R .
W C H	W C H C ., L . (溫州慈寧醫院有限公司), PRC J 25, 2006, C
W O Y E H	W O Y E H C ., L . (溫州甌海怡寧老年醫院有限公司), C M 8, 2021, C
Y P I H	Y P I H (W) C ., L . (怡寧心理互聯網醫院(溫州)有限公司), PRC M 10, 2020, C
Y K H	Y K H C ., L . (永嘉康寧醫院有限公司), PRC D 12, 2012, C
Y K H	Y K H C ., L . (樂清康寧醫院有限公司), PRC S 3, 2013, C
Y Y H	Y Y I T C W M H C ., L . (樂清怡寧中西醫結合醫院有限公司), PRC A 4, 2006, C Y B C & W M H L (樂清邦爾中西醫結合醫院有限公司)
%	

溫州康寧醫院股份有限公司

Wenzhou Kangning Hospital Co., Ltd.